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Summary 
Background: Malaria in pregnancy is an important public health problem in sub Saharan Africa. It is 
known to be the most common and preventable cause of harmful birth outcomes in malaria endemic 
areas. It is therefore important for a pregnant woman to be treated with safe and effective antimalarial 
medication. Drug safety in pregnancy is of a greater concern due to limited safety data available in this 
vulnerable group. This is because pregnant women are not involved in clinical trials related to drug 
development process due to safety reasons and hence, most of these medicines come to market with 
limit information available about their safety in pregnancy. Hence, establishing a drug safety monitoring 
mechanism would be important to generate safety data when a given medicine is already in the market, 
especially medications against tropical diseases. 
Pregnant women are at increased risk of malaria infection and illness than non-pregnant individuals due 
to physiological, hormonal and immunological changes that occur in their body after conception. The 
changes are also responsible for various therapeutic challenges that face this vulnerable group. This 
explains the presence of significant alteration of antimalarial pharmacokinetic (PK) properties in 
pregnancy and hence lead to a reduced drug blood concentration, which will ultimately lower 
antimalarial cure rate. Another factor that affects antimalarial effectiveness in pregnancy is parasite 
resistance against sulfadoxine-pyrimethamine (SP), a drug that is used for intermittent preventive 
treatment of malaria in pregnancy (IPTp).  
The objectives of the thesis were  to assess the magnitude of drugs exposure during pregnancy in 
relation to pregnancy outcomes, to describe the feasibility of establishing active pharmacovigilance 
system in developing countries using Health Demographic Surveillance System (HDSS) platform, to 
determine safety of artemether-lumefantrine (AL) exposure in first trimester of pregnancy, to evaluate 
pharmacokinetics and pharmacodynamics properties of artemether-lumefantrine in pregnant and non-
pregnant women, and to determine the effectiveness of IPTp-SP in prevention of placental malaria, 
maternal anaemia and low birth weight in areas with different malaria transmission intensity. 
Method: Three different study designs were used independently to respond to different specific 
objectives of this thesis; (i) a longitudinal follow up study was conducted to generate 
artemether/lumefantrine (AL) safety data in first trimester secondary to its inadvertent exposure in two 
Health Demographic Surveillance System (HDSS) areas in Tanzania. Pregnant women with gestational 
age ≤ 20 weeks were enrolled and followed up on monthly bases until delivery. Drugs exposures during 
the entire pregnancy period were also recorded. The latter was used to document the feasibility of 
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establishing active pharmacovigilance system using HDSS platform in one of the studied HDSS area. (ii) 
To determine AL PK, a prospective study involving pregnant in second and third trimester and non-
pregnant women, both with uncomplicated P falciparum malaria. Plasma samples were collected at pre-
defined dates for bioassay to determine drug level. Participants were followed up on pre-defined 
schedule visits until day 42. Inter- and intra-individual variability was assessed and covariated effects 
quantified using a nonlinear mixed-effect modeling approach (NONMEM®). (iii) Another prospective 
study enrolling pregnant women to assess the effectiveness of IPTp in two areas with different malaria 
transmission intensity. Pregnant women were recruited in the labor ward and structured questionnaire 
was used for interview. Placental parasitaemia was screened by using both light microscope and real-
time quantitative PCR.  
Findings 
Pharmacovigilance system 
91% (994 of 1089) of pregnant women who were piloted to assess feasibility of establishing active PV 
system completed the follow up until delivery. 98% of pregnant women reported to have taken at least 
one medication during pregnancy, mainly drugs provided in the antenatal program. Other most 
reported drugs were analgesics (24%), antibiotics (17%) and antimalarials (15%), excluding IPTp. Iron 
and folate supplementations were associated with decreased risk of miscarriage/stillbirth (OR 0.1; 0.08 – 
0.3). 
AL safety 
 82% (1783 of 2167) of pregnant women who used and not used antimalarial drugs in first trimester 
were followed until delivery and recorded their pregnancy outcome. 319 (17.9%) used antimalarial 
drugs in first trimester and AL was the most frequent antimalarial used [53.9% (172 of 319)]. Others 
were 24.4 % quinine, 20.7% SP and 3.4% amodiaquine. Quinine exposure in first trimester was 
associated with increased risk of miscarriage/stillbirth (OR 2.5; 1.3 – 5.1) and premature birth (OR 2.6; 
1.3 – 5.3). AL, SP and amodiaquine exposure were found not to be harmful.  
PK analysis 
33 pregnant women and 22 non-pregnant women with malaria were treated with AL (80/480mg) twice 
daily for 3 days. Lumefantrine (LF) bioavailability and metabolism rate into desmethyl-lumefantrine 
were respectively 34% lower and 78% higher in pregnant than in non-pregnant patients. Overall PCR 
uncorrected therapeutic failure was 18% in pregnant and 5% in non-pregnant women (OR 4.0; p value 
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0.22). A higher median day 7 LF concentration was associated with adequate clinical and parasitological 
response. 
Effectiveness of IPTp 
350 pregnant women were recruited and screened for placental parasitaemia (175 each from high and 
low malaria transmission areas). Prevalence of placenta parasitaemia was 16.6% in high transmission 
area and 2.3% in low transmission area. One or more doses of IPTp in high transmission area had 80% 
impact against placental malaria (OR 0.2; CI 0.06 – 0.7; p=0.015) and 60% in low transmission (OR 0.4; CI 
0.04 – 4.5; p=0.478).  Primigravida and residing in high transmission area were significant risk factors for 
placental malaria (OR 2.4; CI 1.1 – 5.0) and (OR 9.4; CI 3.2 – 27.7), respectively. The numbers needed to 
treat (NNT) was 4 (CI 2 – 4) women in high transmission area and 33 (CI 20 – 50) low transmission area 
to prevent one placental malaria. IPTp use was not statistically significant associated with decreased risk 
of maternal anaemia or low birth weight, regardless are of transmission intensity.    
Conclusion:  
Overall medicine use in pregnancy period is very high, including AL exposure in first trimester albeit this 
drug is not the first line treatment for malaria in early pregnancy. AL use in first trimester was safer as 
opposed to quinine, the first line drug which was associated with adverse pregnancy outcomes. We 
therefore recommend to consider other options than quinine for standard antimalarial drug in first 
trimester, and AL could be the best one.    
HDSS platforms represent a reliable and feasible support to build on a pharmacovigilance system to 
assess safety of drugs in pregnancy since it has proved to be feasible. We recommend that 
pharmaceutical companies and other global financial bodies should invest more on the establishment of 
active pharmacovigilance system in pregnancy in tropical developing countries. The latter will boost 
safety data pool of newly marketed medicines and anti-infective agents for treating different illnesses in 
pregnancy.  
LF bioavailability is significantly lowered in pregnant women due to altered PK properties as opposed to 
non-pregnant women in the same area. This may be responsible for therapeutic failure among pregnant 
women secondary to the observed low post-treatment prophylaxis. We recommend to evaluate a 
modified treatment regimen of malaria in pregnancy.  
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Muhtasari 
Utangulizi: Ugonjwa wa malaria kwa mama mjamzito ni tatizo kuu kwenye afya ya jamii hasa Africa 
kusini mwa jangwa la Sahara. Malaria ni miongoni mwa magonjwa yanayoweza kuzuilika. Ugonjwa huu  
unasababisha  mazara makubwa sana kwa mtoto mchanga tokea akiwa tumboni kwa mama yake hasa 
sehemu zenye malaria kwa kiwango cha juu. Hivyo basi ni vema mama mjamzito atibiwe na dawa 
salama na zenye uwezo mkubwa wa kuangamiza vidudu vya malaria. Usalama wa dawa kwa mama 
mjamzito ni kitu chenye changamoto kubwa kutokana na uhaba wa takwimu muhimu za usalama wa 
dawa za malaria kwa  wajawazito. Sababu kuu inatokana na mama wajawazito kutohusishwa kwenye 
majaribio ya dawa kipindi cha za mwanzoni pale ambapo dawa husika bado hazijapewa kibali cha 
kuingia sokoni kwa sababu ya kuhofia usalama wa kiafya hasa kwa mtoto aliyopo tumboni. Hilo 
linapelekea kwa dawa nyingi kuingia sokoni zikiwa na upungufu wa taarifa muhimu juu ya usalama wake 
kwa mama mjamzito. Kwa sababu hiyo, ni muhimu kuwa na mfumo wa kipekee wa kumfuatilia mama 
mjamzito pale atakapotumia dawa ambazo zipo tayari sokoni ili kuboresha taarifa za kiusalama kiafya 
kutokana na matumizi yake kipindi cha ujauzito. 
Mama mjamzito anahatari kubwa ya kuambukizwa ugonjwa wa malaria pamoja na kuuguwa kuliko 
mama ambaye hana ujauzito. Hili linatokana na mabadiliko kipindi cha ujauzito ambayo yanasababishwa 
na kupunguwa kwa kinga ya mwili na mabadiliko ya homoni mwilini mwake. Mabadiliko haya 
yanachangia pia kuathiri ufanisi wa dawa mwilini kwake kupambana na vijidudu vya malaria na hivyo 
kupunguza uwezo wa uponyaji. Usugu wa dawa dhidi ya vijidudu vya malaria, kwa mfano dawa ya SP 
huchangia pia kuathiri uwezo wa kumponya mgonjwa wa malaria. 
Dhumini kuu la utafiti huu ni (i) kujuwa wingi wa dawa anazotumia mama mjamzito ukilinganisha na 
matokeo ya mimba yake, (ii) kuonyesha uwezekano wa kuwa na mfumo pekee wa kudhibitisha matumizi 
ya dawa ambao utaweza  kufuatilia usalama na matumizi ya dawa kwa ujumla kwa mama mjamzito, 
kwenye nchi inayoendelea kwa kutumia mfumo wa HDSS (Health Demographic Surveillance System), (iii) 
kuhakiki usalama wa matumizi ya dawa mseto (ALU) ya malaria kipindi cha mimba changa, (iv) 
kutathimini unyambulisho wa dawa ya mseto mwilini mwa mgonjwa sambamba na kulinganisha ufanisi 
wake wa kuangamiza vijidudu vya malaria, na (v) kutathimini ufanisi wa dawa ya SP ambayo mama 
mjamzito anapatiwa kliniki kama inasaidia kuangamiza vijidudu vya malari kwenye kondo la uzazi, kuzuia 
upungufu wa damu kwa mama na mtoto kutozaliwa na kilo pungufu kwenye maeneo yenye viwango 
tofauti vya maambukizo ya malaria. 
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Methodolojia:  Njia tatu tofauti zilitumika kupata majibu husika ya malengo ya utafiti huu; (i) Kufuatilia 
mama wajawazito tokea kipindi cha mwanzo cha ujauzito wao hadi wanapojifungua na kurekodi taarifa 
za matumizi ya dawa (ikiwemo dawa mseto) na matokeo ya ujauzito. Zoezi hili lilifanyika kwenye vituo 
vya HDSS huko Rufiji na Kigoma mjini. (ii) Unyambulisho wa ufanisi wa dawa mseto uliwahusisha 
wanawake ambao ni wajawazito (wenye umri wa mimba kuanzia wiki 13 na kuendelea) na wale wasio 
wajawazito lakini wote wakiwa wametambulika hawana malaria kali. Walipewa dawa mseto na 
kutolewa damu kwa kipindi tofauti tofauti ndani ya siku 42 za kuwafuatilia ili kupima kiwango cha dawa 
kwenye damu na kuhakiki vijidudu vya malaria vinavyo angamia. (iii) Kuhakiki ufanisi wa SP kama kinga 
ya malaria kwa mama mjamzito (IPTp) ilihusisha kuwatambua akina mama wajawazito wakiwa kwenye 
hospitali mbili tofauti ambazo zipo kwenye maeneo yanye viwango tofauti vya uambukizaji wa malaria. 
Utambuzi wa akinamama hawa ulikuwa muda mfupi kabla hawajajifungua na ulihusisha kukusanya 
damu toka kwenye kondo la uzazi mara tu baada ya kujifungua na kupima kama kuna maambukizi ya 
vijidudu vya malaria. 
Matokea: (i) Mfumo wa ukusanyaji taarifa ya matumizi ya dawa kipindi chote cha ujauzito. Asilimia 90 
(994/1089) ya mama wajawazito waliweza kufuatiliwa mpaka walipo jifunguwa. Jumla ya 98% waliripoti 
kutumia walau aina moja ya dawa kipindi cha ujauzito, hasa zikiwa dawa zinazotolewa kwenye mpango 
maalumu wa mama na mtoto. Dawa nyingi zikiwa ni dawa za kuzuia maumivu (24%), antibayotiki (17%) 
na dawa za kutibu malaria (15%). Imeonekana dawa za kuongeza wingi wa dama zinahusiana na 
kupunguza hatari ya mimba kuharibika na mtoto kuzaliwa njiti.  
(ii) Usalama wa dawa mseto: Jumla ya mama wajawazito 1783 kati ya 2167 (82%) waliyotumia na ambao 
hawajatumia dawa za malaria kipindi cha miezi mitatu ya mwanzo ya ujauzito walifuatiliwa na kurekodi 
matokeo yao ya ujauzito wao. 319 (17.9%) walitumia dawa za malaria kipindi hicho cha mwanzo cha  
ujauzito na kati ya hawa 53.9% walitumia dawa mseto. Wengine walitumia quinine (24.4%), SP (20.7%) 
na amodiaquine (3.4%). Matumizi ya quinine kipindi cha miezi mitatu ya mwanzo ya mimba yalihusishwa 
na kuharibika kwa mimba na kuzaa mtoto njiti. Dawa ya mseto, SP na amodiaquine zilionyesha 
kutokuwa na mathara yeyote. 
(iii) Unyambulisho wa ufanisi ya dawa mseto: Utafiti huu ulihusisha wajawazito 33 na wanawake wasio 
wajawazito 22 waliyo na malaria na kutibiwa na dozi kamili ya dawa mseto mara mbili kutwa kwa siku 3. 
Sehemu ya dawa ya mseto ilionekana kuwa pungufu kwa wajawazito ukilinganisha na wale wasiyo 
wajawazito. Kwenye kipindi cha kuwafuatiliya wagonjwa (ndani ya siku 42), 18% ya wajawazito na 5% ya 
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wasiyo wajawazito waligundulika kuwa bado wana vijidudu vya malaria. Kuwa na kiwango kikubwa cha 
dawa ya mseto kwenye mzunguko wa damu ulihusishwa na kupona malaria kwa ufasaha. 
(iv) Ufanisi wa SP kama kinga ya malaria kwa mama mjamzito. Jumla ya mama wajawazito 350 
walihusiswa kwenye utafiti huu, 175 toka kila sehemu yenye malaria ya kwa kiwango cha juu na pia toka 
kwenye sehemu ya malaria kwa kiwango cha chini. Maambukizo ya malaria kwenye kondo la uzazi 
ilikuwa 16.6% kwenye eneo la malaria cha kiwango cha juu na 2.3% kwenye eneo lenye malaria kwa 
kiwango cha chini. Matumizi ya SP yalionyesha uwezekano wa kuzuia maambukizi ya kondo la uzazi hasa 
eneo lenye malaria ya juu. Kuwa na ujauzito wa kwanza na kuishi eneo lenye malaria ya juu ni kiambata 
hatarishi cha kupata maambukizo ya kondo la uzazi 
Hitimisho: Kwa ujumla matumizi ya dawa kipindi cha ujauzito yapo kwenye kiwangu cha juu, ikiwemo 
matumizi ya dawa mseto kwenye kipindi cha mimba changa, japokuwa dawa hii siyo chaguo la kwanza 
kwenye tiba ya malaria kwenye kipindi hichi. Dawa mseto imeonekana kuwa salama zaidi kuliko quinine 
hivyo ni bora kuanza kufikiria jinsi itakavyoweza kupendekezwa kwa matumizi kipindi cha mimba 
changa. 
Kupitia HDSS imeonyesha inaweza kusaidia kuwa na mfumo wa uhakika na kuaminika wa kukusanya 
taarifa muhimu za matumizi ya dawa kwa mama mjamzito kwenye nchi masikini. Hivyo ni bora 
makampuni ya dawa, wafadhili  kwa kushirikiana na taasisi za afya ndani na nje ya nchi wafikirie jinsi ya 
kufadhili mfumo huu ili kusaidia kuboresha takwimu za usalama wa dawa kwa mama wajawazito.  
Imethibitika kuwa dawa mseto inapunguwa kwa kiasi kikubwa mwilini mwa mwanamke mjamzito 
ukilinganisha na mwanamke asiyo mjamzito. Hili huenda ikapelekea mama mjamzito kutopona kwa 
ufasaa na kupungukiwa uwezekano wa kukabiliyana na maambukizo mapya ya malaria kipindi cha usoni  
hasa baada ya kumaliza dozi ya malaria. Hivyo tunapendekeza kupitiwa upya dozi ya malaria 
inayotumika sasa na mama mjamzito na  kushauri upatikanaji wa dozi mpya kwa hili kundi la wajawazito. 
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PART I: BACKGROUND 
Chapter 1: Introduction 
1.0 Burden of malaria in pregnancy 
Globally, about 125 million pregnancies are at risk of malaria every year and 32 million are in Africa [1], a 
continent which bears 90% of the world’s burden of malaria [2]. It is estimated that sub-Saharan Africa 
has as many as 10,000 malaria related deaths which occur every year in pregnant women and mainly 
secondary to maternal anaemia [3]. Other substantial direct risks of malaria in pregnancy (MIP) include 
severe maternal anaemia and puerperal sepsis, and those affecting the baby are intra-uterine growth 
retardation, intrauterine death, stillbirth, premature delivery, low birth-weight, perinatal and neonatal 
morbidity and mortality [2]. The latter suggest that malaria has severe consequences to both mother 
and fetus. Plasmodium falciparum is the predominant malaria specie in sub-Sahara and carries the 
biggest burden compared to any other malaria specie [4]. Despite of malaria being one of the most 
common and preventable cause for adverse pregnancy and birth outcomes, it continues to be a major 
public health problem in malaria endemic countries [5].  
Pregnant women have a higher risk of malaria compared to non-pregnant adults due to physiological, 
hormonal and immunological changes during pregnancy [6]. Hormonal change is explained by elevation 
of cortisol levels which is associated with increased risk of malaria in pregnant women [7]. Increased 
attractiveness of a mosquito to pregnant woman is explained by both physiological and behavioral 
changes. Increased abdominal temperature and exhaled breathing may explain why pregnant women 
are more easily detected by mosquitoes compared to non-pregnant adults. Physiological changes during 
pregnancy are the reason why pregnant women urinate twice as frequent as non-pregnant women. The 
latter exposes more pregnant women to mosquitoes bites at night when they leave their bed nets to the 
toilet [8, 9], and it is even of a greater concern in most of rural areas whereby toilets are usually located 
outside the main house building. Parasite densities have been reported to be higher in pregnant women 
than in non-pregnant adults and this may suggest that the ability to suppress parasite replication is 
impaired in pregnancy [10]. 
There are maternal factors which are associated with the risk of malaria in pregnancy and include 
maternal age, parity and gestational age. Younger women particularly adolescents are at higher malaria 
risk than older women, regardless of their gestational age or parity. Primigravidae are at higher risk than 
multigravidae and it is more obvious in high malaria transmission areas. Immunological differences 
explain the mentioned malaria risks [11, 12]. Malaria risk increases with the increase of gestational age 
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and reports shows that the risk starts to peak from second trimester. However, risk for malaria infection 
in relation to a given gestational age is still questionable because of limitations for collecting maternal 
related information in first trimester which is explained by most pregnant women tend to start 
antenatal clinic from second trimester [13]. HIV infection, one of the infections which carry the biggest 
burden in sub-Sahara Africa in terms of morbidity and mortality [14], is associated with increased risk of 
malaria in pregnancy. Regardless of the parity or gestational age, HIV infected pregnant women have a 
higher and severe risk for malaria infection than non-pregnant women [15, 16]. HIV infection suppresses 
the ability of a pregnant woman to control P falciparum infection [17]. 
1.1 Malaria pathophysiology and immunology in pregnancy 
Adults including pregnant women in high and moderate malaria transmission areas acquire immunity 
against malaria. The acquired immunity enables them to control malaria infection but not to clear it, 
regardless the immunological maternal variations which are observed in pregnancy [6]. The level of 
acquired immunity which is determined by the degree of transmission intensity to which an individual is 
residing also has an impact on malaria presentation (signs and symptoms) and pregnancy outcome [18]. 
The latter explains why pregnant women in stable transmission areas often have asymptomatic malaria 
infection, lower prevalence of peripheral parasitaemia, higher prevalence of placenta parasitaemia and 
higher prevalence of maternal anaemia as opposed to those in unstable transmission areas [18]. Hence, 
immunological variation which is challenged in pregnancy can better explain differences in malaria 
presentation patterns and its related adverse outcomes.    
Immunological change induced by pregnancy is one of the most important factors that justifies why 
pregnant women are at increased risk for malaria than non-pregnant women. Infected erythrocytes 
express a unique variant surface antigen (VSA) which mediate adhere to chondroitin sulphate A (CSA) 
receptor in the placenta endothelia and sequester in the intervillous spaces. This unique VSA rarely 
binds to the two commonly described receptors (CD36 and intercellular adhesion molecule [ICAM-1]) in 
non-pregnant individuals. Sequestration leads to obstructed blood flow and hence placenta insufficient 
which is due to inflammatory reaction to the infected erythrocytes. The reaction causes vasoconstriction 
and vascular damage which jeopardize haemodynamics of placenta [10, 19]. The expressed VSAs in 
pregnancy are different from those expressed in non-pregnant individuals and are not recognized by the 
immunity system in stable malaria transmission settings. The binding of the VSA with CSA (VAR2CSA) has 
been associated with P falciparum in pregnancy [20]. Anti-VAR2CSA specific IgGs are only found in 
women and its levels increases with parity. The latter suggest why primigradividae are more at risk for 
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malaria than multigravidae [21]. Anti-VAR2CSA are associated with favourable pregnancy outcome and 
explain why malaria risk decreases with increase of parity [20, 21]. There are cytokines to respond to 
VSA in pregnant women with malaria and include Th1, Th2, TNF, IFN gamma, interleukins and 
monocytes [6, 22, 23].  
Intrauterine growth retardation (IUGR) and preterm delivery are important cause of low birth weight 
(LBW) secondary to malaria in pregnancy. LBW due to IUGR is associated with maternal anaemia and 
elevation of cytokines levels. This is explained by the observed reduced foetal circulation and placenta 
insufficient secondary to chronic malaria infection [24]. Preterm delivery have been associated with 
acute infection and high parasitaemia which may explain the presence of fever, anaemia and elevation 
of TNF alpha and interleukin 10 [25, 26]. Figure 1.1 by Rogerson SJ et al., [10] summarizes potential 
pathological mechanisms in which malaria affects placenta function and leads to preterm delivery and 
IUGR. 
 
Figure1.1: Potential pathological mechanism associates malaria in pregnancy and low birth weight 
 
IRBC = Infected red blood cell; CSA = Chondroitin sulfate A; IUGR = Intrauterine growth retardation; PTD = preterm delivery 
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1.2 Malaria control in pregnancy 
Malaria in pregnancy should be control by effective gears because it is responsible for a wider range of 
adverse effects to pregnant woman, foetus and a newborn. World Health Organization (WHO) currently 
recommends a package of malaria control interventions during pregnancy and including use of 
insecticide-treated nets (ITNs), intermittent preventive treatment (IPT) and effective case management 
of malaria illness and anaemia [27]. 
1.2.1 Insecticide-treated nets (ITNs) 
ITNs prevent malaria by reducing physical human-vector contact through excluding mosquito vector 
from feeding on human blood and may even be killed if it lands on an insecticide treated ITN [28, 29]. 
The ITNs use in pregnancy is associated with 23% reduction of placental malaria, 33% reduction of 
miscarriage or stillbirth and 23% reduction of low birth weight prevalence, according to a systematic 
review of ITNs randomized controlled trials [30]. It is important to consider that ITNs use in pregnancy is 
now into policy in 47 sub-Saharan countries including Tanzania [31].    
1.2.2 Intermittent preventive treatment for malaria in pregnancy (IPTp) 
Using an effective antimalarial for IPTp is considered by the WHO as the most effective preventive 
approach for malaria in pregnancy in areas with stable P. falciparum transmission. Sulfadoxine-
pyrimethamine (SP) is still recommended to date as an effective and safer antimalarial for IPTp [27]. 
Recent WHO recommendations regarding IPTp-SP suggests the following: “the first IPTp-SP dose should 
be administered as early as possible during 2
nd
 trimester of gestation; each SP dose should be given at 
least 1 month apart from the other and up to the time of delivery; the last dose of IPTp-SP can be 
administered late (after 36 weeks) in the 3
rd
 trimester of gestation without safety concerns; IPTp should 
be administered as direct observed therapy (DOT); SP can be given on an empty stomach; folic acid at a 
daily dose equal or above 5 mg should not be given concomitantly with SP as this counteracts its efficacy 
as an antimalarial; and SP is contraindicated in women receiving cotrimoxazole prophylaxis” [32]. 
There is a growing concern with the increase P falciparum resistant to SP which might further jeopardize 
importance of IPTp-SP. A study in Tanzania in an area with widespread SP resistant of more than 50% 
have associated IPTp-SP with exacerbation of malaria infection, and it was also observed not to improve 
an overall pregnancy outcome [33]. However, there are strong evidence which still support the benefits 
of IPTp-SP even in areas with high SP resistance because it is reported that effectiveness of SP increases 
with the increase of IPTp-SP doses i.e. two, three or more doses [34]. This has raise awareness that 
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there is a need to find a new antimalarial which is safer and more efficacious than SP for IPTp. The drug 
should have a feasible regimen to be administered in antenatal care services as it is the case in SP.  
1.2.3 Effective case management of malaria illness 
Malaria case management is an essential component of malaria control in pregnancy and aiming at 
complete clearing of the infection. Any level of malaria parasites may have an effect on mother and 
foetus. However, effective case management should be preceded by proper diagnosis of malaria 
(including parasitological confirmation) to reduce unnecessary antimalarial exposure to the mother and 
her developing foetus [27]. Treating malaria in pregnancy is a challenging issue when comes to selection 
of an appropriate drug that would ensure safety of both mother and the foetus.  
There is limited drug safety information in pregnancy which is due to lack of evidence-based data. The 
latter is because pregnant women are not involved in clinical trials related to product development and 
hence safety information comes from animal studies or from inadvertent exposed pregnancies following 
product approval [35].  The scarcity of drug safety information in pregnancy is more serious for 
antimalarials and drugs for treating tropical diseases because these diseases occur mostly in developing 
countries where there is poor medical record system and drug exposure registry system in pregnant 
women does not exist [36]. 
When treating malaria during pregnancy, it is essential to know the gestational age of the woman to 
determine appropriate antimalarial of choice and not just rely on severity as it is the case in non-
pregnant adults. Most antimalarials are not recommended during first trimester due to safety reasons 
as it is when organogenesis mainly takes place in a developing foetus and hence makes it the most at 
risk period for teratogenicity. The safety concern in first trimester is due to insufficient safety 
information of most antimalarial drugs in this early pregnancy stage. Antimalarial which are considered 
to be safe in first trimester namely, quinine, chloroquine, clindermycin and proguanil [37]. 
WHO recommends that pregnant women with uncomplicated falciparum malaria in first trimester 
should be treated with quinine plus clindamycin for seven days or quinine monotherapy if clindamycin is 
not available. If the latter fails then artesunate plus clindamycin for seven days is indicated. ACTs are 
indicated if this is the only treatment immediately available, or if treatment with seven days quinine plus 
clindamycin fails, or if there is uncertainty about patient compliance with a seven days treatment. 
However, artemisinins are considered safe in second and third trimester and hence ACTs are the 
treatment of choice from second trimester of pregnancy [37]. 
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Clindamycin is mostly not available for treating malaria in most of sub-Saharan countries including 
Tanzania due to its high cost. Hence, quinine monotherapy is frequently being prescribed as the drug of 
choice for treating malaria in first trimester [38]. There is growing evidence from several observational 
studies to support artemisinins safety in first trimester [39, 40]. Furthermore, there is strong evidence 
showing effectiveness and tolerability of AL in pregnancy [41] which might outweigh the advantages of 
recommended quinine use for treating uncomplicated malaria in first trimester. Below are some of the 
important reasons which might suggest artemisinins compounds to be considered as first drug of choice 
in early pregnancy for treating uncomplicated malaria and not quinine:  
• Although quinine is believed to be safe in pregnancy, the three-times daily 7-day regimen is not 
ideal because of the adverse events or dosage lead to poor compliance [41, 42]. ACTs such as 
artemether-lumefantrine (AL) has a shorter regimen of two-times daily for three days with less 
to no adverse effects. 
• The taste of most ACTs is preferred compared to the bitter taste of oral quinine. This increases 
tolerability and acceptability of ACTs among the users.  
• Quinine, particularly parenteral administration, is associated with hypoglacaemia by stimulating 
insulin secretion [43].Quinine is associated with premature uterine contraction (commonly seen 
in drug overdose) and hence may lead to premature labour or abortion [44, 45]. Premature 
labour secondary to artemisinin overdose has not been reported. 
• Quinine is a monotherapy and like many other antimalarial monotherapy drugs, it is more 
susceptible to develop resistance against Plasmodium species as it is the case in South-Eastern 
Asia countries [46, 47]. Quinine should therefore be restricted for treating severe cases of 
malaria only. 
Pregnant women as an important vulnerable group for malaria infection need to be treated with an 
effective antimalarial. Unfortunately, pregnancy has a tendency of affecting the efficacy of most of the 
antimalarial drugs by reducing drug absorption, more rapid drug clearance and larger body fluid volume 
for a drug to distribute following physiological changes in pregnancy [48]. It thus, explain thesignificant 
alteration in pharmacokinetic (PK) properties of most of antimalarial drugs during pregnancy which 
leads to reduced drug blood concentrations and lower cure rates in pregnancy, especially in advanced 
pregnancy. Population PK study conducted in Thai pregnant women treated with AL reported that 40% 
of 103 women in the study had low lumefantrine capillary plasma concentration at day 7 which had 
been associated with an increased risk of therapeutic failure in non-pregnant patients [49]. Recent 
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population PK study of artesunate and dihydroartemisinin (DHA) in pregnant and non-pregnant women 
with malaria reported that pregnant women have accelerated DHA clearance compared to non-
pregnant women receiving orally administered artesunate [50]. Low drug blood concentration in 
pregnancy explains why pregnant women tend to have higher treatment failure rates compared to non-
pregnant adults living in the same area [51]. Therefore, there is a need to assess PK properties of 
antimalarial drugs during pregnancy, particularly AL and to determine its optimum dose regimen in 
pregnancy.  
1.3 Pharmacovigilance and antimalarial 
Pharmacovigilance (PV) is defined as the “science and activities relating to the detection, assessment, 
understanding and prevention of adverse effects or any other possible drug-related problem”. It aims at 
insuring client or patient receives safe medicines. There are two major systems in PV which are (i) 
passive PV or spontaneous reporting and (ii) active PV or cohort event monitoring. Passive PV means 
there is no active measures taken to look for adverse drug effects other than encouragement of health 
care professionals to report safety concerns. It is the most common method of surveillance which is easy 
to establish and cheap to run. The reporting rate is very low and subjected to strong biases. There is no 
database of all users or information on utilization of a drug and therefore is subjected to lack of accuracy 
in risk assessment. Active safety surveillance means that active measures are taken to detect adverse 
events through active follow-up after treatment and the events are detected by asking directly to the 
patients or screening patient’s records. It is sometimes very descriptive with more reliable information. 
It has minimal biases as opposed to passive PV but may be expensive to operate [52].   
Since the disaster of thalidomide teratogenicity reported in 1961, there has been a continuous system 
developmentfor detecting previously unknown or poorly understood adverse effects of medicines [53]. 
Currently, WHO program for International Drug Monitoring has been established whereby systems are 
in place in WHO member states for collecting individual case safety reports for evaluation. The reports 
are sent to national drug regulatory authories and forwarded to Uppsala Monitoring Centre (UMC) in 
Sweden, a WHO collaborating centre for international drug monitoring. Until the end of 2010, there 
were 136 countries participating in this program including Tanzania. Unfortunately, less than 27% of 
low- and middle-income countries have national pharmacovigilance systems registered with the WHO 
program compared with 96% of the high income countries [54]. It is therefore important to address 
challenges such as lack of resources, infrastructures and expertise which have been reported to be the 
obstacles for having safety drug monitoring system in developing countries [55]. 
8 
 
In Africa, the number of countries with good PV capacity has increased from 5 in 2000 to 23 by the end 
of 2010 [Figure 1.2]. The increased capacity of PV in Africa is due to different reasons to meet specific 
targets. For example, focus on HIV/AIDS, malaria and tuberculosis has influenced the growth of PV in 
African countries due to demand for greater transparency, accountability and accessibility of the 
information [54]. Several countries in this region have taken advantage of having high disease burdens 
and co-morbidities to establish the frameworks for systematic capture, evaluating and reacting to PV 
information. For example, Senegal and South Africa have tried to report PV of antimalarials in a specific 
geographical area from the established cohort studies. These studies managed to report adverse effects 
of different antimalarial in the population and were supported by their National Malaria Control 
Program [56-58]. Other studies have gone further in PV by trying to assess safety of antimalarial 
exposure in first trimester of pregnancy, particularly artemether-lumefantrine (AL). Zambia conducted 
cohort event monitoring and Senegal analyzed medical database in the health facility [40, 59]. Both of 
the two studies aim at extending marginal safety of ACTs in this vulnerable group. Antimalarial clinical 
trials have also been conducted in different sub Saharan countries with successful outcomes. All these 
justifies that sub Saharan Africa have an important role in monitoring drug safety, particularly newly 
antimalarial drugs because of the greater exposure group in this region and hence, it is important to 
enhance their capacity to carry effectively and successively PV studies at facility and national level. 
 
Figure 1.2: Growth of pharmacovigilance in Africa between 1995 and 2010 
 
The arrow in the first left map of Africa points to Tanzania in shadow 
Source: The world medicines situation 2011: WHO report [54]  
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1.3.1 Pharmacovigilance in Tanzania  
Tanzania has a national health policy which emphasize the need for raising awareness on reporting 
adverse drug reaction (ADR) at all levels of services delivery [Figure 1.3]. PV activities in Tanzania started 
way back in 1989 and the country joined WHO Program for International Drug Monitoring in 1993 and 
making Tanzania one of the earliest countries in Africa joining this program [Figure 1.2]. PV system is 
being coordinated and strengthened by the Tanzania Food and Drugs Authority (TFDA). TFDA operates 
in four zonal PV centers which are geographical distributed in the country namely, Kilimanjaro Christian 
Medical Centre (KCMC) in Kilimanjaro, Muhimbili National Hospital (MNH) in Dar es Salaam, Bugando 
Medical Centre (BMC) in Mwanza and Mbeya Medical Centre (MMC) in Mbeya. The spontaneous 
reporting system has mainly used specifically designed forms (Yellow forms) to collect adverse events 
data from patients. However, TFDA acknowledges that very few reports have been received to its office 
since the inception of the PV system in the country [60].   
Reports on ADR of antimalarial drugs have been collected and received by the TFDA. In 2009, TFDA 
analyzed antimalarial ADR reports collected from 2006 to 2008 involving two medicines i.e. AL and 
sulpha containing antimalarial agents (SP). Although the general reporting rate was very low, there were 
a total of 18 cases of ADR reported which included 12 to AL (Coartem), 2 to Metakelfin 
(Sulfamethoxazole-pyrimethamine), and 4 Fansidar(Sulfadoxine-pyrimethamine) [61]. The latter 
suggests that there may be many more antimalarial ADR which are either not captured or not reported 
to TFDA which is the biggest challenge of spontaneous reporting system. Tanzania like many other 
resources-limited setting countries has limited access to healthcare facilities, high illiteracy rates, high 
drugs prescription from informal market, poor medical record keeping, shortage of qualified health 
personnel and lack of awareness among health healthcare professional on the importance of reporting 
suspected ADR. All these are important responsible factors that limit successful implementation PV 
system in the country [62].  
ALIVE (Artemether-Lumefantrine In Vulnerable patients: Exploring health impact) project was one of the 
biggest antimalarial cohort event monitoring conducted in the country for about three years duration. 
The study was carried in rural Health Demographic Surveillance System (HDSS) area and testified that 
medicine safety monitoring and reporting is possible in settings with weak health infrastructure by 
regular and appropriate training of healthcare providers [62]. In 2009, INDEPTH Effectiveness and Safety 
Studies of Antimalarial Drugs in Africa (INESS) project started to operate in Tanzania and Ghana. An 
important goal of the project was to enable African researchers to carry out phase IV malaria drug 
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studies. This project contributed substantially on national and global safety information of ACT use. 
Therefore, these are all potential opportunities and possibilities to reinforce PV systems in Tanzania with 
great focus in vulnerable groups, especially in pregnant women who are always excluded in clinical trials 
involving unlicensed products.      
 
Figure 1.3: Flow chart of adverse drug reaction information in Tanzania 
 
RHMT = Regional Health Management Team; CHMT = Council Health Management Team 
Source: National Guideline for Monitoring Medicine Safety – TFDA: Ministry of Health [60]  
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Chapter 2: Rationale 
Malaria treatment in pregnancy has special challenges related to safety and efficacy issues which do not 
commonly present in non-pregnant individuals. This might be explained by limited drug safety and 
efficacy information in pregnancy because pregnant women are always excluded in clinical trials. In 
most cases, drugs are commercialized with little knowledge available regarding their safety in pregnancy 
which makes evidence based risk-benefit decision another important issue in this vulnerable group.  
There is a growing concern of increased levels of drug use in most sub Saharan countries where over the 
counter prescription is commonly practiced. Most of these drugs are poorly regulated and become a big 
problem when contraindicated drugs are administered to a pregnant women or women of child bearing 
age. For this reason, it is important to know the actual prevalence, type and safety of drug use in 
pregnancy since there is no active mechanism of monitoring pregnancy exposure in relation to 
pregnancy outcome in almost all developing countries. This is the objective of chapter five where the 
magnitude of drug used during pregnancy is assessed and the feasibility to establish active PV system for 
monitoring drug exposure among pregnant women in resource-limited setting is described, piloting 
HDSS platform as a potential model.  
Although ACTs are not being recommended in first trimester because of associated embryo-foetal 
toxicity in animals, there are at least 600 reported exposures to artemisinins in pregnant women during 
first trimester with no reported maternal or birth adverse outcomes. The number of women exposed to 
artemisinins in first trimester in published safety studies is not sufficient enough to reassure about their 
safety. The current unprecedented ACT roll-out at an affordable price makes inadvertent exposure to 
ACT, particularly AL, inevitable in early pregnancy. Furthermore, most women use antimalarials without 
knowing that they are pregnant. Acquiring medicines from drug venders without formal physician 
consultation and screening for illnesses is indeed a common practice in most African countries. It is 
therefore important to take advantage of the above experiences to increase the safety data pool 
information of ACTs in first trimester. In chapter six, the magnitude of inadvertent AL exposure in first 
trimester is evaluated in comparison to other groups of antimalarial drugs, including quinine which is 
the only antimalarial drug regarded to be safe in first trimester. Safety of AL and other groups of 
antimalarial exposure in first trimester are also described in relation to pregnancy outcomes. 
Efficacy of antimalarial in pregnancy is challenged by the altered physiological changes which occur after 
a woman had conceived. These changes have been associated with altered PK properties of medicines, 
including antimalarial and hence, affect the therapeutic outcome. The latter have raised questions of 
12 
 
whether there is a need to adopt a new AL regimen for treating malaria in pregnancy. Chapter seven 
described PK of AL used to treat pregnant and non-pregnant women with uncomplicated P falciparum 
malaria. The evaluated drug levels in the two study groups are compared with therapeutic outcome.   
Malaria in pregnancy is known to have deleterious consequences on the placenta, which leads to 
multiple adverse maternal and newborns outcomes. IPTp-SP has universally been implemented in 
malaria endemic countries so as to overcome this burden. However, the effectiveness of IPTp regimen is 
jeopardized by SP resistance and its advantage is not well documented in areas with low malaria 
transmission. This is evaluated in chapter eight based on findings from two areas with different 
transmission intensity.   
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PART II: OBJECTIVES AND METHODOLOGY 
Chapter 3: Goal and objectives 
Goals 
To upsurge safety and efficacy information of antimalarial drugs used in pregnancy 
General objective 
To determine the safety, efficacy and pharmacokinetic profile of antimalarial drugs used for treating and 
preventing malaria in pregnancy 
Specific objectives 
i. To assess the magnitude of medicines exposure during pregnancy in relation to pregnancy 
outcome [Chapter 5] 
ii. To described the feasibility of establishing active pharmacovigilance registry system in 
developing country using Health Demographic Surveillance System (HDSS) platform [Chapter 5] 
iii. To determine the safety of artemether-lumefantrine exposure in first trimester of pregnancy 
[Chapter 6] 
iv. To evaluate pharmacokinetics and pharmacodynamics properties of artemether-lumefantrine in 
pregnant and non-pregnant women [Chapter 7] 
v. To determine risk factors associated with placental malaria, maternal anaemia and low birth 
weight in areas with different malaria transmission intensity [Chapter 8] 
vi. To determine the effectiveness of IPTp-SP in preventing placental malaria, maternal anaemia 
and low birth weight in areas with different malaria transmission intensity [Chapter 8] 
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CHAPTER 4: Methods 
4.1 Thesis structure 
The thesis highlights the measures for malaria control in pregnancy in two main areas: (i) ensuring 
effective case management and (ii) preventing deleterious consequences of malaria on maternal and 
baby outcomes with intermittent preventive treatment.  
Data used in this thesis came from two main research projects. The first project with the title ‘safety, 
efficacy and PK profile of antimalarial drugs in pregnancy’ was carried in Rufiji and Kigoma urban district 
in Tanzania mainland. The project started in April 2012 and enrolled prospectively pregnant women who 
did use and not use antimalarial in first trimester, with active follow-up until delivery. The project is still 
ongoing collecting developmental milestone information of the newborns delivered by the enrolled 
study women. The newborn follow up until the age of 12 months is expected to be completed by the 
end of October 2014 and will be an adjunct to this thesis. AL PK bioassays were part of an ancillary study 
conducted in Rufiji involving two groups, pregnant women and non-pregnant women as a comparative 
group. The second project titled ‘effectiveness of IPTp against placental malaria’ was conducted in two 
areas which have different malaria transmission intensity (Moshi urban with low transmission and Rufiji 
rural with moderate to high transmission), beginning in July 2012 and ended up in September 2012. 
When the latter study was conducted, the suggested recommendations of monthly IPTp-SP regimen 
from early second trimester [32] was not implemented. Figure 4.1 and 4.2 shows study area and malaria 
transmission intensity in Tanzania. 
4.2 Study design and population  
4.2.1 Monitoring of antimalarial safety in pregnancy 
Antimalarial safety was assessed in pregnant women having gestational age below 20 weeks, between 
April 2012 and March 2013. The study was conducted in two areas (i) Rufiji HDSS in Rufiji district and (ii) 
Kigoma HDSS in Kigoma urban district. Women were followed until delivery to determine pregnancy 
outcome. Following newborns until the age of 12 months is still ongoing. The primary target of the study 
was to assess safety of different antimalarial exposure in first trimester in relation to pregnancy and 
baby outcomes. Ancillary study was also conducted in Rufiji to evaluate the feasibility of establishing PV 
system in resource-limited setting by piloting a pregnancy exposure registry in Rufiji HDSS as an 
example. Drug exposure history was gathered by interviewing pregnant women under surveillance and 
the given information was verified by reviewing medical registries, patient’s RCH cards and personal 
patient’s medical log. All women were followed up on monthly basis at Reproductive and Child Health 
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(RCH) clinic and at home through house visits. Delivered babies were carefully screened for any physical 
presence of congenital anomalies. Assessment details are presented in chapter five and six. Primary 
endpoints included pregnancy outcome (miscarriage, stillbirth or live birth) and baby outcome (birth 
weight and maturity status).     
4.2.2 Population pharmacokinetics and pharmacodynamics of artemether-lumefantrine 
PK and PD were assessed in pregnant and non-pregnant malaria patients recruited in Kibiti Health 
Centre within Rufiji HDSS between April and September 2012. Main inclusion criteria included adults 
above 18 years, all females patients diagnosed to have uncomplicated P falciparum, second and third 
trimester for pregnant women and no history of chronic illness. Enrolled patients received four tablets 
of AL (Coartem® Novartis Pharma AG, Basel; 20 mg AM and 120 mg LF) for 3 days at 0, 8, 24, 36, 48 and 
60 hour under direct observation. To determine AL plasma levels and their metabolites, 2 ml of venous 
blood sample was drawn from the patient for bioassay at random times between 8 and 11 am on day 0, 
1, 2, 3 and 7. To estimate the parasite density and clearance rate, capillary blood from a finger prick was 
taken at day 0, 3, 7, 14, 28 and 42 for microscopic screening and DNA genotyping. In chapter seven, PK 
and therapeutic outcome evaluation are described in detail. 
4.2.3 Effectiveness of IPTp on placental malaria and pregnancy-associated malaria morbidity 
Prevalence of placental malaria and associated malaria morbidities in pregnancy were assessed in two 
areas with different malaria transmission intensities i.e Moshi urban having low transmission and Rufiji 
having high to moderate transmission intensity. The study used a prospective design with enrolment of 
pregnant women who came for delivery in these facilities, between July and October 2012. Important 
obstetrics history was recorded including episodes of malarial illness and use of SP for IPTp during the 
current pregnancy. Information recorded was verified and supplemented by reviewing patient’s medical 
registries and RCH card. Placental blood sample was collected on a blood slide and onto filter paper 
within one hour post-delivery. Collected samples were screened for presence of malaria parasite using 
light microscope and real-time quantitative Polymerase Chain Reaction (PCR). Parameters assessed 
included placental malaria, maternal age, parity, maternal anaemia, residency, history of malaria illness 
in pregnancy, ITN use, haematemics use, deworming and birth outcome (live birth or stillbirth). Details 
of this evaluation are provided in chapter 8. 
4.2 Statistical methods 
The study findings are mainly analytical, describing odds ratio and confidence interval of the associated 
adverse pregnancy outcome in relation to drug exposure. Magnitudes of various parameters of 
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therapeutic outcomes are presented in percentage, mean and median. STATA® 12.0 (Stata Corporation, 
College Station, Texas, USA) was used for data analysis. For PK study, Inter- and intra-individual 
variability was assessed and covariates effects quantified using a nonlinear mixed-effect modeling 
approach (NONMEM®). Details of specific statistical analytical methods applied in the thesis are 
presented in their respective chapters (chapter 5, 6, 7 and 8). 
4.3 Ethical consideration 
The studies were performed according to the WHO guidelines for (i) assessing exposure to antimalarial 
drugs in clinical field studies, and (ii) methods for surveillance of antimalarial drug efficacy [63, 64]. The 
study protocol was approved by the review board of Swiss TPH, the Ifakara Health Institute (IHI) ethical 
internal review board and ethical committee of National Institute of Medical Research (NIMR) in 
Tanzania. IPTp protocol was approved by Kilimanjaro Christian Medical University College (KCMUCo) 
research ethics committee which is recognized by NIMR. All participants signed voluntarily an informed 
consent prior to enrolment after reading and explained the procedures of the study.   
 
Figure 4.1: Map of Tanzania showing the study sites 
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Figure 4.2: Map of Tanzania showing malaria transmission intensity in different areas of the country 
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Abstract 
Background: There is limited safety information on most drugs used during pregnancy. This is especially 
true for medication against tropical diseases because pharmacovigilance systems are not much 
developed in these settings. The aim of the present study was to assess medication exposure during 
pregnancy, and its relation to pregnancy outcome using a Health Demographic Surveillance System 
(HDSS) platform. 
Methods: Pregnant women with gestational age below 20 weeks were recruited from Reproductive and 
Child Health (RCH) clinics or from monthly house visits carried out for the HDSS. A structured 
questionnaire was used to interview pregnant women. Participants were followed on monthly basis to 
record any new drug used as well as pregnancy outcome. 
Results: 1089 pregnant women were recruited; 994 (91.3%) completed the follow-up until delivery. 98% 
women reported to have taken at least one medication during pregnancy, mainly those used in 
antenatal programmes. Other most reported drugs were analgesics (24%), antibiotics (17%), and 
antimalarial (15%), excluding IPTp. Artemether- lumefantrine (AL) was the most used antimalarial for 
treating illness by nearly 3/4 compared to other groups of malaria drugs. Overall, antimalarial and 
antibiotic exposures in pregnancy were not significantly associated with adverse pregnancy outcome.  
Iron and folic acid supplementations were associated with decreased risk of miscarriage/stillbirth (OR 
0.1; 0.08 – 0.3). 
Conclusion: Almost all women were exposed to medication during pregnancy. Exposure to iron and folic 
acid had a beneficial effect on pregnancy outcome. HDSS proved to be a useful platform to establish a 
reliable pharmacovigilance system in resource-limited countries. Widening drug safety information is 
essential to facilitate evidence based risk-benefit decision making for treatment during pregnancy, a 
major challenge with newly marketed medicines. 
 
 
 
Keywords: Medication, Pregnancy, Pharmacovigilance  
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Background  
Access to different therapeutic drugs such as antibiotics, antimalarial and antiretroviral (ARVs) have 
improved in recent years in most African countries, including Tanzania, thanks to the efforts facilitated 
by government, private sector and donor agencies [65, 66]. Safety of some of these therapies is 
unknown during pregnancy because pregnant women are not involved in clinical trials during the drug 
development process and hence, most pharmaceutical products come to market with little human data 
available regarding safety in pregnancy. Studies from animal models have been used to provide safety 
information during pregnancy at the time the new drug is approved. However, such findings are not 
easily translated into human risk. In most cases, information regarding safety of product or drug use 
during pregnancy is collected post product approval [35, 67]. Sufficient and valid data on safety of drug 
use during pregnancy is of high public health importance so as to facilitate evidence based risk-benefit 
decision making among health providers. 
Drug exposure during pregnancy in Western Europe and US is reported to have increased in the past 10 
years [68, 69]. In most developing countries, where proper drug monitoring system during pregnancy 
does not exist, it is difficult to know the magnitude of drug exposure in pregnancy. There are few studies 
in sub-Saharan Africa which have attempted to assess prevalence of drug use in pregnancy and its 
relation to pregnancy outcome. A study in Mozambique reported that antibiotics agents were the most 
common drugs used (41%), followed by antimalarial drugs (24%); Drug exposure in general was 
associated with a two fold increase risk of stillbirth [36].  
First trimester of pregnancy is the most harmful period for teratogenic exposure because it is when 
organogenesis takes place albeit, some teratogens may have effect in later stage of pregnancy and may 
even cause miscarriage [70, 71]. Common medicines such as tetracycline, metronidazole, albendazole, 
mebendazole, efavirenz (EFV), sulphadoxine-pyrimethamine (SP) and artemisinin-based combination 
therapy (ACT) are some of therapeutic drugs which are not recommended during first trimester due to 
fear of embryo-toxicity [37, 72]. All these reported teratogenic drugs and many other which are known, 
or not yet confirmed, to have deleterious effects on the foetus are still used by women of childbearing 
age and pregnant women to treat different illnesses [73]. Thus, there are insufficient safety studies in 
pregnancy on most drugs used for the treatment of tropical diseases [74].  
Demographic Surveillance System (DSS) is an ideal platform to establish pharmacovigilance system in 
pregnancy. People in DSS area are routinely being followed to update their information in the database. 
It is therefore easy to identify early enough vital events such as pregnancy, birth and death. A link 
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between the DSS members and health care at the nearby facility can be established with facilitated 
follow-up of pregnant women. The present study aimed at assessing the levels of medication exposure 
during pregnancy and its relation to pregnancy outcome. It made use of the Health Demographic 
Surveillance System (HDSS) which was already in place in a rural district, Eastern Tanzania. 
Materials and methods 
Study site and HDSS platform 
The study was conducted using the platform of the Rufiji Health Demographic Surveillance System 
(HDSS) which is located in Coastal region, Eastern Tanzania. The area has hot weather throughout the 
year and two rainy seasons. The asexual parasitaemia prevalence is 14%, and Plasmodium falciparum is 
the predominant species [75]. Rufiji HDSS monitors a population of about 97,000; they are all recorded 
in the database with their social and health characteristics. Data from all 13 health facilities within DSS 
catchment area are also routinely being collected. These health facilities have Reproductive and Child 
Health (RCH) clinic services. A prevalence of 74% of pregnant women deliver in the health facilities. 
Fertility rate is 4.8 and the maternal mortality ratio is 70 per 100,000 live births [76]. Details of the study 
area and population have been described elsewhere [77]. 
Study design and population 
This was an observational prospective study conducted between April 2012 and March 2013. Pregnant 
women with a gestational age below 20 weeks and residing in the HDSS area were enrolled in the study 
and followed until delivery. Participants were recruited from both RCH clinic and in the community 
through monthly house visits. The set-up of HDSS facilitated early identification and recruitment of 
eligible pregnant women. All participants were followed up on a monthly basis until delivery. A 
structured questionnaire was used to interview for socio-demographic information, obstetrics and 
medical history. Physical examination, blood screening test for HIV, syphilis and haemoglobin were 
performed in the health facility. Patient’s information from RCH card or medical registry was also used 
for addition information and for clarifying issues.  
Participants were interviewed for any drug which was taken prior to the enrolment but during the 
current pregnancy. On the day of enrolment, all women were given a small exercise book as patient’s 
medical record log. The latter was used whenever the woman went to health facility for treatment or to 
drug vender to fetch medication. Hence, all clinical information including drug used was filled in this 
personal medical record book. During each monthly follow-up visit, participants were asked for any new 
drug used, and in all cases evidence for the new used medication was verified from prescription sheet, 
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RCH card, hospital record or personal medical record log. Pregnancy risk of a drug exposure during 
pregnancy period was categorized in accordance to US Food and Drug Administration (FDA) [78].  
Pregnancy information was recorded including birth outcomes (miscarriage, stillbirth or live birth), 
mother’s complications at delivery, number of babies born, birth weight, gestational age at delivery 
(calculated from the last date of normal menstrual period), and any congenital abnormalities. For the 
case of home delivery, woman was advised to take the baby to the hospital within seven days post-
delivery for proper examination. 
Sample size 
The sample size was pre-determined by the size of HDSS and the logistically feasible time frame of one 
year. The number of women in their early pregnancy which could be enrolled was estimated before (as 
1000) to be sufficient for pilot implementation of pharmacovigilance system in pregnancy but no formal 
sample size calculation was performed. To comply with the reviewer’s suggestion we consulted our 
senior statistician to guide us on the power calculation. However, he advised us not to perform a post-
hoc power calculation. Calculations which make use of parameter estimates provided by the data 
invariably inflate the actual power, in fact post hoc power is a one-to-one function of the P-value 
obtained [79, 80]. 
Primary endpoints   
The primary endpoint of the study was pregnancy outcome. Pregnancy outcome included miscarriage, 
stillbirth or live birth, birth weight and prematurity status at birth. Miscarriage was defined as loss of an 
embryo or foetus before the 28
th
 week of pregnancy. Stillbirth was defined as a baby born with no signs 
of life at or after 28 weeks of gestation. Low birth weight was defined as a birth weight below 2500 g, 
and premature was defined as birth before 37 weeks of gestational age.  
Statistical analysis  
STATA® 12.0 (Stata Corporation, College Station, Texas, USA) was used for data analysis. Numerical 
variables were summarized into median and range. Categorical variables were summarized using cross 
tabulation to estimate different proportion. Effects of demographic and pregnancy characteristics on 
primary endpoint of the study were assessed by bivariable analysis. Logistic regression models were 
used to estimate the crude odds ratio (OR) for the association between binary pregnancy outcomes 
(birth outcome, birth weight and birth maturity status) and medicines exposure.  The multivariable 
adjusted logistic regression model included maternal age and parity as potential confounding variables. 
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Both were found to be associated with the study endpoints (P < 0.2). Two sided Wald test P-values are 
presented. 
Ethics 
Ethical approval for the study was granted by Ifakara Health Institute (IHI) ethical review board and 
National Institute for Medical Research (NIMR) ethical committee. Written informed consent was 
obtained from all participants. 
Results 
A total of 1089 pregnant women were enrolled into the study and 994 (91.3%) completed the follow-up. 
The latter constitutes the analysis population. 660 (66.4%) were recruited from the health facility during 
their routine RCH visits and 334 (33.6%) from the community through house visit. Overall, 323 (32.5%) 
women were recruited in first trimester of pregnancy with a mean gestational age of 10.4 [standard 
deviation (SD) 2.3] and 671 (67.5%) in first half of second trimester of pregnancy with mean gestational 
age of 16.9 (SD 1.7). Important demographic and clinical characteristics are shown in table 5.1.  
Episodes of reported illnesses during pregnancy 
Out of all 297 (29.9 %) of the enrolled pregnant women reported to have at least one episode of illness 
during pregnancy. Six diseases were reported: malaria 14.9% (148), urinary tract infection (UTI) 9.2% 
(91), sexually transmitted infections (STIs) 3.2% (32), upper respiratory tract infection (URTI) 1.5% (15), 
diarrhoea 1% (10) and chickenpox 0.1% (1). 
Drugs exposure during pregnancy 
15 (1.5%) of all study participants reported not to have used any drug during the pregnancy period. 974 
(98%) used any of the three drug groups that are recommended by the Ministry of Health [81] for 
antenatal intervention, all of which used during second and third trimester of pregnancy. 931 (93.7) 
used vitamins and mineral supplements. 929 (93.5%) used anthelmintic (mebendazole). 946 (95.2%) 
used at least one dose of sulfadoxine-pyrimethamine (SP) for intermittent preventive treatment of 
malaria (IPTp) [735 (73.9%) two doses and 211 (21.2%) one dose] [see tables 5.2a&b].  
For anti-infective drugs used because of illnesses, 170 (17.1%) women used antibiotics, 148 (14.9%) 
antimalarial drugs, 59 (5.9%) antifungals and 29 (2.9%) antiretrovirals. Some women used more than 
one type of either of the mentioned anti-infective drugs during their pregnancy period. Table 5.2a and 
5.2b summarize drugs exposures during pregnancy among study women.  
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Based on United State Food and Drug Administration (US FDA) risk categorization of drugs in pregnancy, 
the most common drugs used under category ‘A’ were ferrous sulfate and folic acid, category ‘B’ 
paracetamol, amoxicillin, erythromycin, metronidazole, benzathine benzylpenicillin and ceftriaxone, 
category ‘C’ antimalarial for treating illness (AL, quinine, SP), antiretroviral (ARV) for HIV infection 
(zidovudine, lamivudine and nevirapine), doxycycline, cotrimoxazole, aspirin, diclophenac, hyoscine 
butylbromide and promethazine, category ‘D’ traditional medicines and phenobarbitone, and no 
category ‘X’.  
Pregnancy outcome 
Out of 994, 897 (90.2%) women delivered in health facilities, 94 (9.5%) at home, and 3 (0.3%) along the 
road side on their way to the health facility. There were three maternal deaths which all occur within 24 
hours post-delivery, two of them due to post-partum haemorrhage and one secondary to eclampsia. 
Pregnancy outcomes included 28 (2.8%) abortions, 41 (4.1%) stillbirth and 925 (93.1%) live births. 
Regarding birth outcomes, 99 (10.0%) were premature and 55 (5.0%) babies had low birth weight. 12 
(1.2%) of the newborns were identified as having congenital anomalies at the time of birth: 8 were 
polydactyl and the remaining 4 had clubfoot, spinal bifida, genital defect or cardiac defect. Two women 
with a newborn having polydactyl each were exposed to ARV and antitussive (coughing syrup), 
respectively and both drugs are under US FDA risk category ‘C’. One woman with a newborn having 
spinal bifida was exposed to phenobarbitone in third trimester, the drug which is in US FDA risk category 
‘D’. The remaining women with congenital anomalies babies were not exposed to neither US FDA 
category ‘C’ nor category ‘D’ drugs. 
Relation of medication exposure to pregnancy outcome 
Maternal age and parity were assessed to determine their effect on pregnancy outcome (as potential 
confounders of drug effect). Maternal age had no significant effect on birth weight (0R 1.0; p value 
0.356) but was associated with 3% increased risk of premature birth (OR 1.03; p value 0.038) and 4% 
increased risk of miscarriage/stillbirth (OR 1.04; p value 0.020). Parity had no significant effect on 
miscarriage/stillbirth (OR 1.1; p value 0.690) but was associated with a 60% increase risk of preterm 
birth (OR 1.6; p value 0.065) and 60% decreased risk of low birth weight (OR 0.6; p value 0.116).  
Antimalarial exposure during pregnancy was not significantly associated with an increased risk of 
miscarriage/stillbirth (adjusted OR 1.3; 95%CI 0.7 -2.4; p=0.494), low birth weight (adjusted OR 0.7; 
95CI% 0.3 – 1.8; p=0.460) or premature birth (adjusted OR 1.2; 95%CI 0.6 – 2.7; p=0.629). Antibiotics 
exposure was neither associated with an increased risk of miscarriage/stillbirth (adjusted OR 0.8; 95%CI 
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0.4 – 1.6; p=0.526), low birth weight (adjusted OR 0.6; 95%CI 0.2 – 1.6; p=0.295) or premature birth 
(adjusted OR 1.4; 95%CI 0.7 – 2.8; p=0.348) [Table 5.3].  
Exposure to drugs under US FDA pregnancy risk category ‘A’, which mainly included ferrous sulfate and 
folic acid were associated with a reduced risk of miscarriage/stillbirth (adjusted OR 0.1; 95%CI 0.08 – 
0.3; p< 0.001). There was no significant association of adverse pregnancy outcome in relation to 
exposure to drugs under category ‘B’, ‘C’ and ‘D’ [Table 5.4].  
Discussion 
The present study shows that there is a considerable amount and several types of drugs exposure during 
pregnancy in this region, as it may apply to other parts of Tanzania and sub Saharan countries. To our 
knowledge, it is the first prospective study conducted in a resource-limited setting that attempted to 
demonstrate the feasibility of establishing a reliable pregnancy exposure registry which followed a large 
group of pregnant women from their early pregnancy stage [59, 82]. All drugs exposure and related 
diseases during pregnancy period were carefully identified and recorded. 
More than 98% of study women reported to have used at least one medication during pregnancy. This is 
more than twice to what was observed in Mozambique in a study conducted seven years ago [36]. Most 
of the drugs used were the ones covered under antenatal intervention program. The coverage of 
anthelmintic, haematemic and SP for IPTp in our study was almost twice that estimated at national level 
[83]. This high use of drugs may be the result of intense health promotion activities in the area under 
HDSS, in close collaboration with local and government authorities. A 94% coverage for iron and folic 
acid supplementations in this rural area is a remarkable achievement.  
Apart from haematemic, anthelminthic and IPTp-SP exposure, analgesics were the most reported 
prescribed drugs. This observation is in agreement with two previous studies in sub-Saharan Africa [36, 
84].  
Malaria was the most often recorded illness during pregnancy (15%). This illustrates the high intensity of 
transmission in the study area (14) and the vulnerability of pregnant women to malaria [6]. It highlights 
the importance of having safe and effective drugs to clear parasites during pregnancy. AL was prescribed 
nearly 3 times more often than quinine. Some of these treatments correspond to inadvertent exposure, 
similarly to what has been observed in Sudan and Zambia [39, 40]. Others represent treatment that 
were probably administered during second and third trimester, as recommended [37]. A better 
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availability of AL when compared to quinine in health facilities and drug shops [66] may have also 
contributed to the frequent use of this drug.  
When taken as a category and irrespective of the timing during pregnancy, antimalarial and antibiotic 
exposures were not associated with adverse pregnancy outcome. This result should be interpreted with 
caution since different types of medications, or the same medication but given at different time during 
pregnancy, may have different effects. A more detailed assessment of antimalarial exposure, taking into 
account the type and time of exposure during pregnancy will be reported elsewhere, including a larger 
sample size of pregnant women from another HDSS area. The present paper was more to pilot the 
feasibility of a pharmacovigilance system embedded in a HDSS in a developing country. 
Iron and folic acid supplementation, the main drugs under US FDA pregnancy risk category ‘A’ were 
protective against miscarriage/stillbirth. However, adherence to these supplements and number of 
doses prescribed were not assessed. There was not much evidence yet to support the added benefits of 
these supplements in preventing miscarriage or stillbirth. Evidence mainly supports the use of these 
drugs to prevent anaemia and iron deficiency at term, to reduce the risk of low birth weight and early 
neonatal death, all factors that have shown to have a beneficial impact on child’s survival [85-87]. The 
observed beneficial effects of recommended iron and folic acid supplementation in pregnancy validate 
the concept of pharmacovigilance system through HDSS.  
About 3% of study women used traditional medicines which in most cases are under pregnancy risk 
category ‘D’. The use of traditional medicines may have been higher than what is reported in the 
present study since participants were interviewed by health care providers who are trained to 
discourage patients to use herbs. Underreporting is a well-known phenomenon in other developing 
countries whereby study participants had difficult to disclose this to health care professionals [36, 88]. 
The observed prevalence of 1.2% congenital anomalies in the study is lower compared to the 3.0% 
global prevalence estimated by the WHO [89]. There is no national register to compare our rate with 
that in other parts of the country. However, there are possibilities of more anomalies to be identified 
later in life as the child grows. Hence, it would be important to follow all delivered babies prospectively 
at defined intervals, at least until the age of one year. Such a monitoring can be easily implemented in 
HDSS settings. In addition, it is also important to consider improving newborn’s screening standards, 
training of health staff and detailed birth registry records to implement a reliable pregnancy 
pharmacovigilance system [82]. 
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The present study demonstrates a way forward to establish a feasible, reliable and manageable active 
pharmacovigilance system in a resource-limited setting by taking advantage of existing monitoring 
platforms such as HDSS. Feasibility of the present proposed pharmacovigilance system is of merit over 
the probabilistic record linkage for monitoring antimalarial safety evaluated in Senegal [59] which is 
subjected to bias because of poor medical record system in most health facilities in developing countries 
and hence, some exposure cases and pregnancy outcome information may easily be missed. The drug 
exposure pregnancy registry proposed by Mehta U et al., [82] appears to be promising but its 
operational costs may be very high in most resource-limited countries where presence of skilled medical 
personnel is still a big problem. 
Pharmacovigilance systems should reduce the uncertainty about safety of newly marketed medication 
against tropical diseases. Such a system that collects systematically and reliably data to determine 
whether a given medication is teratogenic or not through monitoring of a large exposure group could 
provide strong evidence on safety [73, 82]. It could help to overcome the current shortfall which is 
commonly seen in medical practice when treating a pregnant woman with medication that has 
suboptimal efficacy because of potential safety problems. Also, it could assist in the assessment of 
medicines that are not recommended during pregnancy, but are sometimes not avoidable to save the 
mother or the unborn child. 
Conclusion 
Almost all women are exposed to medication during pregnancy, either because drugs are recommended 
during this period, or because women are sick and need treatment. Since exposure to contraindicated 
drugs during pregnancy is sometimes inevitable in either trimester, safety monitoring mechanism should 
be in place in order to generate reliable information for the promotion of safe and effective treatment 
during pregnancy. HDSS sites can have a useful role in providing reliable pharmacovigilance data and the 
experience from its success will be helpful to expand the system to none HDSS areas. 
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Tables 
 
Table 5.1: Demographic and clinical characteristics of study women at the time of enrollment (n = 994) 
Characteristics First trimester 
n = 323  
Second trimester 
n = 671 
Total 
n = 994 
Mean age, (years)* 26.4 (7.3; 14-49) 26.8 (7.0; 14-46) 26.6 (7.0; 14-49) 
Mean BMI* 23.1 (3.8; 14.2-39.6) 23.4 (3.4; 14.0-42.5) 23.3 (3.6; 14.0-42.5) 
Mean gestational age, (weeks)* 10.0 (2.2; 3-12) 16.6 (1.9; 13-20) 14.8 (3.6; 3-20) 
Gravidity
#
    
          Primigravidae 82 (25.4) 198 (29.5) 280 (28.2) 
          Secundigravidae 62 (19.2) 113 (16.8) 175 (17.6) 
          3 – 4 pregnancies 99 (30.7) 192 (28.6) 291 (29.3) 
          ≥ 5 pregnancies 80 (24.8) 168 (25.1) 248 (24.9) 
Recruited sites
#
    
          Health facility 193 (59.8) 467 (69.6) 660 (66.4) 
          Home 130 (40.2) 204 (30.4) 334 (33.6) 
Drinking alcohol
# 
 3 (0.9) 3 (0.4) 6 (0.6) 
Smoking cigarette#  2 (0.6) 0 (0) 2 (0.2) 
Mean haemoglobin level, (g/dl)* 7.8 (4.7; 6.0-12.7) 7.5 (4.6; 5.2-14.3) 7.7 (4.6; 5.2-14.3) 
HIV status
#
    
          Negative 284 (88.0) 603 (89.9) 887 (89.2) 
          Positive 12 (3.7) 35 (5.2) 47 (4.7) 
          No results 27 (8.3) 33 (4.9) 60 (6.0) 
Syphilis test
#
    
          Negative 288 (89.2) 628 (93.6) 916 (92.2) 
          Positive 9 (2.8) 12 (1.8) 21 (2.1) 
          No results 26 (8.0) 31 (4.6) 57 (5.7) 
*represents data presented in mean, (standard deviation [SD]; range)  
#
represents data presented in number (%) 
Abbreviation: BMI = Body Mass Index  
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Table 5.2a: Classes of drugs reported to be used by the pregnant women 
Class of drugs Number of women exposed (%) 
Vitamins and minerals 931 (93.7) 
Anthelmintics
α 
 929 (93.5) 
Analgesics 237 (23.8) 
Antibiotics
 
 170 (17.1) 
Antimalarials
 α
 *
 
 148 (14.9) 
Antifungals 59 (5.9) 
Antiretroviral 29 (2.9) 
Traditional medicine 27 (2.7) 
Antihistamines 15 (1.5) 
Antitussive 8 (0.8) 
Antihypertensives 6 (0.6) 
Antiasthmatics 5 (0.5) 
Pregnancy risk Categories#  
A 931 (93.6) 
B 253 (25.5) 
C 233 (23.4) 
D 46 (4.6) 
X 0 (0.0) 
α 
See table 5.2b for further details 
*Excluding SP for IPTp 
#
 Based on US FDA pregnancy risk categorization 
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Table 5.2b: RCH provided drugs and antimalarials exposure in pregnant women (n = 994) 
Drug group n (%) 
SP for IPTp  
          Single dose 211 (21.2) 
          Two doses 735 (73.9) 
          Not at all 48 (4.8) 
Anthelminthic  (Mebendazole)  
          Yes 929 (93.5) 
          No 65 (6.5) 
Iron and Folic acid supplementation  
          Yes 93 (93.7) 
          No 63 (6.3) 
Patients treated for malaria at least once*  
          Yes 148 (14.9) 
          No 846 (85.1) 
Types of antimalarials used in treating malaria  
          AL only 94 (9.5) 
          Quinine only 28 (2.8) 
          SP only 11 (1.1) 
          AL and Quinine 11 (1.1) 
          AL and SP 4 (0.4) 
*Some women were treated for malaria more than one time during pregnancy period 
Abbreviation: SP = Sulfadoxine-pyrimethamine; IPPTp = Intermittent Preventive Treatment for malaria in pregnancy;  
AL = Artemether-lumefantrine  
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Table 5.3: Antimalarial and antibiotics exposure in relation to pregnancy outcome (n = 994) 
Variables Outcomes Crude OR 
(95% CI) 
P
 µ
     Adjusted OR
α 
(95% CI) 
P
 µ
 
Birth outcome MC/SB 
n (%) 
Live birth 
n (%) 
 
 
Antimalarial exposure*      
          Yes 
          No 
 
12 (17.4) 
57 (82.6) 
 
136 (14.7) 
789 (85.3) 
 
1.2 (0.6 – 2.3) 
 
0.546 
 
1.3 (0.7 – 2.4) 
 
0.494 
Antibiotics exposure 
          Yes 
          No 
 
10 (14.5) 
59 (85.5) 
 
160 (17.3) 
765 (82.7) 
 
0.8 (0.4 – 1.6) 
 
0.551 
 
0.8 (0.4 – 1.6) 
 
0.526 
Birth weight (grams)
 
< 2500 
n (%) 
≥ 2500 
n (%) 
    
Antimalarial exposure*      
          Yes 
          No 
 
5 (11.4) 
39 (88.6) 
 
131 (14.9) 
750 (85.1) 
 
0.7 (0.3 – 1.9) 
 
 
0.523 
 
 
0.7 (0.3 – 1.8) 
 
 
0.460 
 
Antibiotics exposure 
          Yes 
          No 
 
5 (11.4) 
39 (88.6) 
 
155 (17.6) 
726 (82.4) 
 
0.6 (0.2 – 1.5) 
 
 
0.291 
 
 
0.6 (0.2 – 1.6) 
 
 
0.295 
 
Maturity status at birth
a 
Preterm 
n (%) 
Term 
n (%) 
    
Antimalarial exposure*      
          Yes 
          No 
 
8 (16.3) 
41 (83.7) 
 
128 (14.6) 
748 (85.4) 
 
1.1 (0.5 – 2.5) 
 
0.742 
 
 
1.2 (0.6 – 2.7) 
 
 
0.629 
 
Antibiotics exposure 
          Yes 
          No 
 
11 (22.5) 
38 (77.5) 
 
149 (17.0) 
727 (83.0) 
 
1.4 (0.7 – 2.8) 
 
 
0.329 
 
 
1.4 (0.7 – 2.8) 
 
 
0.348 
 
MC/SB = Miscarriage or stillbirth; OR = odds ratio; CI = confidence interval  
* Excluding SP for IPTp 
µ
 Estimated from the logistic regression model with Wald type P-value 
α 
Adjusted for parity and maternal age 
a
Maturity status = Birth <37 weeks of gestation being preterm and ≥37 weeks of gestation being term 
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Table 5.4: US FDA pregnancy risk categories of drugs exposure in relation to pregnancy outcome 
Variables Outcomes Crude OR 
(95% CI) 
P
 µ
   Adjusted OR
α 
(95% CI) 
P
 µ
 
Birth outcome MC/SB 
n (%) 
Live birth 
n (%) 
 
 
Drugs category ‘A’ 
          Yes 
          No 
 
51 (73.9) 
18 (26.1) 
 
880 (95.1) 
45 (4.9) 
 
0.1 (0.1 – 0.3) 
 
< 0.001 
 
0.1 (0.08– 0.3) 
 
< 0.001 
Drugs category ‘B’ 
          Yes 
          No 
 
12 (17.4) 
57 (82.6) 
 
241 (26.1) 
684 (73.9) 
 
0.6 (0.3 – 1.1) 
 
0.115 
 
0.6 (0.3 – 1.1) 
 
0.111 
Drugs category ‘C’ 
          Yes 
          No 
 
20 (29.0) 
49 (71.0) 
 
213 (23.0) 
712 (77.0) 
 
1.4 (0.8 – 2.3) 
 
0.261 
 
1.4 (0.8 – 2.4) 
 
0.257 
Drugs category ‘D’ 
          Yes 
          No 
 
3 (4.3) 
66 (95.7) 
 
41 (4.4) 
884 (95.6) 
 
1.0 (0.3 – 2.9) 
 
0.974 
 
0.9 (0.3 – 3.2) 
 
0.939 
Birth weight (grams) < 2500 
n (%) 
≥ 2500 
n (%) 
    
Drugs category ‘A’ 
          Yes 
          No 
 
40 (90.9) 
4 (9.1) 
 
840 (95.4) 
41 (4.6) 
 
0.5 (0.2 – 1.4) 
 
 
0.191 
 
 
0.5 (0.2 – 1.5) 
 
 
0.207 
 
Drugs category ‘B’ 
          Yes 
          No 
 
7 (15.9) 
37 (84.1) 
 
234 (26.6) 
647 (73.4) 
 
0.5 (0.2 – 1.2) 
 
 
0.122 
 
0.5 (0.2 – 1.2) 
 
 
0.125 
 
Drugs category ‘C’ 
          Yes 
          No 
 
8 (18.2) 
36 (81.2) 
 
205 (23.3) 
676 (76.3) 
 
0.7 (0.3 – 1.6) 
 
 
0.436 
 
 
0.7 (0.3 – 1.6) 
 
 
0.387 
 
Drugs category ‘D’ 
          Yes 
          No 
 
1 (2.3) 
43 (97.7) 
 
40 (4.5) 
841 (95.5) 
 
0.5 (0.1 – 3.6) 
 
 
0.485 
 
 
0.6 (0.1 – 3.4) 
 
 
0.449 
 
Maturity status at 
birth 
Preterm 
n (%) 
Term 
n (%) 
    
Drugs category ‘A’ 
          Yes 
          No 
 
45 (91.8) 
4 (8.2) 
 
835 (95.3) 
41 (4.7) 
 
0.6 (0.2 – 1.6) 
 
 
0.277 
 
0.5 (0.2 – 1.5) 
 
 
0.231 
 
Drugs category ‘B’ 
          Yes 
          No 
 
17 (34.7) 
32 (65.3) 
 
224 (25.6) 
652 (74.4) 
 
1.5 (0.8 – 2.8) 
 
 
0.160 
 
 
1.5 (0.8 – 2.8) 
 
 
0.175 
 
Drugs category ‘C’ 
          Yes 
          No 
 
14 (28.6) 
35 (71.4) 
 
199 (22.7) 
677 (77.3) 
 
1.4 (0.7 – 2.6) 
 
 
0.345 
 
 
1.4 (0.8 – 2.7) 
 
 
0.269 
 
Drugs category ‘D’ 
          Yes 
          No 
 
4 (8.2) 
45 (91.8) 
 
37 (4.2) 
839 (95.8) 
 
2.0 (0.7 – 5.9) 
 
 
0.201 
 
 
2.0 (0.7 – 6.0) 
 
 
0.200 
 
MC/SB = Miscarriage or stillbirth; OR = odds ratio; CI = confidence interval  
µ
 Estimated from the logistic regression model with Wald type P-value 
α 
Adjusted for parity and maternal age  
35 
 
Chapter 6: Safety of artemether-lumefantrine exposure in early pregnancy: an observational cohort  
 
Dominic Mosha
1,2
*, Festo Mazuguni
1
, Sigilbert Mrema
1
, Esperanca Sevene
3
, Salim Abdulla
1
, Blaise 
Genton
2,4 
 
 
 
 
1
Ifakara Health Institute, Rufiji HDSS, Tanzania 
2
Swiss Tropical and Public Health Institute, University of Basel, Switzerland 
3
Universidade Eduardo Mondlane, Faculdade de Medicina, Manhica Health Centre, Maputo, 
Mozambique 
4
Department of Ambulatory Care and Community Medicine & Division of Infectious Diseases, University 
Hospital, Lausanne, Switzerland 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Accepted in Malaria Journal 
 
36 
 
Abstract 
Introduction: There is limited data available regarding safety profile of artemisinins in early pregnancy. 
They are therefore not recommended by WHO as a first line treatment for malaria in first trimester due 
to associated embryo-foetal toxicity in animal studies. The aim of the study was to assess birth outcome 
among pregnant women inadvertently exposed to artemether-lumefantrine (AL) during first trimester in 
comparison to those of women exposed to other antimalarial drugs or no drug at all during the same 
period of pregnancy. 
Methods: Pregnant women with gestational age ≤ 20 weeks were recruited and followed prospectively 
until delivery. Women were recruited from Reproductive and Child Health (RCH) clinic or from monthly 
house visits (demography surveillance) and followed prospectively until delivery. A structured 
questionnaire was used to interview participants.  
Results: Total of 2167 pregnant women were recruited and 1783 (82.3%) completed the study until 
delivery. 319 (17.9%) used antimalarials in first trimester, of whom 172 (53.9%) used AL, 78 (24.4%) 
quinine, 66 (20.7%) sulfadoxine-pyrimethamine (SP) and 11 (3.4%) amodiaquine. Quinine exposure in 
first trimester was associated with an increased risk of miscarriage/stillbirth (OR 2.5; 1.3 – 5.1; p=0.009) 
and premature birth (OR 2.6; 1.3 – 5.3; p=0.007) as opposed to AL with (OR 1.4; 0.8 – 2.5; p=295) for 
miscarriage/stillbirth and (OR 0.9; 0.5 – 1.8; p=0.865) for preterm birth. Congenital anomalies were 
identified in 4 exposed groups namely AL only (1/164 [0.6%]), quinine only (1/70 [1.4%]), SP (2/66 
[3.0%]), and non-antimalarial exposed group (19/1464 [1.3%]).  
Discussion and conclusion: Exposure to AL in first trimester was more common than to any other 
antimalarial drugs. Quinine exposure was associated with adverse pregnancy outcome, which was not 
the case following other antimalarial intake. Since AL and quinine were used according to their 
availability rather than to disease severity, it is likely that the effect observed was related to the drug, 
and not to the disease itself. Detailed information on developmental milestone up to 12 months is 
ongoing to rule out any adverse effect on infancy as a result of AL exposure in first trimester. Even with 
this caveat, a change of policy from quinine to AL for the treatment of uncomplicated malaria during the 
whole pregnancy period could be already envisaged. 
  
 
Keywords: Pregnancy, safety, artemether-lumefantrine, exposure 
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Background 
Over 60% of all pregnancies globally are at risk of malaria and more than 32 million are in sub-Sahara 
Africa [1].  Malaria infection is associated with high maternal and perinatal mortality in tropical and 
subtropical regions [90]. Severe maternal anaemia, intrauterine growth retardation, intrauterine death, 
stillbirth, premature delivery and low birth-weight are some of the reported substantial direct risks of 
malaria in pregnancy [2, 90]. Although malaria in pregnancy is a serious public health problem, there is 
limited information available regarding safety profile of most of licensed antimalarial in pregnancy 
because pregnant women are routinely not involved in clinical trials related to drug development for 
fear of harming the women and or developing foetus [91].  
Artemisinin-based combination therapies (ACT) are the most effective drugs against Plasmodium 
falciparum and have been recommended by the World Health Organization (WHO) as a drug of choice 
for the treatment of P falciparum malaria [37]. ACTs are only recommended in pregnancy during second 
and third trimester, but not in first trimester, unless they are the only treatment available, or if the 
patient’s life is threatened. Safety concerns of artemesinins in first trimester are the associated risks of 
visceral and skeletal anomalies following animal studies in early stage of pregnancy [92, 93]. Two 
previous small-scale studies assessing Zambian and Sudanese pregnant women exposed to artemisinin 
during first trimester could not find any association between drug exposure and maternal or birth 
adverse outcomes [39, 40]. However, evidence is still scarce to ensure safety of ACT during first 
trimester. 
Artemether-lumefantrine (AL) (20 mg and 120 mg respectively) (Coartem©, Novartis Pharm AG)  is one 
of the most popular and efficacious fixed dose of ACT which is currently available [94]. AL was 
introduced in Tanzania as a first line therapy for malaria in 2006 to replace sulphadoxine-pyrimethamine 
(SP) [95]. Inadvertent exposure to artemisinin during first trimester of pregnancy is possible due to its 
high availability at a subsidized cost in both private and public health facilities in the country [65, 66]. 
Furthermore, self-malaria treatment without consulting trained professional is common in sub-Sahara 
Africa; indeed, 70% of malaria episodes in rural Africa and 50% in urban areas are self-treated cases [96]. 
It is therefore important to take advantage of the latter to extend the margin safety information of 
artemisinin compounds in pregnancy by evaluating maternal and birth outcomes of inadvertently AL 
exposure to women in their first trimester.    
There is increasing evidence supporting efficacy, safety and tolerability of ACT which outweigh 
advantages of quinine in treating malaria [41, 97]. Despite its reactogenicity profile and several reports 
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of resistant strains of P falciparum [98, 99], quinine remains the only recommended drug for treating 
both uncomplicated and complicated P falciparum malaria during first trimester of pregnancy [37, 95]. 
The present study aims at assessing the maternal and birth outcomes in pregnant women who were 
inadvertently exposed to AL during first trimester in comparison to those of women exposed to other 
antimalarial drugs or no drug at all during the same period of pregnancy using two Health Demographic 
Surveillance System (HDSS) platforms in Tanzania.  
Methods 
Study area 
The study was conducted in Rufiji and Kigoma HDSS in Tanzania. Rufiji HDSS is in a rural setting while 
Kigoma HDSS is in an urban one, both areas have moderate to high malaria transmission intensity [100]. 
The study involved a total of 22 health facilities in the two HDSS sites. There was no clinical 
interventional research activity in the area during the study period.  
Study design 
The study enrolled pregnant women with gestational age of 20 weeks and below between March 2012 
and April 2013. Only women residing in HDSS were eligible for the study. They were recruited from 
Reproductive and Child Health (RCH) clinic during their routine visits and from the community through 
monthly round-based house visits. The set-up of HDSS allows identification of pregnancy status in 
women of childbearing age through routine HDSS quarterly census. On the day of enrollment, 
participants were interviewed for obstetrics and previous medical history including history of chronic 
illness or disease, use of alcohol and smoking. Important laboratory test such as maternal haemoglobin 
level, screening for HIV and syphilis were performed. Use of any antimalarial during first trimester of the 
presenting pregnancy was the key question during interview. The reported drug use information by a 
participant was verified by assessing patient’s medical record from the attended health facility, 
prescription sheet and maternal RCH card. Participants who had inadvertently used AL for malaria 
treatment in first trimester were compared with pregnant women who were treated with either quinine 
(Qn), sulphadoxine-pyrimethamine (SP), amodiaquine or women who had not used antimalarial drug(s) 
at all during the same period of pregnancy. Thus, women were not randomized but allocated to the 
study arm according to their antimalarial exposure history in first trimester.   
Women were followed on monthly basis until delivery to monitor pregnancy and birth outcomes. The 
assessed pregnancy outcome included maternal mortality, spontaneous abortion (pregnancy lose ≤ 28 
weeks of gestation), ectopic gestation, stillbirth and live birth. Birth outcome include birth weight, 
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maturity status at birth (estimated from the last normal menstrual period) and presence of congenital 
anomalies.  All newborns were assessed for congenital abnormalities post-delivery by a study clinician or 
health facility midwife.  
Primary endpoint 
Primary endpoints of the study were pregnancy and baby outcomes. Pregnancy outcome included 
miscarriage, stillbirth or live birth whereas baby outcome included birth weight and maturity status at 
birth. Low birth weight was defined as a birth weight below 2500 grams and premature was defined as 
birth before 37 weeks of gestational age.  
Statistical analysis 
STATA® 12.0 (Stata Corporation, College Station, Texas, USA) was used for data analysis. Numerical 
variables were summarized into mean and standard deviation. Categorical variables were summarized 
using cross tabulation to estimate different proportion. The effect of demographic and pregnancy 
characteristics on primary endpoint of the study was assessed by bivariable analysis. Logistic regression 
model were used to estimate the crude odds ratio (OR) for the associated between binary pregnancy 
outcomes (birth outcome, birth weight and birth maturity status) and medicine exposure. The 
multivariable adjusted logistic regression model included maternal age and parity as potential 
confounding variables.  Both were found to be associated with the study endpoints (P < 0.2). Two sided 
Wald test P-values are presented.   
Ethics 
Ethical approval was granted by the Ifakara Health Institute (IHI) ethical review board and the National 
Institute for Medical Research (NIMR) ethical committee. Written informed consent was obtained from 
all participants. 
Results 
A total of 2167 pregnant women were enrolled in the study and 1783 (82.3%) were followed until 
delivery [Figure 6.1]. 19.2% (342) were recruited from the community through house visit and 80.8% 
(1441) from the facility during their routine RCH clinic visits. 602 (33.8%) women were recruited in first 
trimester of pregnancy with mean gestational age of 10.5 [standard deviation (SD) 2.6] and 1181 (66.2%) 
during the first half of second trimester of pregnancy with mean gestation age of 16.9 (1.5). 559 (31.4%) 
were primigavidae, 336 (18.8%) secundigravidae and 888 (49.8%) were multigravidae with gravidity of 3 
and above. Important demographic and clinical characteristics are summarized in Table 6.1. 
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Drug exposure 
319 (17.9%) women used antimalarial in first trimester of pregnancy because of a morbid episode. 164 
(51.4%) used AL only, 70 (21.9%) quinine only, 8 (2.5%) both AL and quinine, 66 (20.7%) SP and 11 (3.4%) 
amodiaquine. At least 88% of study women used three group of drugs that are in antenatal intervention 
as recommended by the Ministry of Health [95] namely, anthelminthic, sulfadoxine-pyrimethamine (SP) 
for intermittent preventive treatment of malaria (IPTp) and iron and folic acid supplementation. 
Anthelminthic and IPTp-SP are prescribed in second and third trimester of pregnancy. 1579 (88.6%) used 
anthelminthic (mebendazole), 1626 (91.2%) used iron and folic acid supplementation and 1636 (91.8%) 
used at least one dose of IPTp-SP.  
Pregnancy outcome and antimalarial exposure 
Among 1783 deliveries, there were 5 maternal deaths that occurred within 24 hours, three were due to 
post-partum haemorrhage and the remaining two each was secondary to eclampsia and disseminated 
intravascular coagulopathy (DIC), respectively. Pregnancy outcomes included 44 (2.5%) abortions, 62 
(3.5%) stillbirth and 1677 (94.1%) live births. Baby outcomes included 81 (4.8%) low birth weight babies 
and 113 (6.7%) premature births. 23 (1.3%) of the newborns were identified to have congenital 
anomalies at birth including, polydactyl 17 (73.9%), club foot 2 (8.7%), genital defect 2 (8.7%), spinal 
bifida 1 (4.3%) and cardiac defect 1 (4.3%). Congenital anomalies were identified in 4 exposed groups 
namely AL only (1 [0.6%] of 164), quinine only (1 [1.4%] of 70), SP (2 [3.0%] of 66), and non-antimalarial 
exposed group (19 of [1.3%] of 1464). Table 6.2 summarizes pregnancy outcomes parameters in relation 
to antimalarial exposure status in first trimester. 
Quinine exposure during first trimester was associated with an increased risk of miscarriage/stillbirth 
(adjusted OR 2.5; 95%CI 1.3 – 5.1; p=0.009) and premature birth (adjusted OR 2.6; 95%CI 1.3 – 5.3; 
p=0.007) as opposed to AL, SP and amodiaquine exposure which were not associated with increased risk 
of either miscarriage/stillbirth, low birth weight or premature birth [see details in Table 6.3]. 
Maternal age and parity were assessed to determine their effect on pregnancy outcome as potential 
confounders of the drug effect. Increase of maternal age in years was associated with 5% decreased risk 
of low birth weight (OR 0.95; p=0.009), 5% increased risk of miscarriage/stillbirth (OR 1.05; p=0.001), 
and 3% increased risk of preterm birth (OR 1.03; p=0.016). Multigravidae had 50% decreased risk of low 
birth weight (OR 0.5; p=0.006), 60% increased risk of miscarriage/stillbirth (OR 1.6; p=0.048), and 30% 
increased risk of preterm birth (OR 1.3; p=0.099) compared to primigravidae.  
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Discussion 
The study findings provide further evidence on the safety profile of AL use in early pregnancy to treat 
malaria. It differs from previous first trimester artemisinine derivatives safety studies [39, 40] by having 
a larger sample size and a broader comparative exposure group. Also, the low mean gestational age at 
enrolment improves accuracy of drug exposure history, and thus reduces recall bias. It also increases the 
chances of identifying adverse pregnancy outcomes which commonly occurs during early stage of 
pregnancy, such as abortion [101].  
Although AL is not recommended as first-line treatment for malaria during first trimester of pregnancy, 
it was used by 54% of women in this indication. Exposure to AL in first trimester was twofold higher than 
quinine, the drug of choice for malaria treatment during first trimester in Tanzania [95]. This observation 
suggests that AL is a popular drug. It reflects its high accessibility in most of the health facilities and by 
drug vendors in the country [65, 66]. In practice, quinine was frequently out of stock and its replacement 
could easily take several weeks, particularly in public health facilities. Since shortage of drugs is common 
in resource-limited settings [102, 103], inadvertent or voluntary exposure to contraindicated drugs is 
inevitable.  Limited access to quinine may also explain the observed high SP and amodiaquine exposure, 
drugs which are currently not recommended for treating malarial illness [37].  
Quinine exposure was associated with a twofold increased risk of miscarriage/stillbirth and preterm 
birth. The harmful effect of quinine during pregnancy has been known for a long time. Its abortive 
properties in relation to the induction of uterine contractions have long been reported by Maxwell JP 
[44]. The strength and prolongation of these contractions were reported to be dose dependent. A 
randomized control trial in Uganda showed oral quinine to have a twofold increased incidence of 
adverse effects compared to AL among pregnant women treated for uncomplicated malaria in second 
and third trimesters. There were nearly twofold increases in intrauterine foetal deaths in the quinine 
group than in the AL one, although the numbers were low. On the other hand, there was no difference 
in proportions of spontaneous abortions in the two study groups [41].   
In the present study, these adverse pregnancy outcomes were not observed following AL, SP or 
amodiaquine exposure, which suggests that the deleterious effect of quinine was more related to the 
drug itself, rather than to the malaria episode. This is supported by the observation made by 
fieldworkers that quinine was not given to a particular group of women because of more severe disease, 
but just because AL was more readily accessible on the shelf of the health facility. Also, all women took 
quinine tablets, and not intravenous doses, which speaks for a similar degree of severity of the disease 
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in women who took quinine and AL. However, since it was not a proper randomized double-blind 
controlled trial, it is not possible to formally exclude a selection bias that would lead to different effects 
of the malaria disease itself. Whatever is the cause, the magnitude of the adverse effects associated 
with quinine exposure is alarming, when considering that this drug is viewed at present as the safest 
antimalarial drug in first trimester. There is a remote possibility of a deleterious effect of AL on the 
foetus, and hence on infant development, that could not be assessed at this stage in the study. We hope 
to be able to definitely exclude an adverse consequence of AL exposure during pregnancy on the infant 
when analysing the results of the 12-month follow-up of the offsprings. Precise information on 
neurological scores, including motor and sensory patterns, should assist policy decisions after careful 
analysis of the time of antimalarial exposure. The preliminary results of the first infant cohort are 
encouraging.  
The observed prevalence of 1.3% congenital anomaly in the present study is lower than the global 
prevalence (3.0%) estimated by WHO [89]. No national figures of congenital anomalies are available for 
comparison in Tanzania. Also, there is a possibility of more anomalies be identified later in life as the 
child grows. Congenital anomalies was twice in the non-antimalarial exposed group compared to AL 
exposed group (1.3% vs 0.6%). Polydactyly was the most reported congenital anomaly (74%) but it is 
believed to be genetically determined rather than triggered by external exposure [104]. In animal 
studies, umbilical hernia has been reported to be associated with artemisinin exposure during 
pregnancy [92]. Our study had limitation to assess occurrence of umbilical hernia since the newborns 
were screened only once at the time of delivery. At this time, hernias may hardly present, and cannot 
therefore be identified. Also, umbilical hernia is commonly observed in most parts of Africa and is not 
viewed as an abnormality, it is often not brought to medical attention unless it manifest itself with 
complications such as intestinal obstruction [105, 106].  
Conclusion 
Exposure to AL in first trimester was more common than to any other antimalarial drugs. Quinine 
exposure was associated with adverse pregnancy outcome, which was not the case for other 
antimalarials. Since AL and quinine were used according to their availability rather than to disease 
severity, it is likely that the effect observed was related to the drug, and not to the disease itself. More 
information of developmental milestone up to 12 months is needed to rule out any adverse effect on 
infancy as a result of AL exposure in first trimester. Even with this caveat, a change of policy from 
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quinine to AL for the treatment of uncomplicated malaria during the whole pregnancy period could be 
already envisaged. 
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Figures and Tables 
 
Figure 6.1: Flow chart of participants in the study  
 
 
 
 
 
 
 
 
 
                                      
 
 
 
 
 
_____________________________________________________________________________________ 
  AL=Artemether-lumefantrine; Qn=Quinine; SP=Sulfadoxine-pyrimethamine; AQ=Amodiaquine; None=No antimalarial   
 
 
 
 
 
 
 
 
E
n
ro
ll
e
d
 
E
xp
o
su
re
 g
ro
u
p
s 
Lo
st
 f
o
ll
o
w
-u
p
 
fo
ll
o
w
e
li
ve
re
d
 
D
e
li
ve
re
d
 
AL 
n = 168 
(7.8%) 
AL & Qn 
n = 8 
(0.4%) 
Qn 
n = 88 
(4.1%) 
AQ 
n=13 
(0.6%) 
None 
n=1,791 
(82.6%) 
SP 
n=99 
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45 
 
Table 6.1: Characteristics of pregnant women enrolled in the study 
Characteristics 1
st
 Trimester 
n = 602 
First half of 2
nd
  Trimester 
n = 1181 
All Trimesters 
n = 1783 
Mean age, (years)* 25.7 (6.8; 14 – 49) 25.9 (6.7; 13 – 46) 25.8 (6.8; 13 – 49) 
Mean BMI* 23.2 (3.9; 14.2-39.6) 23.3 (3.6; 14.0 – 42.5) 23.4 (3.7; 14.0 – 42.5) 
Mean gestational age, (weeks)* 10.5 (2.6; 3 – 12) 16.9 (1.5; 13 – 20) 14.8 (3.7; 3 – 20) 
Gravidity
#
    
          Primigravidae 182 (30.0) 377 (31.9) 559 (31.4) 
          Secundigravidae 109 (18.0) 227 (19.2) 336 (18.8) 
          3 – 4 pregnancies 180 (29.6) 315 (26.7) 495 (27.8) 
          ≥ 5 pregnancies 131 (21.4) 262 (22.2) 393 (22.0) 
Recruited sites
#
    
          Health facility 468 (22.3) 973 (82.4) 1441 (80.8) 
          Home 134 (77.7) 208 (17.6) 342 (19.2) 
Drinking alcohol
# 
 14 (2.7) 27 (2.3) 41 (2.3) 
Smoking cigarette
# 
 5 (0.8) 2 (0.2) 7 (0.4) 
Haemoglobin level (g/dl)* 10.8 (1.5; 5.0 – 14.6) 10.7 (1.5; 5.4 – 14.9) 10.7 (1.5; 5.0 – 14.9) 
HIV status#    
          Negative 533 (88.5) 1086 (92.0) 1619 (90.8) 
          Positive 18 (3.0) 46 (3.9) 64 (3.6) 
          No results 51 (8.5) 49 (4.1) 100 (5.6) 
Syphilis test
#
    
          Negative 521 (86.5) 1082 (91.6) 1603 (89.9) 
          Positive 12 (2.0) 15 (1.3) 27 (1.5) 
          No results 69 (11.5) 84 (7.1) 153 (8.6) 
*represents data presented in mean, (standard deviation [SD]; range) 
#
represent data presented in number (%) 
Abbreviation: BMI = Body Mass Index 
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Table 6.2: Pregnancy and baby outcomes in relation to antimalarial exposure status during first trimester 
Pregnancy outcome AL only 
164 (%) 
AL & Quinine 
8 (%) 
Quinine only 
70 (%) 
SP 
66 (%) 
Amodiaquine 
11 (%) 
None 
1464 (%) 
Abortion 5 (3.0) 2 (25.0) 3 (4.3) 0 (0.0) 0 (0.0) 34 (2.3) 
Stillbirth 6 (3.7) 0 (0.0) 5 (7.1) 2 (3.0) 0 (0.0) 49 (3.3) 
Live birth 153 (93.3) 6 (75.0) 62 (88.6) 64 (97.0) 11 (100) 1381 (94.3) 
Birth maturity* 
          Preterm birth 
          Full term birth 
 
8 (5.2) 
145 (94.8)  
 
2 (33.3) 
4 (66.7) 
 
8 (12.9) 
54 (87.1)  
 
7 (10.9) 
57 (89.1)  
 
0 (0.0) 
11 (100) 
 
88 (6.4) 
1293 (93.6) 
Birth weight* 
          Low birth weight 
          Normal birth weight 
 
8 (5.2) 
145 (94.8) 
 
1 (16.7) 
5 (83.3) 
 
1 (1.6) 
61 (98.4) 
 
2 (3.1) 
62 (96.9) 
 
0 (0.0) 
11 (100) 
 
69 (5.0) 
1312 (95.0) 
Congenital anomalies 1 (0.6) 0 (0.0) 1 (1.4) 2 (4.1) 0 (0.0) 19 (1.3) 
*Excluding abortion and stillbirth outcomes 
Abbreviation: AL = Artemether-lumefantrine; SP = Sulfadoxine-pyrimethamine 
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Table 6.3: Pregnancy outcomes in relation to antimalarial exposure status in first trimester 
Variables Outcomes Crude OR 
(95% CI) 
P
 µ
 Adjusted OR
α 
(95%CI) 
P
 µ
 
Birth outcome MC/SB 
n (%) 
Live birth 
n (%) 
    
AL exposure 
          Yes 
          No 
 
13 (12.3) 
93 (87.7) 
 
159 (9.5) 
1518 (90.5) 
 
1.3 (0.7 – 2.4) 
 
 
0.348 
 
 
1.4 (0.8 – 2.5) 
 
 
0.295 
 
Quinine exposure 
          Yes 
          No 
 
10 (9.4) 
96 (90.6) 
 
68 (4.1) 
1609 (95.9) 
 
2.5 (1.2 – 4.9) 
 
 
0.011 
 
 
2.5 (1.3 – 5.1) 
 
 
0.009 
 
SP exposure 
          Yes 
          No 
 
2 (1.9) 
104 (98.1) 
 
64 (3.8) 
1613 (96.2) 
 
0.5 (0.1 – 2.0) 
 
 
0.318 
 
 
0.5 (0.1 – 2.0) 
 
 
0.312 
 
Amodiaquine exposure 
          Yes 
          No 
 
0 (0.0) 
106 (100) 
 
11 (0.7) 
1666 (99.3) 
 
- (0) 
 
 
- 
 
 
- (0) 
 
 
- 
 
No antimalarial exposure 
          Yes 
          No 
 
83 (78.3) 
23 (21.7) 
 
1380 (82.3) 
297 (17.7) 
 
0.8 (0.5 – 1.3) 
 
 
0.301 
 
 
0.8 (0.5 – 1.2) 
 
 
0.260 
 
Birth weight (grams) < 2500 
n (%) 
≥ 2500 
n (%) 
    
AL exposure 
          Yes 
          No 
 
9 (11.1) 
72 (88.9) 
 
150 (9.4) 
1446 (90.6) 
 
1.2 (0.6 – 2.5) 
 
 
0.608 
 
 
1.2 (0.6 – 2.5) 
 
 
0.573 
 
Quinine exposure 
          Yes 
          No 
 
2 (2.5) 
79 (97.5) 
 
66 (4.1) 
1530 (95.9) 
 
0.6 (0.1 – 2.4) 
 
 
0.463 
 
 
0.6 (0.1 – 2.4) 
 
 
0.461 
 
SP exposure 
          Yes 
          No 
 
2 (2.5) 
79 (97.5) 
 
62 (3.9) 
1534 (96.1) 
 
0.6 (0.2 – 2.6) 
 
 
0.520 
 
 
0.7 (0.2 – 3.0) 
 
 
0.639 
 
Amodiaquine exposure 
          Yes 
          No 
 
0 (0.0) 
100 (100) 
 
11 (0.7) 
1585 (99.3) 
 
- (0) 
 
 
- 
 
 
- (0) 
 
 
- 
 
No antimalarial exposure 
          Yes 
          No 
 
69 (85.2) 
12 (14.8) 
 
1311 (82.1) 
285 (17.9) 
 
1.3 (0.7 – 2.3) 
 
 
0.485 
 
 
1.2 (0.6 – 2.3) 
 
 
0.564 
 
Maturity status at birth Preterm 
n (%) 
Term 
n (%) 
    
AL exposure 
          Yes 
          No 
 
10 (8.9) 
103 (91.1) 
 
149 (9.5) 
1415 (90.5) 
 
0.9 (0.5 – 1.8) 
 
 
0.812 
 
 
0.9 (0.5 – 1.8) 
 
 
0.865 
 
Quinine exposure 
          Yes 
          No 
 
10 (8.9) 
103 (91.1) 
 
58 (3.7) 
1506 (96.3) 
 
2.5 (1.3 – 5.1) 
 
 
0.010 
 
 
2.6 (1.3 – 5.3) 
 
 
0.007 
 
SP exposure 
          Yes 
 
7 (6.2) 
 
57 (3.6) 
 
1.7 (0.8 – 3.9) 
 
0.177 
 
1.8 (0.8 – 4.1) 
 
0.160 
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          No 106 (93.8) 1507 (96.4)    
Amodiaquine exposure 
          Yes 
          No 
 
0 (0.0) 
113 (100) 
 
11 (0.7) 
1553 (99.3) 
 
- (0) 
 
 
- 
 
 
- (0) 
 
 
- 
 
No antimalarial exposure 
          Yes 
          No 
 
88 (77.9) 
25 (22.1) 
 
1292 (82.6) 
272 (17.4) 
 
0.7 (0.5 – 1.2) 
 
 
0.205 
 
 
0.7 (0.5 – 1.1) 
 
 
0.168 
 
OR= Relative Risk; CI = Confidence Interval 
µ
 Estimated from the logistic regression model with Wald type P-value 
α
 = Adjusted for age and parity 
Abbreviation: MC = Miscarriage; SB = Stillbirth; AL = artemether-lumefantrine; SP = Sulfadoxine-pyrimethamine 
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Abstract 
Background: Artemether-Lumefantrine (AL) is the first line treatment for uncomplicated malaria in 
second and third trimester of pregnancy. Its efficacy has recently been challenged in pregnancy due to 
altered pharmacokinetic (PK) properties in this vulnerable group. The aim of this study was to determine 
the PK profile of AL in pregnant and non-pregnant women and assess their therapeutic outcome.  
Methods: Thirty-three pregnant women and 22 non-pregnant women with malaria were treated with AL 
(80/480mg) twice daily for 3 days. All patients provided five venous plasma samples for drug 
quantification at random times over 7 days. Inter- and intra-individual variability was assessed and 
covariates effects quantified using a nonlinear mixed-effect modeling approach (NONMEM
®
).  
Results: A one-compartment model with first-order absorption and elimination with linear metabolism 
from drug to metabolite fitted the data best for both arthemether (AM), lumefantrine (LF) and their 
metabolites. Pregnancy status and diarrhea showed a significant influence on LF PK. Lumefantrine 
relative bioavailability and metabolism rate into desmethyl-lumefantrine were respectively 34% lower 
and 78% higher in pregnant women than in non-pregnant patients. Overall PCR-uncorrected treatment 
failure was 18% in pregnant women and 5% in non-pregnant women (OR = 4.04; p value 0.22). A high 
median day 7 lumefantrine concentration was associated with adequate clinical and parasitological 
response. 
Conclusion: The observed reduction in lumefantrine relative bioavailability in pregnant women may 
explain the higher treatment failure in this group, mostly due to lower post-treatment prophylaxis. 
Hence, a modified treatment regimen of malaria in pregnancy should be considered. 
 
 
 
Keywords: Pharmacokinetics, Arthemether, Lumefantrine, Pregnancy 
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Background 
Malaria in pregnancy is a major public health problem, which is associated with high maternal and 
perinatal mortality in tropical and subtropical regions [90]. Pregnant women are at increased risk of 
clinical malaria compared to non-pregnant women because of the associated immunological and 
hormonal changes in pregnancy [10]. Substantial direct risks to pregnant women include severe 
maternal anaemia, and those affecting the baby are intra-uterine growth retardation, intrauterine 
death, stillbirth, premature delivery, low birth-weight, and perinatal and neonatal morbidity and 
mortality [2]. Because of all this, malaria in pregnancy should be treated effectively. 
Artemether-lumefantrine (AL) (20mg and 120mg, respectively) is one of the most popular and 
efficacious fixed dose artemisinin-based combination therapies (ACT) against Plasmodium falciparum. It 
is currently available at a subsidized cost in most malaria endemic countries. AL has proved to be non-
inferior to quinine in East Africa for the treatment of P falciparum infection in second and third trimester 
of pregnancy [41]. ACTs are recommended by the World Health Organization (WHO) as the first line 
treatment for uncomplicated malaria in second and third trimester of pregnancy [37]. Unfortunately, 
general inter-individual variability on drug absorption, distribution to different compartments of the 
body and tissues, plasma binding proteins, rate of metabolism, enterohepatic recirculation, and 
excretion may be associated with changes in bioavailability of a drug and consequently may affect the 
therapeutic efficacy [107].    
Pregnancy has been reported to affect the efficacy of some drugs, including antimalarials. This is due to 
physiological changes which lower drug absorption, speed up drug clearance and increase body fluid 
volume of distribution [48, 108, 109]. Elevation of estrogens, progesterone, cortisol and prolactin 
hormones during pregnancy have been linked to altered metabolic activity of several hepatic 
cytochrome P450 enzymes. For instance, catalytic activity of CYP3A4, CYP2C9 and CYP2A6 enzymes 
increases during pregnancy [110, 111], and these enzymes are responsible for lumefantrine and 
artemether metabolism [112, 113]. Hence, it is expected that significant alteration of the 
pharmacokinetics (PK) of most antimalarial drugs during pregnancy occurs, which may be associated 
with lower drug concentrations and lower antimalarial cure rate, especially in advanced pregnancy [47, 
51, 114]. A higher treatment failure rate has indeed been observed in pregnant women when compared 
to non-pregnant ones living in the same area [51]. Several PK studies on artemether (AM), lumefantrine 
(LF) and their respective metabolites, dihydroartemisinin (DHA) and debutyl-lumefantrine (DLF) have 
demonstrated low plasma concentration of these drugs in pregnant women compared to non-pregnant 
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adults. However, most of these studies included healthy male adult volunteers as a comparative group 
rather than female malaria patients [49, 51, 115, 116]. Because of various determinants of PK and 
therapeutic outcome, it is essential to have a comparative population of non-pregnant women of the 
same study area with the same disease.  
An important concern during the course of AL treatment is to achieve adequate residual LF level after 
complete elimination of AM and DHA so that it may clear all residual malaria parasite [48]. Therefore, 
day 7 LF concentration level has been proposed as a surrogate marker for AL efficacy [64, 117]. Recent 
pharmacokinetics study of AL in Cambodia and Tanzania reported that the targeted day 7 LF 
concentration was also not achieved in a significant number of non-pregnant adult patients. In Tanzania, 
35% of samples had LF concentration below the cut-off value of 175 ng/ml at day 7 [118]. In pregnancy, 
whereby host antiparasitic immunity is somehow compromised [10], a higher day 7 venous 
concentration of LF may be required than what has previously been proposed in studies involving non-
pregnant adult patients i.e. a cut-off values of 175 ng/ml or 280 ng/ml in order to achieve effective 
therapeutic outcome and 600 ng/ml for maximal efficacy [119, 120]. Some predictive models have 
suggested that a twice-daily regimen of AL for 5 days would be preferable in later pregnancy in order to 
achieve sufficient drug concentration in plasma [49]. Increasing the duration of AL administration is 
indeed expected to increase the residual LF levels in the subsequent post-treatment cycle so as to 
reduce chances of recrudescence [118]. This should be interpreted with caution because extending the 
duration of treatment regimen may possibly lead to lower adherence. Doubling the dose might be 
another option but actually it may not be appropriate because absorption of LF is dose-limited [121]. 
The aim of the present study was to characterize the PK profile of AL and their metabolites, to 
determine their variability and to identify factors that might explain variations in drugs and metabolites 
levels in pregnant (second and third trimester of pregnancy) and non-pregnant women of the same 
area, and to assess cure rate and parasitological clearance in these two groups. The model developed 
for lumefantrine was used to simulate day 7 concentrations under standard and alternative dosage 
regimens and quantify the percentages of pregnant and non-pregnant women having concentrations 
below different proposed cut-off thresholds.  
Material and methods 
Study design and procedures 
This study was conducted in Rufiji district, within a Coastal region in Eastern Tanzania. The asexual 
parasitaemia prevalence is 14% and Plasmodium falciparum is the predominant species [75]. The study 
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was carried out at Kibiti health center from April to September 2012. Approval for the study was granted 
by two independent ethical review bodies; (i) Research Ethics Committee of Ifakara Health Institute (IHI) 
and (ii) National Institute for Medical Research (NIMR) Ethical Committee. All women signed an 
informed consent prior to enrolment. 
Pregnant and non-pregnant women diagnosed with uncomplicated malaria were recruited from either 
out-patient department or Reproductive and Child Health (RCH) clinic. Inclusion criteria were women 
aged 18 year and above, resident of Rufiji study area, pregnant during their second and third trimester, 
and having signs or symptoms suggestive of uncomplicated malaria with fever (axillary temperature ≥ 
37.5
0
C) or history of fever for the past 24 hours, P falciparum detected by microscopy, and hemoglobin 
level ≥ 7 g/dl. Exclusion criteria were known allergy to AL or quinine, history of renal, liver or heart 
problem, hyperparasitaemia above 200,000/µL, reported intake of any antimalarial within the past 28 
days, unable to take oral medication, and vomiting the medication within 1 hour of first dose intake. The 
same criteria applied to non-pregnant women (control group) that were recruited concurrently during 
the same study period after informed consent. A full medical history including concomitant illness and 
concomitant medication was recorded. Clinical examination on the day of enrollment was performed by 
an experienced physician. Patients were also seen by the clinician during follow up visits at day 1, 2, 3, 7, 
14, 28 and 42 whereby axillary temperature was measured as well as evaluation of malaria related 
symptoms [37].  Gestational age was determined from the estimated first day of the last normal 
menstrual period and compared to clinical examination of a fundal height. In case of any discrepancy, 
gestational age was recalculated from the estimated age at first RCH visit.  
Drug regimen 
Enrolled participants received four tablets of AL (Coartem® Novartis Pharma AG, Basel; 20 mg AM and 
120 mg LF) over the course of 3 days at 0, 8, 24, 36, 48 and 60 hours. Each dose was administered with 
200 ml of milk containing 4.5 g of fat because of the associated increase in LF bioavailability when taken 
with a fat rich meal [122]. All patients were asked to come back to the health center for each drug 
administration and observed for one hour after dose intake. None of the patient was admitted during 
the course of AL treatment but one pregnant woman who developed severe malaria at day 1 was 
admitted and the treatment was changed to intravenous quinine. A limited number of patients were 
administered drug at home by the study’s clinician or field assistant. 
Blood samples 
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To determine AM, DHA, LF and DLH concentration, 2 ml of venous blood sample was drawn from the 
patient at random times between 8 and 11 am on day 0, 1, 2, 3 and 7. Day 0 blood sample was collected 
before starting the medication as a baseline so as to determine the presence of any antimalarial in 
patient’s plasma prior to treatment due to intake of non-declared drugs [123, 124]. The blood samples 
in an EDTA vacutainer® tube were centrifuged at 2,000 x g for 5 minutes and the plasma stored in 
cryotubes. Samples were kept at -25
0
C for at most 6 weeks before transferred to Ifakara Health Institute 
(IHI) Bagamoyo clinical laboratory for temporary storage at -80
0
C. All samples were packed in dry ice and 
shipped to clinical pharmacology laboratory of the University Hospital in Lausanne, Switzerland, to 
perform the drug bioassay.  
To estimate the parasite density and clearance rate, capillary blood from a finger prick was taken at day 
0, 3, 7, 14, 28 and 42. Samples were collected on blood slide Giemsa stained thick and thin blood smear 
were examined by two different experienced microscopists using light microscopy. Parasite in thick film 
fields were counted per 200 leukocytes and the parasite count was multiplied by a factor of 40 to give 
parasites per µl of blood. Approximately, 50µl of finger pricked blood was spotted onto Whatman® filter 
paper cards (3MM). DNA was extracted from Whatman® filter paper cards by Chelex method [125]. In 
order to differentiate between recrudescence and new infection, samples were genotyped by the most 
polymorphic marker the merozoite surface protein 2 (MSP 2) and the amplicons were visualized in a 2% 
agarose gel as described elsewhere [126]. 
Drug assay 
Plasma concentrations of AM, DHA, LF and DLF were determined using a validated liquid 
chromatography-tandem mass spectrometry method (LC-MS/MS) [127]. The presence of 10 other 
antimalarial drugs and metabolites i.e. artesunate, amodiaquine, N-desethyl-amodiaquine, piperaquine, 
pyronaridine, mefloquine, chloroquine, pyrimethamine and sulfadoxine were also assessed at the same 
time. This is a standard procedure on how LC-MS/MS operates, so as to ensure that the malaria 
outcome that was observed was due to AL intake. The preciseness of the method is 3.1% – 12.6% for 
inter-day variation coefficient and its sensitivity is 0.15 – 3.0 ng/dl for lower limit quantification (LOQ) of 
basic or neutral antimalarial and 0.75 – 5 ng/dl for artemisinin derivatives. The bioassays were carried 
out at the Laboratory of clinical pharmacology of the Lausanne University Hospital, which takes part in 
the quality control system of the worldwide antimalarial resistance network (WWARN). 
Efficacy assessment 
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AL efficacy was determined by cure rate and parasitological clearance. The definition of treatment 
response was according to WHO recommendations on the methods for surveillance of antimalarial drug 
efficacy [63]. Treatment response was thus classified into early treatment failure (ETF), late clinical 
failure (LCF), late parasitological failure (LPF) and adequate clinical and parasitological response (ACPR). 
Participants who developed either clinical or parasitological failure as defined above received quinine 10 
mg/kg of body weight three times a day for 7 days, quinine is a second line drug of choice. 
Pharmacokinetic analysis  
Drugs and their metabolites were modeled using the NONMEM computer program version 7.2 (NM-
TRAN version II) [128]with the PsN-Toolkit version 3.5.3 [129]. The program uses mixed (fixed and 
random) effects regression to estimate population means and variances of the pharmacokinetic 
parameters and to identify factors that influence them.  
Structural model. One and two-compartment models with first-order absorption and elimination and 
linear metabolisation to DLF and DHA were compared to describe, respectively, LF and AM 
pharmacokinetics with an additional compartment used to characterize metabolite data. The final 
estimated parameters were drug and metabolite systemic clearances (CL and CLmet), volume of 
distribution of the central compartment (VC) and metabolism rate constant from the drug to the 
metabolite compartment (K23). Owing to identification problems, the volume of distributions of DLF and 
DHA could not be estimated and were assumed to be equal to those of LF and AM, respectively. Because 
of the limited number of measurements in the absorption phase, the absorption rate constants (Ka) 
could not be adequately estimated and were thus fixed to 0.7 and 0.54 h
-1
 to achieve AM and LF peak 
plasma concentrations, respectively, 2 h and 6-8 h after drug intake [130]. Finally, the known pre-
systemic conversion of AM into DHA was modeled estimating the fraction of the AM dose directly 
converted into the metabolite in the gut using 1-F1, with F1 = 1 representing AM relative bioavailability. 
Since the drugs were given orally, these parameters represent apparent values. In case the analysis of 
baseline plasma samples showed non-zero concentration of the drugs (suggesting that AL was 
previously taken), a factor (F0) was introduced in the model in order to estimate the residual doses from 
previous treatments.  
Statistical model. Inter-patient variability of all the PK parameters was described by exponential errors 
following a log-normal distribution, as illustrated by the equation θj=θ·exp(ηj), where θj is the 
pharmacokinetic parameter associated with the j
th
 individual, θ is the average population value, and ηj is 
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the j
th
 individual component of the inter-patient random effect, an independent, normally distributed 
variable with mean 0 and variance ω
2
. In order to constrain individual F1 to vary between 0 and 1, a logit 
function (logit F1) was used. Correlations between PK parameters were also investigated.  Finally, 
proportional, additive and combined proportional-additive error models were compared to describe the 
intrapatient (residual) variability for both drug and metabolite. The correlation between drug and 
metabolite concentration measurements was tested using the NONMEM
® 
L2 item.  
Covariate model. Available covariates were: pregnancy status, body weight, body mass index (BMI), age, 
gestational age and diarrhea. The covariate analysis was performed using a stepwise insertion/deletion 
approach. Visual inspection of the correlation between post hoc individual estimates of the PK 
parameters and the available patients’ characteristics was first conducted. Potential covariates 
influencing the kinetic parameters were then incorporated sequentially and tested for significance in 
NONMEM
®
. This goal was achieved by modeling the typical value of the pharmacokinetic parameters θ 
to depend linearly on the covariate X (continuous covariates centered on the population median; 
dichotomous variables coded as 0 and 1) using	=a· 1+b·X, where θa is the mean estimate and θb is 
the relative deviation of the mean due to the X covariate. In addition, body weight (BW) effect was 
modeled using the allometric function =a·  BWMBW
θc
, where MBW is the median population BW and θc 
was fixed to literature values, i.e. 0.75 for CL and 1 for V. 
Selection of the model and parameter estimation. Drugs and metabolites were fitted by use of the first-
order conditional (FOCE) method with interaction using the subroutine ADVAN5. Concentrations below 
the quantification limit (BQL) of the assay were generally treated using the M3 method described by 
Beal as implemented in the paper of Ahn et al [131, 132].  When using the L2 function, BQL data were 
replaced by LOQ/2 and handled with the M6 approach [132]. The log likelihood ratio test, based on 
differences in the OFV value (ΔOFV) provided by NONMEM
®
, was employed to discriminate between 
hierarchical models. Since a ΔOFV between any two models approximates a χ
2
 distribution, a change of 
the objective function was considered statistically significant if it exceeded 3.84 (p < 0.05) or 6.63 (p < 
0.01) for 1 additional parameter in model-building and backward-deletion steps respectively. Additional 
criteria for model selection were diagnostic goodness-of-fit plots, precision of pharmacokinetic 
parameters estimates, and the reduction of the parameters inter-patient variability. 
Validation of the model. The stability of the final model was assessed by means of the bootstrap 
method implemented in PsN, generating two-thousand datasets by re-sampling from the original 
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dataset. Mean parameters values with their 95% confidential interval (CI95%) were derived and compared 
with the final pharmacokinetic model estimates. Model validation was performed by visual predictive 
checks (VPC), simulating data for 1000 individuals based on the final model and generating 2.5
th
, 50
th
 
and 97.5
th
 percentiles. The observed concentrations were plotted against the 95% prediction interval 
(PI95%) of the simulated dataset at each time point and visually compared. Figures were generated with 
GraphPad Prism® (Version 6.00 for Windows, GraphPad Software, San Diego California USA, 
http://www.graphpad.com/).  
Model-based stimulation for LF.  The concentration-time profiles of LF in 1000 individuals receiving two 
different regimens of 6 doses over 3 days (at 0, 8, 24, 36, 48 and 60 h) and 5 days (at 0, 8, 24, 48, 72 and 
96 h.) were derived by simulations based on the final model including inter-patient variability. Day 7 
predicted median concentrations with their PI95% for pregnant and non-pregnant women were derived. 
In addition, these simulations allowed quantifying the percentages of pregnant and non-pregnant 
women having a day 7 concentrations below different proposed cut-off thresholds of 175 ng/ml, 280 
ng/ml and 600 ng/ml associated with treatment efficacy [64, 119].  
Statistical analysis 
Predicted lumefantrine day 7 concentrations for pregnant and non-pregnant women were compared 
using a t-test. The relationship between treatment failure and potential predictors associated with it, 
namely day 7 LF concentration, pregnancy status, gestational age, baseline parasite count, residual 
antimalarial and BMI was assessed by logistic regression estimating odds ratio (OR) and CI95%. A p-value 
below 0.05 was considered statistically significant. All the statistical analyses were performed using 
STATA® 12.0 (Stata Corporation, College Station, Texas, USA). 
Results 
Demographic and clinical parameters. Thirty-five pregnant women and 22 non-pregnant women with 
acute Plasmodium falciparum malaria were enrolled in the study from 23
rd
 April to 5
th
 September 2012. 
Two of the enrolled pregnant women were withdrawn from the study at day 2 and 7 because they 
refused to continue participating in the study. Two (9.1%) non-pregnant women were lost for follow-up 
at day 42. None of the pregnant women were lost for follow up. Baseline characteristics of pregnant and 
non-pregnant women are presented in Table 7.1. Two pregnant women presented with diarrhea at the 
day of enrollment and throughout the course of treatment. None of the study participants vomited the 
drug. All participants had normal physical condition on examination with no history of any chronic 
disease or smoking. Twenty-six women (14 pregnant and 12 non-pregnant) reported to have taken 
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paracetamol before enrollment. The median gestational age among pregnant women was 27 (14 – 37) 
weeks with relatively equal numbers of women in the second and third trimester of pregnancy. 
Residual antimalarial. Blood samples from all 57 recruited participants in the study were screened to 
determine the presence of any antimalarial drugs prior to initiation of malaria treatment. Fifty-five 
(96.5%) had at least one antimalarial in their plasma: 89.5% (29 pregnant and 22 non-pregnant) of 
participants had plasma LF above the LOQ but the drug concentration was generally low with the 
average of 37.3 ng/ml. Other antimalarial drugss which were detected were DHL (14.0%) 8, AM (7%) 4, 
DHA (0.0%) 0, sulfadoxine (24.6%) 14, pyrimethamine (19.3%) 11 and quinine (1.8%) 1.  Summarized 
statistics are shown in Table 7.2. Out of 14 participants detected with sulfadoxine, 13 were pregnant 
with a median baseline parasitaemia of 72086 (range 3920 – 198080) counts/µL [Figure 7.1]. Sulfadoxine 
concentration persisted at relative constant concentration throughout the first 7 days of monitoring 
plasma drug levels.  
Population pharmacokinetic analysis 
A total of 265 LF, 263 DLF, 146 AM, and 98 DHA plasma concentrations were included in the analysis. 
Twenty-five percent (n=37) AM, 7% (n=7) DHA and 2% (n=4) DLF concentrations were below the 
respective LOQs. The median (range) of samples available per study subject was 5 (4 – 5) for LF, 4 (3 – 5) 
for DLF, 3 (1 – 5) for AM and 2 (1 – 4) for DHA.  
Artemether 
AM and DHA pharmacokinetics were best described using a one-compartment model with first-order 
absorption from the gastrointestinal tract and linear metabolism to DHA, including pre-systemic 
conversion into the metabolite. Elimination of both compounds was modeled using a first-order process. 
The few basal AM concentrations did not allow estimating a residual dose from previous treatments. 
Inclusion of an inter-patient variability on Vc, CLM, K23 or F1 in addition to AM CL did not improve 
description of the data (ΔOFV ≥ -1.9, p ≥ 0.17). A mixed error model best described residual intra-patient 
variability for AM and a proportional one for DHA. No correlations between the drug and the metabolite 
concentrations could be identified. Our results show that 21% of the AM dose is converted pre-
systemically into DHA. None of the available covariates significantly affected AM or DHA 
pharmacokinetics (ΔOFV ≤ 3.0, p ≥ 0.08). Although non-significant, an increase of 37% in drug CL in 
pregnant women compared to non-pregnant ones was however observed (ΔOFV = -1, p = 0.32). The 
final model parameters’ estimates and bootstrap evaluations are given in Table 7.3. The model was 
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considered reliable since the obtained parameter estimates laid within the bootstrap CI95%. VPC graphs 
of AM and DHA are shown in Figure 7.2A.            
Lumefantrine 
A one-compartment model with first-order absorption and elimination adequately described LF data. A 
two-compartment model did not improve the model fit (ΔOFV = -0.1, p = 0.75). Average dose from 
previous treatment (F0) was estimated to be 3.2 mg with a large inter-individual variability (ΔOFV = -40, 
p  = 2.5·10
-10
). In addition to CL, an inter-patient variability on Vc (ΔOFV = -23, p = 1.6·10
-6
) and a 
correlation between CL and Vc improved significantly the fit (ΔOFV = -117, p = 2.9·10
-27
). The assignment 
of an inter-patient variability on LF bioavailability F1 (fixed to 1) accounting for the correlation between 
CL and Vc and their variability resulted in additional improvement of the model fit (ΔOFV = -9.5, p = 
8.7·10
-3
). Metabolite concentrations were included in the model using a supplementary compartment 
with linear metabolism from the LF central compartment. The addition of an inter-individual variability 
on K23 improved significantly the description of the data (ΔOFV = -41, p = 1.5·10
-10
), while no 
enhancement was observed when assigning variability on CLM (ΔOFV = -0.02, p = 0.89). Residual intra-
patient variability was best described using a proportional and mixed error model for LF and DLF, 
respectively. The model was further improved by including a correlation between drug and metabolite 
concentrations (ΔOFV = -85, p = 3.0·10
-20
). 
In univariable analyses, pregnancy and diarrhea were identified as significant covariates for both F1 
(ΔOFV = -5.1, p = 0.024 and ΔOFV = -15, p = 1.1·10
-4
) and K23 (ΔOFV = -13, p = 3.1·10
-4
 and ΔOFV = -4, p = 
0.045). None of the remaining covariates influenced LF and DLF pharmacokinetics (ΔOFV ≥ -1.4, p ≥ 
0.24). Multivariable combination of the significant covariates showed an additive influence of pregnancy 
and diarrhea on F1 and pregnancy on K23 (ΔOFV = -33, p = 3.2·10
-7
 with respect to the model without 
covariates). Our results show that relative bioavailability is 34% lower and metabolism rate 78% higher 
in pregnant women compared to non-pregnant patients. A decrease of 83% in F1 was observed in 
women with diarrhea as compared to those who had no diarrhea. Table 7.3 illustrates the final model 
parameters’ estimates together with their bootstrap evaluations. The model was considered reliable 
since the obtained parameter estimates laid within the bootstrap CI95%. Figure 7.2B shows the 
concentration time-plots of LF and DLF for pregnant and non-pregnant women included in the analysis 
with average population predictions and 95% intervals.  
Concentration-time simulation of lumefantrine 
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The day 7 predicted median concentrations of LF after administration of a 6-dose regimen over 3 days 
were 908 (PI95% : 217 – 3256) ng/ml for pregnant women and 1382 (PI95%: 386 – 5135) ng/ml for non-
pregnant women (p = 0.10). While considering the large inter-patient variability in the kinetics of LF, 3% 
of the pregnant women would have day 7 concentrations below the cut-off value of 175 ng/ml, 9% 
below 280 ng/ml and 31% below 600 ng/ml. For non-pregnant women, 1% would exhibit day 7 
concentrations below the cut-off value of 170 ng/ml, 2% below 280 ng/ml and 15 % below 600 ng/ml. 
Prolonging the time of drug administration over 5 days among pregnant women would provide median 
concentrations of 1374 (PI95% 367 – 5536) ng/ml, with 0.1%, 2% and 16% of patients with concentrations 
below the cut-off value of 175 ng/ml, 280 ng/ml and 600 ng/ml, respectively [Figure 7.3]. 
Pharmacodynamics  
There were a total of 7 therapeutic failures in the study, 6 (18.2%) pregnant women and 1 (4.5%) non-
pregnant woman (OR = 4.04; p = 0.22). Among pregnant women, one developed ETF at day 1. She 
presented with signs and symptoms suggestive of severe malaria, was admitted and kept on full dose of 
intravenous quinine. One pregnant women had LCF, presented with fever (body temperature = 38.7
0
C) 
at day 20, blood slide confirmed to have parasitaemia of 10,750 counts/µL. The remaining four pregnant 
women had LPF, one at day 28 and three at day 42. One non-pregnant woman had LPF at day 28. Hence, 
the overall PCR uncorrected efficacy of AL in the study was 87%, 82% (6/33) in pregnant women and 
95% (1/22) in non-pregnant women. PCR investigation confirmed recrudescent infection in two women, 
one with ETF and the other with LCF, both pregnant; the remaining 5 (71%) had new infections.   
The median and inter-quarterly range (IQR) for day 7 plasma concentration was 957 (409 – 1541) ng/ml 
in pregnant and 1179 (782 – 1807) ng/ml in non-pregnant women [Figure 7.4A]. Although non-
significant, day 7 LF concentration was lower among women with therapeutic failure than those with 
ACPR. The median (and IQR) for LF concentration among women with ACPR was 1070 (751 – 1665) 
ng/ml whereas, for the women with LCF and LPF it was 730 (227 – 774) ng/ml (p = 0.075) [Figure 4B]. 
Twenty percent of study participants had day 7 LF concentrations below 600 ng/ml. Only two patients 
(33%) out of six among the ones who developed LCF and LPF had day 7 LF concentrations below 600 
ng/ml and all were pregnant. Potential predictors of treatment failure in addition to day 7 LF 
concentration were pregnancy status, gestational age, baseline parasite count, residual antimalarial and 
BMI and none was statistically significant. No participant during the study period had miscarriage, 
stillbirth or any other severe adverse effect(s) related to AL.   
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Discussion 
The study describes the pharmacokinetic properties of AM, LF and their active metabolites DHA and DLF 
in pregnant and non-pregnant women with malaria. The role of different covariates that could influence 
AL bioavailability, distribution and clearance in the two groups were carefully analyzed. The study differs 
from previous reports of population pharmacokinetics of AM and LF in pregnancy [49, 51, 116] by having 
a comparative group of non-pregnant women with malaria from the same population with relatively 
similar characteristics.  
Prior treatment. Detectable residual antimalarial among recruited participants was unexpectedly high. 
This might be explained by uncontrolled prescription of AL, a first line malaria treatment, which is highly 
available and easily accessible from both private and public facilities [65, 66]. Prevalence of residual 
antimalarial among participants was higher than what was reported five years ago from in vivo studies in 
Ifakara (Tanzania) and Praeh Vihear (Cambodia) which was 74.3% and 50%, respectively [123, 124]. Such 
high prevalence of residual antimalarial levels in this population, particularly LF, is alarming because it 
can promote emergence and spread of drug resistance parasite. Also, the high residual prevalence of LF, 
irrespective of pregnancy trimester suggests a considerable AL exposure in the first trimester. There is 
an urgent need to monitor closely the implementation of standard malaria treatment guideline and 
discourage self-treatment by not acquiring antimalarial from drug venders without attended and 
screened for presence of malaria parasitaemia. Significant levels of detected sulfadoxine among 
pregnant women were probably the result of SP received from RCH clinic for Intermittent Preventive 
Treatment (IPTp).  
Pharmacokinetics. The important study finding was the lower LF plasma concentration among pregnant 
patients compared to non-pregnant ones. This is similar to what has been observed in a Thailand study 
in which the concentration of LF was approximately half that of non-pregnant patients from historical 
data in the same population [51]. The reason for low LF concentration may be due to physiological 
changes related to pregnancy status which accounts for reduced absorption, expanded volume of 
distribution, elevated drug metabolism and clearance rate [107]. The observed increase in LF 
metabolism rate among pregnant women is explained by hormonal changes in pregnancy which 
increases catalytic activity of   hepatic enzymes such as CYP3A4, an important enzyme for LF metabolism 
[111]. The design of the study did not allow displaying the effect of reduced absorption on LF 
bioavailability. 
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Altered bowel condition such as having diarrhea during malaria treatment has a significant effect on 
drug absorption and consequently lowers drug bioavailability. Increase of gastro-intestinal motility due 
to diarrhea reduces intestinal transit time of a drug, and this time is important to maximize drug 
absorption [133]. The latter explains why LF concentration, a high lipophilic compound, was 83% lower 
in women with diarrhea compared to the ones with no diarrhea. It is therefore important to assess for 
presence of diarrhea in patients and correct dosage regimens accordingly. 
It is important to study concentration levels of a slowly eliminated partner antimalarial drug such as LF 
so as to determine minimum parasiticidal concentration (MPC) and minimum inhibitory concentration 
(MIC) of malaria parasite [117]. The observed day 7 median concentration of LF was lower in pregnant 
than in non-pregnant women. However, the concentration among pregnant women was twofold higher 
compared to what had been observed in Thai pregnant patients [49]. It is also higher than the 
concentrations previously reported in non-pregnant adults and paediatric patients in Ifakara-Tanzania, 
Thailand, Cambodia and the Lao People’s Democratic Republic [118, 120, 134, 135]. Higher day 7 LF 
levels in the present study may be due to the administration of a standard recommended adult dose of 
AL with food [37] to all patients regardless of the patient’s body weight.  
.  
The simulations under the standard 6 dose of AL over 3 days schedule show that a non-negligible 
number of pregnant women would have LF concentrations below various proposed therapeutic 
threshold targets at day 7. Splitting the same recommended total dose over a 5 day regimen would 
greatly improve the probability of exhibiting therapeutic drug concentrations. The latter has already 
been shown in other pharmacokinetics studies [118, 119, 136], but the benefit might be jeopardized by 
poor adherence to treatment in the prolonged regimen. Hence, a formal assessment of feasibility should 
be performed.   
Pharmacodynamics. The observed cure rate and parasite clearance in pregnant women was lower 
compared to that of non-pregnant patients despite having the same median baseline parasitaemia. The 
observed lower LF concentration at day 7 among the patients with therapeutic failure could be one of 
the reasons explaining this difference. In order to improve therapeutic efficacy, it is therefore important 
to consider dose increase or modifying treatment regimen to allow higher day 7 LF concentrations. Day 
7 LF concentration above 600 ng/dl was associated with 100% efficacy among pregnant patients in 
Thailand [137]. The latter was not observed in our study; indeed 3 out of the 5 (60%) pregnant women 
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with LCF or LTF had day 7 LF concentration above 600 ng/ml. This observation suggests that the 
proposed 600 ng/dl cut-off value better predicts parasite clearance of ongoing infection, rather than 
occurrence of new infection in the follow-up period. 600 ng/dl LF concentration at day 7 is not high 
enough to ensure post-treatment prophylaxis effect up to day 42.  Indeed, reinfections were not all 
prevented with a day 7 LF concentration of 600 ng/ml. Partner drugs with longer half-life might offer 
better protection [117]. 
Baseline parasitaemia was not an important factor to determine therapeutic response among study 
participants. Indeed mean baseline parasite count in patients with ACPR was twofold higher compared 
to the ones with therapeutic failure. This is contrary to what has been reported in previous studies 
involving pregnant and non-pregnant patients in which patients with higher baseline parasitaemia were 
more likely to fail treatment [136, 137]. However, therapeutic failure rate among pregnant women in 
our study was much lower than that observed in Thailand in recent AL pharmacodynamics studies 
whereby therapeutic failure among pregnant patients was more than 30% [49, 137]. We have reason to 
believe that AL is more efficacious in Africa than in Southeast Asia where resistance to other antimalarial 
drugs such as quinine, mefloquine and artesunate has increased [47, 138].  
Conclusion 
The current AL treatment regimen in pregnancy is challenged by having low post-treatment prophylactic 
effect. Pregnancy is an important associated factor for low plasma concentration of LF probably due to 
reduced drug absorption, elevated drug metabolism and rapid clearance rate. It is therefore important 
to evaluate new treatment regimens of AL in this vulnerable group that would target higher day 7 LF 
concentration levels.  
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Tables and figures 
Table 7.1: Characteristics of study participants with P falciparum malaria on the day of enrollment
 
 
Characteristics 
Pregnant women (n=33) Non-pregnant women (n=22) 
Median (range) Median (range) 
Age (years) 25 (18 -41) 21.5 (18 -35) 
Body weight (Kg) 52 (40 – 80) 48.5 (41 – 79) 
Height (cm) 158 (147 – 169) 157 (150 – 174) 
BMI 21.8 (16.5 – 30.1) 20.3 (16.4 – 33.3) 
Haemoglobin (g/dl) 10.2 (7.1 – 13.3) 13.4 (8 – 15.5) 
Temperature (
0
C) 37.1 (36.0 – 39) 37.2 (36.0 – 39.6) 
Parasitaemia (counts/µL) 25,280 (560 – 198,080) 22,280 (560 – 195,680) 
Gestation age (weeks) 27 (14 – 37) NA 
*Pregnancy – trimesters   
Second trimester (%) 17 (52) NA 
Third trimesters (%) 16 (48) NA 
*Trimester presented in number (%). NA means not applicable 
Abbreviation: BMI = Body Mass Index 
 
Table 7.2: Plasma concentration of residual antimalarial drugs detected prior to treatment with AL in 57 
recruited study patients [ng/ml] 
 
Antimalarial 
 
Patients (%) 
 
 
Plasma concentration [ng/ml] 
Mean Median Minimum Maximum 
Lumefantrine 51 (89.5)  37.3 24.9 5.4 205.5 
Desbutyl-
limefantrine 
8 (14.0)  2.5 1.5 0.3 6 
Artemether 4 (7)  26.4 2.9 0.4 157.3 
Sulfadoxine 14 (24.6)  1,334.3 1,298.1 5.3 3,615.6 
Pyrimethamine 11 (19.6)  6.9 5.3 1.7 18 
Quinine 1 (1.8)  12.3 12.3 12.3 12.3 
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Table 7.3: Final population parameter estimates of artemether, lumefantrine and their metabolites and 
their bootstrap evaluations in 2000 replicates 
Population pharmacokinetics analysis Bootstrap evaluation 
Parameter Estimate  SEa 
(%) 
IIVb 
(%) 
SEc 
(%) 
Estimate CI95%
d IIVb 
(%) 
CI95%
d 
Artemether  
CL (L/h) 98 24 99 65 102 69-140 93 66-120 
Vc (L) 373 16   354 225-492   
LogitF1 1.4 27   1.5 0.7-2.6   
Ka (h
-1
) Fixed to 0.70       
VM (L) Fixed to Vc       
K23 (h
-1
) 0.084    0.088 0.05-0.16   
CLM(L/h) 71 46   69 38-136   
σprop,AM (CV%) 72 26   69 49-87   
σadd,AM (μmol/L) 0.13 7   0.13 0.03-0.20   
σprop,DHA (CV%) 53 14   51 44-59   
Lumefantrine         
CL (L/h) 2.8 12   2.8 2.2-3.6   
Vc (L) 134 14   134 101-174   
F1 Fixed to 1 65 50    61 43-77 
θPregF1 -0.33 37   -0.31 -(0.52-0.05)   
θdiarrF1 -0.84 15   -0.78 -(0.95-0.44)   
Ka (h
-1
) Fixed to 0.54       
VM (L) Fixed to Vc        
F0 (mg) 2.7 18 87 46 2.95 1.9-4.4 116 70-164 
K23 (h
-1
) 1.6·10
-4
  46 54 1.6·10
-4
 (1.2-2.0)·10
-4
 44 31-57 
θPregK23 0.80 32   0.80 0.4-1.3   
CLM(L/h) 2.6 15   2.6 1.9-3.5   
σprop,LF (CV%) 51 32
c
   51 45-56   
σprop,DLF(CV%) 39 40
c
   38 32-44   
Correlation 
LF/DLF 
68 18   67 63-69   
σadd,DLF(μmol/L) 4.4·10
-3
 17
c
   4.9·10
-3
 (3.8-6.1)·10
-3
   
Abbreviations: CL: clearance, VC: central volume of distribution, logitF1: logit F1 expressed as a logit 
function, ka: first-order absorption rate constant, VM: volume of distribution of the metabolite, F0: 
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residual amount from the previous treatment, k23: metabolism rate constant, CLmet: metabolite 
clearance, σprop: exponential residual error, σadd: additive residual error, θX PAR: effect of the X 
covariate on the parameter PAR expressed as (1- θX PAR X). 
a
 Standard error (S.E.) of the estimate θi defined as S.E estimate/estimate, expressed as a 
percentage  
b
 Inter-individual variability  
c
 Standard error (S.E.) of the coefficient of variation or the additive component of the residual 
error defined as √S.E eshmate/eshmate, expressed as a percentage 
d
 95% confidence interval (C.I.)  
 
 
 
 
Figure 7.1: Relationship between parasite density at enrollment and plasma residual levels of 
sulfadoxine prior treatment in 14 pregnant women  
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Figure 7.2A:  Observed AM (left panel) and DHA plasma concentrations (right panel). Filled and empty 
circles represent pregnant and non-pregnant women, respectively. The solid line represents the average 
predicted concentrations and the dashed lines the 95
th
 prediction intervals. 
Figure 7.2B: Observed LF (upper panels) and DLF plasma concentrations (lower panels) in pregnant and 
non-pregnant women. Triangles residual plasma concentrations of LF and DLF found prior treatment 
initiation. The solid lines represent the mean population prediction and the dotted lines PI95%. 
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Figure 7.3: Predicted median concentration of lumefantrine (LF) after administration of 6·480 mg 
regimen over 3 (continuous line) and 5 days (dotted line) in pregnant women. Day 7 (168h) 
median predicted concentrations (circles) with their PI95% are shown for the two dosage regimens.  
 
 
Figure 7.4A: Day 7 plasma concentration of lumefantrine in pregnant (n = 32) and non-pregnant (n = 22) 
study women 
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Figure 7.4B: Day 7 plasma concentration of lumefantrine in women with ACPR (n = 48) and those with 
treatment failure (n = 6) * 
 
* Day 7 lumefantrine concentration could not be assessed in one woman since a rescue treatment with quinine was given at 
day 1 because of early treatment failure.   
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Abstract 
Background 
Intermittent Preventive Treatment during pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) has 
been shown to decrease placental malaria and pregnancy-associated malaria morbidity, and improve 
birth outcomes in highly endemic areas, but its benefit is unclear in areas with moderate to low 
transmission intensity and where parasite resistance to SP is high.  The aim of the study was to assess 
the effectiveness of IPTp in areas with two different malaria transmission intensity. 
Method 
A prospective study recruiting pregnant women was conducted in two health facilities situated in areas 
with high and low malaria transmission intensity. A structured questionnaire was used to interview for 
socio-demographic characteristics and obstetrics history. Placental parasitaemia was screened using 
both light microscopy and real-time quantitative PCR.  
Results 
350 pregnant women were recruited and screened for placental parasitaemia, 175 from each area. 
Prevalence of placental parasitaemia was 16.6% (CI 11.4–22.9) in high transmission area and 2.3% (CI 
0.6–5.7) in low transmission area. Primigravidae and residing in high transmission area were significant 
risk factors for placenta malaria (OR 2.4; CI 1.1–5.0; p=0.025) and (OR 9.4; CI 3.2–27.7; p< 0.001), 
respectively. IPTp was associated with decreased risk of placental malaria (OR 0.3; CI 0.1–1.0; p=0.044); 
the effect was more pronounced in high transmission area (OR 0.2; CI 0.06–0.7; p=0.015) than in low 
transmission area (OR 0.4; CI 0.04–4.5; p=0.478). IPTp use was not associated with decreased risk of 
maternal anaemia or low birth weight, regardless of transmission intensity. The number needed to treat 
(NNT) was 4 (CI 2 – 6) women in high transmission area and 33 (20 – 50) in low transmission area to 
prevent one case of placental malaria.  
Conclusion 
IPTp may have effect on lowering the risk of placental malaria in areas of high transmission, but this 
effect did not translate into a benefit on risk of maternal anaemia or low birth weight. The NNT needs to 
be considered, and weighted against that of other protective measures, eventually targeting areas 
which are above a certain threshold of malaria transmission in order to maximize the benefit.  
 
Keywords: IPTp-SP, Placental malaria, Anaemia, Low birth weight 
74 
 
Background 
Approximately 85 million pregnant women throughout the world are at risk of Plasmodium falciparum 
infection every year, two-third are in sub-Sahara Africa [1]. Pregnancy-associated malaria (PAM) is an 
important known cause of maternal and neonatal morbidity such as severe maternal anaemia, intra-
uterine growth retardation, low birth weight (LBW), premature delivery, intrauterine death, stillbirth, 
and can lead to maternal or neonatal mortality [90]. Apart from malaria, anaemia in pregnancy may be 
secondary to iron, folate and vitamin B deficiency, sickle cell diseases, HIV or helminthic, which may also 
lead to LBW [139]. 
Human placenta is a preferred site for P. falciparum to accumulate and hence lead to deleterious 
consequence to both mother and the unborn baby [140].Infected erythrocytes express a unique variant 
surface antigen (VSA) which mediates adherence to chondroitin sulphate-A (CSA) receptors in the 
placental endothelium and sequester in the intervillous spaces. Sequestration leads to placental 
insufficiency which is due to inflammatory reaction to the infected erythrocytes. The reaction causes 
vasoconstriction and vascular damage which jeopardize haemodynamics of placenta [10, 19]. 
Primigravidae are particularly vulnerable to placental malaria than multigravidae because they lack 
neutralizing antibodies to CSA binding parasites that cause placental sequestration [141]. Placental 
parasitaemia, maternal anaemia and LBW are known to be more frequent in areas with stable malaria 
transmission because of the considerable higher level of acquired malaria immunity among women than 
in unstable transmission areas [142]. 
Prompt and effective case management of malaria illness and anaemia, use of insecticide treated nets 
(ITNs), and use of at least 2 doses for intermittent preventive treatment during pregnancy with 
sulfadoxine-pyrimethamine (IPTp-SP) after quickening have long been recommended by the WHO for 
malaria control especially in areas with stable malaria transmission [27]. IPTp regimen has recently been 
modified: it is now required that the first IPTp-SP dose to be administered as early as possible during 
second trimester and SP doses be given at least one month intervals up to delivery [32]. There is a 
growing concern that IPTp-SP effectiveness may be jeopardized by the high degree of resistance of P 
falciparum to SP. The latter is reported to be a major concern in East Africa and hence questions the 
viability of IPTp-SP use in this area [33, 143-145]. However, a meta-analysis by Kayentao et al [34] 
confirms the beneficial effects of 3 or more doses of IPTp in reducing the risk of LBW. 
With the reported significant decline of malaria in most areas of East Africa including Tanzania [100, 146, 
147], it becomes essential to evaluate the benefit of routine IPTp-SP, especially in areas with low malaria 
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transmission. This may assist decision-making on the relevance of advocating universal IPTp in areas 
where the rate of SP adverse reactions may outweigh the benefit of the treatment. For example, SP is 
not recommended to HIV infected women receiving cotrimoxazole prophylaxis or antiretroviral drugs 
due to fear of an increased occurrence of adverse drug reaction [148]. Little is known regarding 
effectiveness of IPTp-SP over other preventive measures for PAM morbidity in areas with low malaria 
transmission [32]. The aim of the study was to assess the effect of IPTp on placental malaria, PAM 
morbidity and birth outcomes in areas with high and low malaria transmission intensity.  
Methods 
Study area 
The study was carried out in Moshi municipal, north-eastern Tanzania and Rufiji district in the eastern, 
coastal area of the country. Moshi is a low malaria transmission area with malaria prevalence of 1.0% 
while Rufiji district is a moderate to high malaria transmission area with prevalence of 20.8% [149]. The 
prevalence of P falciparum dihydropteroate synthase (Pfdhps) gene 581G mutation was 56% in infected 
malaria cases, according to the evaluation conducted six years ago in Tanga, a region adjacent to the 
two study areas [150]. This same area had a day 14 SP treatment failure rate as high as 68% among 
children [151]. Mawenzi Hospital in Moshi and Kibiti health Centre (HC) in Rufiji were involved to recruit 
study participants. In the year 2012, malaria accounted for 4% of the total out-patient cases in Mawenzi 
Hospital and 51% in Kibiti HC [152]. Both health facilities are public own with free antenatal care and 
delivery services. The standard of care and capacity to handle obstetrics emergences in the two facilities 
is similar. 
Study design 
A prospective study was conducted from July to October 2012, enrolling pregnant women who came for 
delivery in Mawenzi Hospital and Kibiti HC obstetric wards. The selection criteria for recruiting the 
participants included residency in the study area for at least one year, age of 16 years and above, 
gestational age of 28 weeks and above, and presence of up-to-date medical information. Cases of 
multiple pregnancies, severe conditions such as eclampsia, haemorrhage and sepsis were excluded. A 
structured questionnaire was used to interview women. Information from the mother’s medical registry 
and Reproductive and Child Health (RCH) clinic card were used to verify and complement the generated 
information. Recorded information included social demographic characteristics, parity, ITNs use, history 
of malaria illness during pregnancy, use of IPTp-SP, haematemics and anthelmintic drugs. Gestational 
age was estimated based on the date of last normal menstrual period and compared with the estimated 
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fundal height recorded during first RCH booking. Birth weight below 2,500 grams was defined as LBW, 
preterm birth below 37 weeks of gestational age, and maternal anaemia was haemoglobin level below 
11 g/dl. Placental malaria infection was defined as parasite positive results based on either blood slide 
smear reading or Polymerase Chain Reaction (PCR) results. Purpose of performing the two malaria 
screening tests was to maximize chances of detecting infected placentas.  
Sample collection and examination 
Placental blood was collected within one hour after delivery. Incision was made from at least three 
different sites of placenta on the maternal side where accumulated intervillous blood was collected 
using a blunt syringe. About two drops of collected blood (about 100 µL) were spotted onto a 
903whatman® filter paper (3MM), air dried and preserved in plastic zipped locked bags for PCR 
genotyping. Filter papers were then transferred to the laboratory and DNA was extracted using Chelex® 
method [125]. The DNA was stored at -20
0
C until further used. Malaria parasite positivity was 
determined by quantitative real-time PCR targeting the P falciparum S-type gene as described by 
Wampfler et al [153]. 
Thick and thin blood smear were also prepared and stained with Giemsa. Blood slide were examined 
independently by two experienced laboratory technicians using light microscope. Discrepancy findings 
were reviewed by a third independent technician and hence a consensus on positivity was reached. 
Parasite in thick film fields were counted per 200 leukocytes and the parasite count was multiplied by a 
factor of 40 to give parasites per µl of blood. 
Statistical analysis 
Data analysis was performed using STATA® 12.0 (Stata Corporation, College Station, Texas, USA). 
Numerical variables were summarized into median and range. Categorical variables were summarized 
using cross tabulation to estimate different proportion. The primary outcome was the proportion with 
placental malaria. The bivariable models included IPTp, maternal age, gravidity, transmission intensity 
level, history of malaria illness in pregnancy, HIV status, and ITNs as explanatory variables. Variables 
associated with the outcome having a p value < 0.2 in the bivariable model were retained in the final 
adjusted logistic regression model to estimate odds ratio (OR) and 95% confidence intervals (CI). The 
same method was done for secondary outcomes, i.e maternal anaemia and LBW. 
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Ethics 
Ethical approval for the study was granted by the Kilimanjaro Christian Medical University College 
(KCMUCo) research ethics committee, recognized by the National Institute for Medical Research (NIMR). 
Written informed consent was obtained from all participants after each was informed individually 
regarding study’s procedures. For a participant below 18 years, written consent was provided by a 
guardian or husband who was above 18 years. 
Results 
A total of 350 pregnant women were recruited and screened for placenta parasitaemia, 175 from the 
high malaria transmission area (Rufiji) and 175 from low malaria transmission area (Moshi). There was 
no early maternal death or referral to a tertiary health facility during the study period. The mean 
maternal age and gestational age at the time of recruitment was 25.2 years (standard deviation [SD] 6.9) 
and 37.2 (SD 2.2) weeks, respectively. 319 (91%) of recruited women reported to have used one or more 
dose of IPTp. The median (interquartile range [IQ] gestational age when the first IPTp dose was 
administered was 24 weeks (19 – 32) while, the median (IQ) gestational age at the second 
administration of IPTp dose was 30 weeks (24 – 36). Main demographic, screening parameters and 
pregnancy outcome information are presented in table 8.1. 
Prevalence of placental malaria and associated factors 
Prevalence of placental malaria was 16.6% (29/175) in the high transmission area and 2.3% (4/175) in 
the low malaria transmission. In high malaria transmission area, the prevalence of placenta malaria was 
8% (14/175) by light microscopy and 15.4% (27/175) by PCR, whereas in low transmission area, it was 
1.1% (2/175) and 1.7% (3/175) respectively. 
Details of variables associated with placental malaria by bivariable and logistic regression model are 
shown in Table 8.2. Women living in high transmission areas were nine times more likely to have 
placental malaria than those living in low transmission areas (adjusted OR 9.4; CI 3.2 – 27.7; p< 0.001). 
Primigravidae were twice more likely to have placental malaria than multigravidae (adjusted OR 2.4; CI 
1.1 – 5.0; p=0.025). There was no evidence of the association between placental malaria and HIV status 
or history of malaria during pregnancy.  
Effectiveness of IPTp on placental malaria 
In high transmission area, out of the 163/175 (93.1%) women who reported to have used at least one 
dose of IPTP, 24 (14.7%) were found to have placental malaria, while 139 (85.3%) had no placental 
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malaria. Among the 12/175 (6.9%) who reported not to have used IPTp during their pregnancy, 5 
(41.7%) were found to have placental malaria. In low transmission area, of the 156/ 175 (89%) women 
who reported to have used at least one dose of IPTp, 3 (2.0%) were found to have placental malaria. 
Among the 19 (10.9%) who reported not to have used IPTp, one had placental malaria. In multivariate 
analysis, one dose or more of IPTp had 80% protective efficacy against placental malaria in high 
transmission area (adjusted OR 0.2; CI 0.06 – 0.7; p=0.015), while it was 60%,in low transmission area 
(adjusted OR 0.4; CI 0.04 – 4.5; p=0.478) [Table 8.3a and 8.3b]. There was no significant relationship 
between number of IPTp doses taken and prevalence of placental malaria in high transmission area or in 
low malaria transmission (Figure 8.1). 
Number needed to treat (NNT) with IPTp to prevent placental malaria 
In high transmission area, 24 out of 163 women who used IPTp had placental malaria versus 5 out of 12 
women who did not use IPTp. This gives an absolute reduced risk of 27% for women to have placental 
malaria after using at least one dose of IPTp. Thus, in high malaria transmission area, 4 (CI 2 – 6) 
pregnant women needed to be treated with IPTp to prevent one case of placental malaria (NNT = 1/0.27 
= 3.7 = ~ 4 women). By stratifying for gravidity, 14 out of 54 primigravidae who used IPTp in the same 
transmission area had placental malaria versus 2 out of 4 primigravidae who did not use IPTp. Among 
multigravidae, 10 out of 109 who used IPTp had placental malaria versus 3 out of 8 women who did not 
use IPTp. The absolute reduced risk in primigravidae in this area was 24% (0.5 – 0.26 * 100) while it was 
29% (0.38 – 0.09 * 100) in multigravidae. Therefore, 4 (CI 2 – 4) primigravidae needed to be treated in 
high transmission area with at least one dose of IPTp to prevent one case of placental malaria (NNT = 
1/0.24 = 4.2), versus 3 (CI 3 – 11) for multigravidae (NNT = 1/0.29 = 3.4). 
In low transmission area, 3 out of 156 women who used at least one dose of IPTp had placental malaria 
versus 1 out of 19 women who did not use IPTp. This gives an absolute reduced risk of 3% (0.05 – 0.02 * 
100). Therefore, in low transmission area, 33 (CI 20 – 50) pregnant women needed to be treated with at 
least a single dose of IPTp to prevent one case of placental malaria (NNT = 1/0.03 = 33.3 = about 33 
women). One out of 69 primigravidae in the same transmission area had placental malaria whereas 
there was none among those who did not use IPTp at all. For multigravidae in this transmission area, 2 
out of 87 who used IPTp had placental malaria versus one out of 15 of who did not use IPTp. The 
absolute reduced risk in primigravidae in this area was less than 0 and for multigravidae was 4% (0.067-
0.023 * 100). Therefore, 25 (CI 14 – 50) multigravidae needed to be treated in low transmission area 
with at least a single dose of IPTp to prevent one placental malaria (NNT = 1/0.04 = 25). 
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IPTp and maternal anaemia 
A total of 223/350 (63.7%) study women had haemoglobin concentration measured before delivery. The 
prevalence of maternal anaemia in high transmission area was 60.4% (81/134; CI 51.6 – 68.8) whereas it 
was 43.8% (39/89; CI 33.3 – 54.7) in low transmission area. Hence, living in area of high malaria 
transmission was associated with a significant increased risk of maternal anaemia when compared to 
low endemic area (adjusted OR 1.8; CI 1.0 – 3.2; p =0.036) [Table 8.4]. The prevalence of maternal 
anaemia in high transmission area among women who used at least one dose of IPTp was 61% (76/125), 
not much different than the 56% (5/9) among those who did not use IPTp (adjusted OR 1.2; CI 0.3 – 4.8; 
p = 0.755) [Table 8.3a]. In low transmission area, prevalence of anaemia was 46.2% (36/78) among 
women who used at least one dose of IPTpversus27.3% (3/11) among those who did not (adjusted OR 
2.6; CI 0.6 – 10.7; p = 0.191) [Table 8.3b].Among other explanatory variables, placental malaria, 
gravidity, history of malaria infection during pregnancy, HIV status, anthelminthic and use of iron and 
folate supplementation at least a month during pregnancy period all had no statistical significant effect 
on maternal anaemia [Table 8.4]. 
IPTp and low birth weight  
The prevalence of LBW in the high transmission area was 6.3% (11/175; CI 3.2 – 11.0) versus 4% (7/175; 
CI 1.6 – 8.1) in low transmission area (adjusted OR 1.7; CI 0.6 – 4.5; p = 0.293) [Table 8.5]. The 
prevalence of LBW in high transmission area among women who used at least one dose of IPTp was 
5.5% (9/163) versus 16.7% (2/12) for those who did not use IPTp (adjusted OR 0.3; CI 0.1 – 1.5; p = 
0.146) [Table 8.3a]. The prevalence of LBW in low transmission area among women who used at least 
one dose of IPTp was 3.8% (6/156) versus 5.3% (1/19) for those who did not (adjusted OR 0.7; CI 0.1 – 
6.4; p = 0.757) [Table 8.3b]. Among other explanatory variables, placental malaria, gravidity, history of 
malaria infection during pregnancy, HIV status, anthelminthic and use of iron and folate 
supplementation at least a month during pregnancy period all had no statistical significant effect on the 
risk of LBW [Table 8.5]. 
Discussion 
To our knowledge, the present study is the first to evaluate the effectiveness of IPTp in relation to 
placental malaria in areas with different malaria transmission intensities and high parasite resistance to 
SP. The evaluation takes into account other malaria preventive measures such as ITNs, and other 
preventive measures against maternal anaemia such as routine anthelminthic, iron and folate 
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supplementation. The study responded to a call from WHO that emphasized the importance of 
enhanced regular monitoring of IPTp effectiveness [32]. 
The prevalence of placental malaria was eight times higher in the high transmission area compared to 
the low transmission area (17% vs 2%). The overall prevalence of 9% in the present study corresponds to 
8% prevalence which was observed nine years ago in Ifakara, another part of the country [154]. It shows 
that malaria in pregnancy is still an important health issue in Tanzania, especially in high transmission 
settings, that need to be addressed by effective preventive measures. Self-reporting of ITNs use by 95% 
of pregnant women is encouraging considering the reported ITNs efficacy of 23% against placental 
parasitaemia, 33% against miscarriage/stillbirth and 23% against LBW according to a systematic reviews 
of randomized trials [30]. In the present study, all women with placental malaria reported to have used 
ITNs, which precludes any effectiveness calculation. Our assessment of IPTp effectiveness applies thus 
only in condition of full ITN coverage. 
Use of IPTp was associated with 80% protection against placental malaria in the high transmission area, 
and 60% in the low transmission one. The study findings agree with previous studies and reviewed 
evidence of IPTp to reduce the risk of placental malaria [34, 155-157]. This is achieved because each 
IPTp dose clears or suppresses any concurrent malaria parasites in the placenta and provides about 6 
weeks post treatment prophylaxis [27, 158]. There was no IPTp dose increase relationship with reduced 
risk of placental malaria. The latter is opposite to what was reported by Kayentao K et al [34] in a 
systematic review that risk of placental infection decreases with increased number of IPTp doses which 
lead to the new WHO IPTp regimen of monthly IPTp administration from early second trimester[32]. 
However, our study was not powered to determine the effect of increasing dose on placental malaria. 
On the other hand, it may well be that the time interval between the last IPTp administrated dose and 
screening for placental malaria is a stronger determinant for detecting parasitaemia rather than the 
cumulative number of doses a woman received during her pregnancy. Indeed, the prophylactic effect of 
a drug declines when its plasma concentration decreases with time. The present study had a limitation 
to document the period interval between the last IPTp dose and delivery date, the moment when 
placenta sample was collected for screening of parasitaemia. This is essential to consider, particularly in 
high transmission areas whereby daily chances for a woman to have infectious mosquito bites are 
higher.  
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Due to the observed significant risk of having placental malaria when residing in high transmission area, 
the value for money of IPTp was much higher in areas of high transmission intensity due to its observed 
effect of reducing risk for placental malaria. Indeed, it was generally required to treat eight times less 
women in this area compared to low transmission area with at least one dose of IPTp to prevent one 
case of placental malaria. Because of the known higher risk of placental malaria in primigravidae, we 
attempted to estimate the NNT in this group versus the multigravida ones in both areas, but the small 
sample size and uneven representation of the exposure groups, both being potential biases of the study 
did not allow having meaningful results. In view of the importance to determine NNT in other malaria 
interventions in pregnancy such as ITN use, 18 and 50 pregnant women are the NNT with ITN to prevent 
at least one placental malaria and a LBW respectively, observed in a randomized trial of ITN in high 
malaria transmission area in Kenya [29]. The NNT should be more regularly used as criterion to prioritize 
interventions, especially so in moderate to low transmission areas. This estimation is essential in an era 
of declining malaria. Other preventive measures of malaria in pregnancy, such as intermittent screening 
and treatment (IST) with an effective antimalarial, have shown to be non-inferior to IPTp-SP against 
placental malaria, severe maternal anaemia and LBW in a randomized control trial in Ghana [159]. 
Effectiveness and/or value for money of IST in East Africa region may be higher than IPTp-SP because of 
the considerable higher SP resistance in this area as opposed to West Africa. Combining both IST and ITN 
use could help to overcome unnecessary monthly exposure to SP, especially in low transmission areas. 
However, having an effective, cheaper and user-friendly malaria screening test in pregnancy for 
universal coverage in antenatal clinics is an important challenge. The additional benefit of indoor 
residual spraying (IRS) in different level of malaria endemicity should probably also be part of this 
exercise 
It is important to note that the coverage of IPTP second dose in most of sub Saharan countries is below 
60% [31]. In the present study, IPTp second dose coverage was 51% with no difference between either 
of the two transmission areas. The key question is if the observed coverage of IPTp second dose is so 
low, what will be the coverage achieved for third and more doses. All this call for effective evaluation of 
the proposed IPTp regimen in comparison with novel proposed preventive measures of malaria in 
pregnancy.  
The primary aim of malaria preventive measures in pregnancy is to prevent deleterious effects of 
malaria in woman and the baby. The usual concept is that IPTp reduces maternal parasitaemia, and 
hence maternal anaemia, placental malaria and LBW. IPTp effectiveness was challenged by Harrington 
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et al., [33] who conducted a study in Muheza, Tanzania, an area known to have high SP resistance, 
where IPTp did not decrease the risk of placental malaria, nor had an effect on improving maternal 
anaemia or LBW. A further challenging finding was reported by Gutman et al., [160] in Malawi which 
showed that IPTp did not reduce the frequency of placental malaria but was associated with improved 
birth outcomes. We ourselves found that IPTp did reduce placental malaria, but had no effect on 
maternal anaemia. For LBW, there was still a beneficial effect but the latter was not significant, probably 
due to the low rate in both study areas. Women deliver at home may have had an adverse outcome but 
our study had limitation of recruiting at delivery. However, inconsistences of IPTp effectiveness on 
improving maternal anaemia and LBW have also been reported in a systematic review by McClure EM et 
al., [161]. It is likely that malaria is only one of the important contributors of maternal anaemia and LBW 
in developing countries. It will be thus essential in the coming years to monitor the changes in maternal 
malaria morbidity and the dynamic of LBW rates in areas of declining malaria transmission [146, 147] to 
better understand the respective role of malaria, malnutrition, infections (apart from malaria) and 
social-economic factors on maternal and baby outcomes. 
Conclusion 
The study shows that IPTp was associated with a lower rate of placental malaria, but this effect did not 
translate into protection against maternal anaemia and low birth weight. The NNT may suggest IPTp as 
an appropriate malaria control intervention, at least in areas with high level of malaria transmission. 
IPTp benefit is questionable in areas of low transmission. The NNT should be regularly evaluated in 
different level of malaria transmission and parasite resistance, different geographic settings, and on 
both mother and infant outcomes to best maximize benefit at reasonable costs.  
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Tables and figures 
Table 8.1: Characteristics of study participants from the Moshi and Rufiji study sites 
Characteristics Moshi (n = 175) 
n (%) 
Rufiji (n = 175) 
n (%) 
Total 
350 (%) 
Age (years) 
               < 20 
               20 – 35  
               > 35  
 
35 (20.0) 
126 (72.0) 
14 (8.0) 
 
50 (28.6) 
104 (59.4) 
21 (12.0) 
 
85 (24.3) 
230 (65.7) 
35 (10.0) 
Gravidity 
               Primigravidae 
               Multigravidae 
 
73 (41.7) 
102 (58.3) 
 
58 (33.1) 
117 (66.9) 
 
131 (37.4) 
219 (62.6) 
IPTp use 
               Not at all 
               Single dose 
               Two or more doses 
 
19 (10.9) 
66 (37.7) 
90 (51.4) 
 
12 (6.9) 
72 (41.1) 
91 (52.0) 
 
31 (8.9) 
138 (39.4) 
181 (51.7) 
ITNs use 
               Yes 
               No 
 
161 (92.0) 
14 (8.0) 
 
170 (97.1) 
5 (2.9) 
 
331 (94.6) 
19 (5.4) 
HIV status 
               Positive 
               Negative 
               No results 
 
8 (4.5) 
160 (91.4) 
7 (4.0) 
 
4 (2.3) 
171 (97.7) 
0 (0.0) 
 
12 (3.4) 
331 (94.6)  
7 (2.0) 
Haemoglobin level (g/dl)* 11.1 (1.7) 10.5 (1.4) 10.7 (1.6) 
Parasite density (count/µl)* 18 (14.1) 269.9 (336.5) 238.4 (324.9) 
Pregnancy outcome    
Birth outcome 
               Live birth 
               Stillbirth  
 
172 (98.3) 
3 (1.7) 
 
172 (98.3) 
3 (1.7) 
 
344 (98.3) 
6 (1.7) 
Birth weight 
               ≥ 2500 gram 
               < 2500 gram 
 
168 (96.0) 
7 (4.0) 
 
164 (93.7) 
11 (6.3) 
 
332 (94.9) 
18 (5.1) 
Gestational age at birth 
               Term 
               Preterm  
 
149 (85.1) 
26 (14.9) 
 
150 (85.7) 
25 (14.3) 
 
174 (49.7) 
176 (50.3) 
*Haemoglobin level and placenta parasite density presented in mean (sd) 
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Table 8.2: Strength of association between placental malaria and other factors 
Variable Placental malaria Crude OR 
(95% CI) 
 
p Adjusted OR
α
 
(95% CI) 
p
 µ
 
Yes 
33 (%) 
No 
317 (%) 
Age (years) 
     < 25 
     ≥ 25 
 
14 (42) 
19 (58) 
 
146 (46) 
171 (54) 
 
0.9 (0.4 – 1.8) 
 
0.860 
 
2.5 (0.7 – 9.5) 
 
0.164 
Gravidity 
     Primigravidae 
     Multigravidae 
 
17 (52)  
16 (48) 
 
114 (36) 
203 (64) 
 
1.9 (0.9 – 3.9) 
 
0.083 
 
2.4 (1.1 – 5.0) 
 
0.025 
 
Transmission  
     High 
     Low 
 
29 (88) 
4 (12) 
 
146 (46) 
171 (54) 
 
8.5 (2.9 – 24.7) 
 
< 0.001 
 
9.4 (3.2 – 27.7) 
 
< 0.001 
History of malaria 
     Yes 
     No 
 
6 (18) 
27 (82) 
 
62 (20) 
255 (80) 
 
0.9 (0.4 – 2.3) 
 
0.849 
 
1.1 (0.4 – 2.9) 
 
0.846 
HIV status* 
     Positive 
     Negative 
 
1 (3) 
31 (97) 
 
11 (4) 
300 (96) 
 
0.9 (0.1 – 7.0) 
 
0.904 
 
1.2 (0.1 – 11.2) 
 
0.883 
ITNs use 
     Yes 
     No 
 
33 
0 
 
317 
0 
 
- 
 
- 
 
- 
 
- 
*Seven women had no HIV results 
µ
Estimated from the logistic regression model 
α
Adjusted for gravidity and area of malaria transmission 
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Table 8.3a: IPTp use in relation to placenta malaria, maternal anaemia and low birth weight in high 
malaria transmission areas 
Variable Frequency Crude OR 
 (95% CI) 
p Adjusted OR
α 
(95% CI) 
p
 µ
 
 
Placental malaria 
Yes 
29 (%) 
No 
146 (%) 
    
IPTp use 
               Yes 
               No 
 
24 (82.8) 
5 (17.2) 
 
139 (95.2) 
7 (4.8) 
 
0.2 (0.1 – 0.8) 
 
0.023 
 
0.2 (0.1 – 0.7) 
 
0.015 
Maternal anaemia* Yes 
81 (%) 
No 
53 (%) 
    
IPTp use 
               Yes 
               No 
 
76 (93.8) 
5 (6.2) 
 
49 (92.5) 
4 (7.5) 
 
1.2 (0.3 – 4.8) 
 
0.756 
 
1.2 (0.3 – 4.9) 
 
0.755 
Low birth weight Yes 
11 (%) 
No 
164 (%) 
    
IPTp use 
               Yes 
               No 
 
9 (81.8) 
2 (18.2) 
 
154 (93.9) 
10 (6.1) 
 
0.3 (0.1 – 1.5) 
 
0.146 
 
0.3 (0.1 – 1.5) 
 
0.146 
*No haemoglobin level information in 41 women 
µ
Estimated from the logistic regression model 
α
Adjusted for gravidity 
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Table 8.3b: IPTp use in relation to placenta malaria, maternal anaemia and low birth weight in low 
malaria transmission areas 
Variable Frequency  Crude OR 
 (95% CI) 
p Adjusted OR
α 
(95% CI) 
p
 µ
 
 
Placental malaria 
Yes 
 4 (%) 
No 
171 (%) 
    
IPTp use 
               Yes 
               No 
 
3 (75.5) 
1 (25.5) 
 
153 (89.5) 
18 (10.5) 
 
0.4 (0.03 – 3.6) 
 
0.378 
 
0.4 (0.04 – 4.5) 
 
0.478 
Maternal anaemia* Yes 
39 (%) 
No 
50 (%) 
    
IPTp use 
               Yes 
               No 
 
36 (92.3) 
3 (7.7) 
 
42 (84.0) 
8 (16.0) 
 
2.3 (0.7 – 9.3) 
 
0.247 
 
2.6 (0.6 – 10.7) 
 
0.191 
Low birth weight Yes 
7 (%) 
No 
168 (%) 
    
IPTp use 
               Yes 
               No 
 
6 (85.7) 
1 (14.3) 
 
150 (89.3) 
18 (10.7) 
 
0.7 (0.1 – 6.3) 
 
0.767 
 
0.7 (0.1 – 6.4) 
 
0.757 
* No haemoglobin level information in 41 women 86 
µ
Estimated from the logistic regression model 
α
Adjusted for gravidity 
 
 
 
 
 
 
 
 
 
 
 
 
87 
 
Table 8.4: Strength of association between maternal anaemia and other factors 
Variable Anaemia Crude RR 
(95%CI) 
p  Adjusted 
RR
α
(95% CI) 
p
 µ
 
Yes 
120 (%) 
No 
103 (%) 
Placental malaria 
     Infected 
     Not infected 
 
20 (16.7) 
100 (83.3) 
 
10 (9.7) 
93 (90.3) 
 
1.9 (0.8 – 4.2) 
 
0.133 
 
1.5 (0.6 – 3.4) 
 
0.362 
Gravidity 
Primigravidae 
Multigravidae 
 
42 (35.0) 
78 (65.0) 
 
44 (42.7) 
59 (57.3) 
 
0.7 (0.4 – 1.2) 
 
0.238 
 
0.7 (0.4 – 1.3) 
 
0.261 
Transmission  
     High 
     Low 
 
81 (67.5) 
39 (32.5) 
 
53 (51.5) 
50 (48.5) 
 
 
2.0 (1.1 – 3.4) 
 
0.015 
 
1.8 (1.0– 3.2) 
 
0.036 
History of malaria 
     Yes 
     No 
 
24 (20.0) 
96 (80.0) 
 
19 (18.4) 
84 (81.6) 
 
1.1 (0.6 – 2.1) 
 
0.769 
 
1.1 (0.6 – 2.2) 
 
0.737 
HIV status* 
     Positive 
     Negative 
 
4 (3.4) 
115 (96.6) 
 
4 (3.9) 
99 (96.1) 
 
0.9 (0.2 – 3.5) 
 
0.835 
 
0.9 (0.2 – 3.9) 
 
0.912 
Iron & folates
≠
 
     Yes 
     No  
 
105 (88.2) 
14 (11.8) 
 
91 (89.2) 
11 (10.8) 
 
0.8 (0.4 – 2.1) 
 
0.819 
 
0.8 (0.3 – 1.8) 
 
0.552 
Anthelminthic 
     Yes 
     No 
 
108 (90.0)  
12 (10.0) 
 
89 (86.4) 
14 (13.6) 
 
0.3 (0.4 – 1.2) 
 
0.406 
 
1.1 (0.5 – 2.6) 
 
0.804 
*One woman had no HIV result; 
≠
missing iron and folate use information in two women;  
µ
Estimated from the logistic regression model 
α
Adjusted for placental malaria, and transmission intensity 
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Table 8.5: Strength of association between low birth weight and other risk factors 
Risk factor Low birth weight Crude RR 
(95% CI) 
p  Adjusted RR
α
 
(95% CI) 
p
 µ
 
Yes 
18 (%) 
No 
332 (%) 
Placental malaria 
     Infected 
     Not infected 
 
3 (16.7) 
15 (83.3) 
 
30 (9.0) 
302 (91.0) 
 
2.0 (0.6 – 7.4) 
 
0.290 
 
2.1 (0.6 – 7.5) 
 
0.279 
Gravidity 
     Primigravidae 
     Multigravidae 
 
7 (38.9) 
11 (61.1) 
 
124 (37.3) 
208 (62.7) 
 
 
1.1 (0.4 – 2.8) 
 
0.895 
 
1.1 (0.4 – 3.1) 
 
0.809 
Transmission  
     High 
     Low 
 
11 (61.1) 
7 (38.9) 
 
164 (49.4) 
168 (50.6) 
 
1.6 (0.6 – 4.3) 
 
0.337 
 
1.7 (0.6 – 4.5) 
 
0.293 
History of malaria 
     Yes 
     No 
 
6 (33.3) 
12 (66.7) 
 
62 (18.7) 
270 (81.3) 
 
 
2.2 (0.8 – 6.0) 
 
0.134 
 
2.2 (0.8 – 6.1) 
 
0.130 
µ
Estimated from the logistic regression model 
α
Adjusted for history of malaria 
 
 
Figure 8.1: Prevalence of placental malaria in relation to IPTp doses taken in low and high malaria 
transmission areas 
 
HTA = High transmission area; LTA = Low transmission area 
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PART V: GENERAL DISCUSSION, CONCLUSION AND RECOMMENDATIONS 
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Chapter 9: Discussion 
This chapter discusses the main study findings on antimalarial drugs used for the treatment of malaria 
during pregnancy. It includes important challenges and pending answers regarding safety and 
effectiveness of antimalarial drugs in pregnant women. The feasibility of having active 
pharmacovigilance system in pregnancy in Tanzania, as may apply to other resource-limited countries, 
has also been assessed. This thesis responds to pronounced uncertainties on safety and effectiveness of 
antimalarial in this vulnerable group. The chapter also presents general thesis recommendations on 
practical application and potential further studies based on the main study findings.  
9.1 Safety of antimalarial drugs in pregnancy and potential platform for generating reliable drug 
safety information during pregnancy  
There is insufficient safety information on both antimalarial and non-antimalarial drugs administer in 
pregnancy to establish the effect of medication on embryo or developing fetus. This is a significant 
public health problem which leaves the healthcare providers with limited means to weigh risks versus 
benefits when using a given medication. Limited medicine safety information during pregnancy is due to 
the genuine reason that pregnant women are routinely excluded from drug development trials for fear 
of harming the mother and/or the fetus. Part of pregnancy safety information is based on findings from 
animal studies which are not always easy translated to humans and hence, medicines come to market 
with limited safety information available for their use in pregnancy [35]. The latter explains why most 
medicines are not recommended for use during pregnancy period which may be due to justifiable safety 
uncertainties rather than causal relationship derived from rigorous trials. This lack of evidence based 
risk-benefit information may explain why pregnant women sometimes end up treated with less effective 
drugs or a non-friendly treatment regimen as opposed to non-pregnant individuals. However, 
contraindicated medicines in pregnancy cannot always be avoided in chronic diseases such as epilepsy, 
HIV, TB or in case of acute medical emergencies that are life-threatening for the mother and/or the 
fetus if not treated appropriately. Furthermore, most women of child bearing age use these medicines 
without knowing that they are pregnant which, in most cases, tends to be the consequence of 
unplanned pregnancy. Use of contraindicated drugs among pregnant women is also inevitable because 
over-the-counter prescription is common in Africa, including Tanzania [162]. The latter is of a great 
concern with the current observed increasing number of private drug vendors in most developing 
countries where monitoring of safety practice by the responsible authorities may be a problem too.  
Drug safety in pregnancy can best be assessed through active PV system or pregnancy exposure registry 
system. Active PV involves active cohort event monitoring and reporting of adverse drug effects when 
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the drug is already on the market (post-approval). It assists to determine any minor or rare drug 
reactions which were not detected during phase III clinical trials. In pregnancy, PV system helps to 
determine whether the drug has an effect in inducing foetal risks or not [73]. Active cohort event 
monitoring such as use of pregnancy exposure registry do exist in most developed countries and its 
operation is strongly supported by the (i) US Food and Drug Administration (US FDA) in USA and (ii) 
European Medicine Agency for drugs or products in European countries, so as to provide reliable drug 
safety information following exposure in pregnant women or women of childbearing age. This facilitates 
additional safety information of products, especially the ones for which safety in pregnancy is 
questionable secondary to pre-clinical animal data that suggest teratogenicity, for example ACTs [163, 
164].  
PV databases on drug safety information in pregnancy or pregnancy exposure registries do not exist in 
almost all developing countries, including Tanzania, due to some reported complexities such as limited 
health skilled personnel, inadequate clinical record of the data and lack of quality birth registry system 
[36]. These challenges have existed for long time and it appears that there is no promising solution yet in 
place to overcome these challenges.  Under TFDA in Tanzania, drug safety information is collected 
spontaneously, but the reporting rate is very low which is one of disadvantages of passive PV system 
[61]. Furthermore, in passive PV system, it is difficult to detect adverse drug reaction that takes longer 
to appear in a patient following exposure, as it may be the case in pregnancy whereby adverse event 
that affects the baby in a womb may be detected after delivery or later in child’s life. The latter will not 
be missed in active PV system since it involves monitoring of a cohort for events in a defined period of 
time.    
It is an ample time to consider having an effective mechanism in place for generating reliable drug safety 
information during pregnancy in a tropical developing country. Chapter 4 of the thesis shows that there 
is a potential opportunity to overcome this challenge in the country, and thus to achieve having a 
feasible, reliable and manageable PV system for cohort event monitoring among pregnant women in the 
country. The latter is possible by using HDSS platform which has existed for quite some time in 
monitoring various vital events such as pregnancies, births and deaths. Added advantages of using HDSS 
platform for a successful and reliable PV system in pregnancy include: well-established HDSS database of 
its residence which is routinely updated on quarterly basis in a year during HDSS census, have 
experienced field workers who are equipped with skills and transport means to facilitate follow up, 
strong established relationship between health facility personnel with HDSS staff team who had long 
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been cooperating in various cohort studies which involves gathering various clinical data from patients 
and finally, good relation between HDSS staff team and HDSS residence or patients which facilitates 
confidentiality and corporation that is important to ensure effectiveness in gathering health 
information. It is important to note that implementation of monitoring drug safety in pregnancy in a 
resource limited settings is also supported by the WHO protocol that encourage individual countries and 
sentinel sites such as HDSS to contribute for data pooling into a common WHO database on safety of 
medicine exposure in pregnancy [82]. To my knowledge, there is no developing country, particularly in 
sub-Saharan Africa which has tried so far to come forward and implement active PV system in pregnancy 
that would involve monitoring of all drugs exposure during pregnancy.  
Achieving the establishment of an effective PV system for cohort event monitoring during pregnancy in 
Tanzania using HDSS platform will be a get way through of cascading this success story to other HDSS 
and non-HDSS areas in resource-limited countries. It is important to emphasize that other countries 
should buy in the use of sentinel sites such as HDSS platform through INDEPTH network to facilitate the 
set-up of active cohort event monitoring of anti-infective agents. Having a larger and reliable safety data 
pool will ensure a timely risk-benefit profile assessment of a given medicine and a strong scientific 
power to conclude the observed safety results. The latter will assist to overcome the current challenge 
whereby nearly all developing countries rely on medicine safety data from industrialised countries in 
which there are no pregnancy safety data for medicines that aim at treating tropical diseases because 
they are hardly being used in these countries [74].   
There are 49 HDSS sites registered under INDEPTH network in 20 countries; 36 in Africa, 12 in Asia and 1 
in Papua New Guinea (Oceania) [165]. Implementation of active PV system using HDSS sites should have 
a geographical representation of countries and continents in the respective sites. This will allow a wide 
diversity assessment of different medicines exposure and diseases in relation to pregnancy outcome 
because there is no a common treatment guideline to all these countries and furthermore, health 
seeking behavior among patients is not always the same. The selection criteria of study sites for PV 
system should be (i) having a large population of HDSS residence, (ii) high number of health facilities 
with good coverage of antenatal services in HDSS catchment area, and (iii) HDSS experience to carry 
clinical related cohort studies. It is important to have strong scientific and capacity building support 
during the initial implementation stage of PV system in HDSS sites. This is possible because most HDSS 
sites in the South have a long-standing scientific collaboration with research centers in the North, for 
example Ifakara HDSS in Tanzania with Swiss TPH in Switzerland, Manhica HDSS in Mozambique with 
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Barcelona center for international health research in Spain and Farafenni HDSS in Gambia with London 
School of Hygiene and Tropical Medicine (LSHTM). Having such a bounding in the operation will assist to 
enhance this system through technical support that would ensure an effective monitoring mechanism. 
The latter will facilitate having reliable and quality PV reports that would be produced on a timely basis. 
The success story of achieving the proposed active PV system in HDSS areas should later on be applied in 
areas with no HDSS. In none HDSS areas, criteria for consideration should be a country with good health 
information system, good coverage of antenatal services and commitment of the ministry of health to 
support the system through its available resources. In addition, the facilitation and supportive role of 
pharmaceutical companies should be clearly defined, as well as that of donor agencies.         
The pilot PV system reported in chapter 4 has shown that almost all women (98%) had used at least one 
medication during pregnancy. Anti-infective including anthelminthic, antibiotics and antimalarial were 
highly used among pregnant women. Such a high magnitude of anti-infective exposure justifies an active 
PV monitoring system in the country. High anti-infective exposure among pregnant women in resource-
limited countries is known. A study conducted in Mozambique seven years ago reported antibiotics and 
antimalarial exposure among 3105 studied pregnant women was 41% and 24%, respectively. Exposure 
to these drugs in pregnancy was associated with increased risk of stillbirth [36]. It is important to 
emphasize that having effective PV system in pregnancy should go parallel with effective improvement 
of newborn screening and birth registry. The latter will facilitate proper detection of any adverse birth 
outcome and good data linkage between pregnancy exposure information and birth outcomes records.    
The first 12 weeks of pregnancy (first trimester) is an important pregnancy period in baby’s 
development and is highly sensitive to drug safety issues because it is when organogenesis takes place 
and therefore, congenital malformation or miscarriage commonly occurs if harmful chemicals or 
biological agents are used in pregnant woman [71]. There is a limited armamentarium of antimalarial 
drugs recommended in early pregnancy period. So far, chloroquine, proguanil, clindamycin and quinine 
are the only recommended antimalarial, knowing that the first two are no more effective [37]. It is 
important to evaluate the safety of quinine when compared to more recent drugs such as ACT, due to 
ongoing queries of clinicians regarding potential adverse pregnancy outcome. Quinine has long been 
associated with abortive properties which are often linked with overdose. The first report questioning 
quinine safety was published for the first time almost a century ago [44]. Quinine overdose in treating 
patients is inevitable in most health facilities in developing countries because dosage is mainly provided 
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based on age group rather than body weight. This is a matter of concern, especially in poor rural 
communities whereby malnutrition is also a problem too. 
It is time to explore the appropriateness of using ACTs as first line drugs during first trimester . Currently, 
there is no safety signal in humans to question the introduction of these drugs during first trimester [39, 
40, 166]. Furthermore, additional information from interim analyses of two studies in Africa, at present 
are in their final stages, collecting ACTs safety information in first trimester do support the evidence that 
ACTs are safe in early pregnancy (ter Kuile FO, personal communication). One may argue that the 
available information is not yet sufficient enough to justify policy change, especially well designed 
studies that include infant development follow-up. However, it is also not clear how much  safety 
information is needed to change recommendation. Based on the available promising information of 
artemisinins safety in first trimester, it is time to plan a randomized controlled trial that would involve 
ACTs versus quinine for uncomplicated malaria and parental artesunate versus parental quinine for 
severe malaria, both in first trimester. The latter may be important for consideration following 
AQUAMAT trial (compared artesunate verses quinine in treating children with severe malaria) that 
recommended artesunate to replace quinine as a drug of choice for severe P. falciparum  malaria [97].   
9.2 Antimalarial efficacy in relation to alteration of PK properties due to pregnancy condition  
It is essential to consider that pregnant women should be treated with effective medicine that will 
ensure good therapeutic outcome within a minimum period of time. However, there are key factors that 
determining therapeutic outcome of any given disease condition and that includes; (i) host or patient 
factor that influence drug properties (pharmacokinetic) in terms of drug absorption, distribution, 
biotransformation and excretion, (ii) host immunity against infectious agent, and (iii) the efficacy of 
therapeutic agent or a drug in eliminating the infectious agent from the host and to prevent new 
infection into the host for a defined period of time. The two host factors are greatly altered during 
pregnancy as opposed to non-pregnant individuals. In addition to safety issues, all these factors are 
important parameters which drug manufacturers in most cases have to consider during drug 
development process and while modeling to determine appropriate dose regimen.  
It is unfortunate that doses used in pregnancy are often extrapolated from adult because of the same 
reason that pregnant women are not involved in PK studies of a pre-licensed medicine. Hence, PK 
alterations that occur during pregnancy period are not reflected in the formulated dose that a pregnant 
woman will need to take to clear or prevent a given infection. This is a key weakness in malaria 
chemotherapy in pregnancy which may explain lower effectiveness of artemether-dihydroartemisinin, 
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lumefantrine, artesunate-dihydroartemisinin, dihydroartemisinin, piperaquine, atovequone and 
proguanil in pregnancy [49, 51, 114, 167]. The PK alteration may increase the likelihood of malaria 
treatment failure in pregnancy due to lowered plasma drug levels and considering that host immunity 
against malaria and many other infections is compromised during pregnancy [10]. The sub-optimal dose 
which will be circulating in a woman’s body system will lead to incomplete elimination of a parasite and 
hence recrudescence, but also to a lower post-treatment prophylactic effect. It is therefore essential to 
reassess the current recommended dose regimen of all antimalarial drugs in pregnancy so as to reassure 
the expected therapeutic outcome in this vulnerable group.  
Most antimalarial PK studies preferably monitor the longer partner drug with a higher half-life clearance 
in plasma such as LF in AL and not the shorter one because the longer partner drug is more informative 
to display its minimum parasiticidal concentration (MPC) and minimum inhibitory concentration (MIC) of 
the study drug. Chapter 6 of the thesis reported LF bioavailability among pregnant women in the study 
was lower by 34% as opposed to non-pregnant women. There was a higher metabolism rate of LF into 
DLF by 78% among pregnant women as opposed to non-pregnant women and this may be one of the 
underlying reasons for lower LF bioavailability in pregnancy. This shows that pregnancy is an important 
responsible factor in the alteration of PK properties of AL. The latter has also been reported in other PK 
studies conducted in Thailand and hence agrees that physiological changes in pregnancy remain the 
most responsible factor for lowering plasma drug level in pregnant women [51].  
Higher MIC and prolonged post-treatment prophylaxis is one of the merits for an effective antimalarial. 
This may be a weakness of AL when compared to other ACTs, particularly dihdroartemisinin-piperaquine 
(DP). DP has been reported to be the ACT with the longest post-treatment prophylactic effect because 
of the prolonged half-life of piperaquine [168-170]. Beneficial effect of post-treatment prophylaxis is 
more visible in area with high malaria transmission as opposed to low transmission due to difference in 
chances of having new infection. Protecting a pregnant woman from new infection for a reasonable 
interval of time post treatment will help her body to recover effectively from weakness associated with 
the existed infection which is important too for the health gain of unborn baby in the womb. DP has 
shown to be efficacious, safe and tolerable for treating uncomplicated malaria in Ghanaians pregnant 
women [171].   
To increase bioavailability of LF, it is advisable to take AL with a meal rich in fat because LF is a 
hydrophobic lipophilic compound which is absorbed slowly. In our study, the median day 7 
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concentration of LF in pregnant women was 908 ng/ml as opposed to non-pregnant women who had a 
much higher concentration of 1382 ng/dl. These values in either of the two study groups are higher than 
the median day 7 LF concentrations from another PK study conducted in Tanzania and Cambodia [118] 
where meal rich in fat was not concomitantly administered during AL intake. Encouraging AL 
administration with a meal rich in fat should be considered as an immediately solution to increase 
bioavailability of this drug in pregnancy while planning for the possibility of further study that would 
propose a modified AL treatment regimen in pregnant women.  
9.3 Malaria preventive measures in pregnancy and IPTp-SP effectiveness 
Pregnant women are known to be important vulnerable group for malaria infection. One of the reasons 
that may explain their vulnerability are the changes that occur in a placenta which makes human 
placenta a favorable harbor site for malaria parasite [10, 19]. With time, malaria infection in the 
placenta may lead to harmful consequences to a woman and hence may be responsible for pregnancy-
associated malaria morbidities. High malaria transmission areas have been reported to carry a big 
burden as opposed to low transmission areas because of likelihood of having asymptomatic malaria 
infection which is explained by their developed immunity [6]. Thus, there have been effective preventive 
measures advocated for preventing malaria in pregnancy especially in malaria endemic areas. Cost-
effectiveness of some of these preventive measures are challenged because of the reported decline of 
malaria in most areas which were previously known to have high transmission [146, 147] and hence call 
for the need to determine the role of other non-malarial factors in relation to adverse pregnancy 
outcome. Furthermore, there is a growing concern of parasite resistance to antimalarial drugs [172] and 
mosquito resistance to pyrethroids, insecticide commonly used in ITN and indoor residual spraying [173, 
174]. All these changes call for a continuous evaluation of the cost-effectiveness of the existing and 
newly proposed malaria preventive measures in pregnancy, and identify the effective gears which will 
be applied in the defined range of malaria transmission settings [5].  
Use of at least two doses of SP for IPTp from second trimester of pregnancy and ITNs are important 
malaria preventive measures which have been in place to prevent malaria and associated morbidities in 
pregnancy in malaria endemic areas for almost a decade [27]. SP resistance jeopardizes the reliability of 
the existing IPTp regimen for controlling malaria in pregnancy considering that there is no alternative for 
SP which have been recommended to date. Little is known regarding effectiveness of the current IPTp 
regimen for malaria control in pregnancy particularly in low malaria transmission settings. Interaction of 
SP with other drugs is also a questionable issue due to safety and efficacy reasons, a greater concern is 
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its interaction with anti-retroviral (ARV) or cotrimoxazole in HIV individual, consider the high prevalence 
of HIV in sub-Sahara Africa and most infected people are on ARV  [175]. However, IPTp use is still 
routinely advocated and practice in most of sub Saharan countries regardless the presence of an existing 
chronic illness or intensity of malaria transmission to which a given pregnant woman is residing. 
Prevention of pregnancy associated malaria morbidity such as maternal anaemia and LBW are the 
primary benefits of IPTp use [176]. There have been inconsistences to support the latter effects of IPTp 
[161], even in chapter 8 of the thesis which also did not support IPTp effectiveness on preventing 
maternal anaemia and LBW in either area of transmission intensity. WHO has currently issued a new 
IPTp guideline which requires monthly administration of SP early from second trimester following 
studies that supported this regimen in order to enhance net benefits of IPTp [34, 157]. However, it is still 
important to question the added benefits of this novel regimen in areas with low malaria transmission 
considering that unnecessary drug exposure in pregnancy is not an ideal practice. It is also questionable 
in terms of feasibility and acceptability of having high coverage of all proposed IPTp doses in the newly 
regimen since the coverage of IPTp second dose in the previous regimen was still below 60% in most 
malaria countries in sub-Sahara [31]. We therefore expect the coverage of third or fourth IPTp dose to 
be even lower, and the expected added benefit may thus be very low. 
ITN has long been advocated for use as an effective means of malaria prevention in both pregnant and 
non-pregnant individuals. ITNs have reduced more than 15% of all pregnancy associated malaria 
morbidities [143]. Thus, it is important to promote ITNs use in pregnancy and, unlike IPTp, it does not 
expose directly a pregnant woman to a drug. Added benefit to ITN is infancy protection because most 
women sleep with their newborns. Acceptability of ITNs is also higher in the community as observed in 
chapter 8, 95% ITN coverage versus 51% IPTp second dose although, the figures may differ with the 
findings observed in other malaria areas within and outside Tanzania.  
Indoor residual spray in an effective means of malaria vector control and should be considered for use in 
prevention of malaria in pregnancy albeit, its specific effect in this vulnerable group has not yet been 
evaluated [5]. However, the emerging and spread of pyrethroids resistance [174] is a key challenge to 
scientists because pyrethroids are well tolerated by pregnant women and there is no reported toxicity to 
the fetus when used according to the given safety procedure [177]. The role of mosquito repellant in 
preventing malaria in pregnancy has not well been evaluated despite of diethyltoluamide (DEET), a 
common active ingredient of mosquito repellent, to be known of being safe in pregnancy [178]. 
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Mosquito repellents are not part of malaria control intervention in pregnancy. This preventive measure 
might be beneficial particularly for pregnant women living in high transmission areas during their late 
out-door activities or women travelling from low to high transmission areas. Effectiveness and safety of 
mosquito repellents in pregnancy should be evaluated.      
Intermittent screening with a rapid diagnostic test (RDT) and treatment to those whose result is positive 
(IST) in every antenatal visit has been thought as the right alternative for IPTp. IST with an effective 
antimalarial has shown to be non-inferior to IPTp-SP in West Africa [159]. Implementation of IST will 
help to reduce unnecessary SP exposure to pregnant women, particularly the ones in low transmission 
areas. And if implemented in areas with high SP resistance, it will ensure more effective cure of 
parasitaemia when compared to SP. The type of screening test to detect parasitaemia in pregnancy is 
important and RDT might have the advantage over microscopy to detect circulating antigenemia, 
eventually from parasites sequestered in the placenta. This is more theoretical than practical. It has 
indeed been shown that RDTs are more sensitive than microscope to detect placenta malaria (81% vs 
72%). Histidine rich protein 2 (HRP2)-based RDTs may be preferred than plasmodium lactate 
dehydrogenase (pLDH)-based RDTs because they are more sensitive and thermo stable [179].   
It is important to evaluate the effectiveness of malaria preventive measures in pregnancy according to 
levels of transmission intensity. Proposed interventions should be considered based also on the 
perceptions, acceptability and cost implication in the targeted community. All these parameters are 
important to assure effective coverage of a particular intervention.  
9.3 Conclusion 
There is a big gap of knowledge about malaria treatment in pregnancy which is due to limited 
information available on the potential effective and safer treatment to be used in this vulnerable group. 
It is an ample time to have effective mechanism of addressing the knowledge gap of safety therapies 
used during pregnancy. The latter is possible by establishing an active cohort even monitoring 
mechanism of drug exposure in pregnancy so as to contribute busting a safety data pool which would be 
useful for evidence-based medicine. It is time to make effective use of the available AL safety 
information so as to increase its marginal safety for use in all trimesters as this drug may be safer than 
the current recommended quinine. Effectiveness of IPTp use should actively be monitored and evaluate 
its potential benefits especially in areas with high SP resistance.  
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9.4 Recommendation 
Malaria treatment and prevention is still a major challenging area in pregnancy with a lot of pending 
questions which need concrete answers and immediate solutions. It needs both local and international 
partners to come together and address these challenges in order to improve maternal and neonatal 
health. The answers to these challenges should address both immediate and long term action plan on 
malaria chemotherapy in pregnancy. It is also recommended that pharmaceutical companies and other 
global financial bodies should invest more on building drug monitoring capacity that could assess and 
reporting PV issues of antimalarial drugs in malaria endemic areas. We therefore recommend on the 
following practical application and further studies as outlined below:   
Practical application areas 
a. Establish a safety monitoring mechanism of drug exposure during pregnancy period in malaria 
endemic countries. This will increase the safety data pool particularly for newly marketed 
medicines and other anti-infective drugs for treating tropical diseases in which there is more 
need to be addressed regarding their safety use in pregnancy.  
b. Use of HDSS platform in limited-resource countries to establish pregnancy exposure registry 
system. This should go along with the improvement of birth registry system as well as maternal 
and neonatal care services.   
c. Continuous train and advocate to health care provider on abiding to standard treatment 
guidelines for treatment and care among pregnant women. This should effectively involve both 
public and private health sectors, including drug venders. It should also target to discourage use 
of non-recommended medicines in pregnancy and the use of anti-infective after standard 
screening of a particular infection in the facility.   
d. Reduce the intensity of pierce statement in the WHO malaria treatment guideline that cautions 
ACTs use and the risk of embryo-foetal toxicity because such risk has not yet been confirmed in 
any human studies to date. Furthermore, a plan should be developed for the use of alternative 
drugs such as ACTs that are safer than quinine and hence to be considered as first line malaria 
treatment for uncomplicated malaria during first trimester of pregnancy.  
e. Restrict quinine use to severe cases of malaria in all trimesters of pregnancy. This is due to its 
safety problems and secondly it has high possibility to develop resistance, being a monotherapy.  
f. Modify ACT regimen in pregnancy to improve its efficacy in this vulnerable group. It should 
target to increase MPC and MIC. 
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g. Continuously advocate on the administration of AL with meal rich in fat so as to maximize LF 
absorption, especially in pregnant women. 
h. Regularly estimate the Number Needed To Treat with IPTp and eventually apply this 
intervention in selected groups in defined transmission level areas. 
Further research areas 
a. Determine safety of antimalarial and other anti-infective drugs in pregnancy in relation to their 
specific period of exposure during pregnancy using active PV system (Cohort event monitoring). 
b. Assess the strength of achieving establishment of active PV system in HDSS area and how best 
can the experience be applied to none HDSS areas. Cost-effective analysis and sustainability 
should also be evaluated. 
c. Evaluate the available evidence on ACTs safety in first trimester by the policy makers and advise 
a way forward on expanding its marginal safety in pregnancy. 
d. Consider a way forward for planning and conduct a randomized control trial that would target to 
assess ACTs safety in first trimester. 
e. Reevaluate quinine safety in pregnancy and advise on whether there is a need to keep on using 
this drug in pregnant women or it is time to substitute it with a safer medicine. Studies should 
be conducted to assess the safety and efficacy of artesunate as first-line treatment for severe 
malaria during pregnancy 
f. Assess the effectiveness and compliance of the proposed 5 days AL regimen for treating 
uncomplicated malaria in pregnancy. 
g. Assess the effectiveness of the newly proposed IPTp regimen by the WHO in East Africa region, 
an area with the highest SP resistance. 
h. Assess the effectiveness and cost implication of active screening and treatment of malaria in 
pregnancy verses the newly proposed IPTp regimen in East Africa region. 
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